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Introduction
Monoclonal antibodies (MAb) to the clonotypic structure of the T-cell receptor 
(TCR) may be useful tools in the study and therapy of T-cell mediated diseases 
such as rheumatoid arthritis. However thus far, a suitable method for the 
generation of anti-clonotype MAb to a given antigen-specific T-cell clone is not 
available.
This thesis describes the development of a novel approach for the immortalization 
of murine and human B cells. Using this approach, it was possible to immortalize a 
small number of preselected B cells specific for the clonotype of a human 
autoreactive T-cell clone. Thus, a set of anti-clonotype MAb was generated. These 
MAb were investigated for their immunomodulating capacities on this T-cell clone 
in vitro.
In the first part of this chapter, an overview of the current status of MAb 
technology is given, as well as the major strategies that have been used for the 
generation of human MAb. The second part describes the use of MAb to T-cell 
surface markers as reagents for T-cell modulation. More specifically, the use of 
anti-clonotype MAb for the modulation of T cells is described. One of the 
mechanisms by which such MAb can exert their T-cell modulatory function may 
be the induction of anergy. An overview of different models for T-cell anergy is 
given.
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Generation of MAb
Antibody development and monoclonal antibodies
Antibodies or immunoglobulins are produced by B cells. They are composed of 
two identical heavy and two identical light chains which each consist of a constant 
(C) region and a variable region (V). Together they create two unique antigen- 
binding sites and a Fc-region. The latter is responsible for effector functions such 
as complement activation, and opsonization by attachment to Fc-receptors on 
neutrophils and macrophages (Figure 1). Immunoglobulins are classified into 5 
classes according to the type of heavy chain they possess: IgG, IgM, IgA, IgE and 
IgD. The variable regions of individual heavy and light chains contain three 
hypervariable regions (complementarity-determining regions or CDR’s) separated 
by four highly homologous ‘framework’ regions. The CDR’s of heavy and light 
chain together form the antigen-binding sites of the antibody molecule.
Figure 1: Heavy chains are constructed by recombination of four gene segments 
(V, D, J  and C genes). Each gene is encoded by a relatively small number of 
germline gene segments but random recombination gives rise to large numbers of 
different heavy chains (left). A similar process occurs with V, J  and C genes for 
the light chains. Pairing of two identical heavy and two identical light chains 
results in the formation of an antibody molecule (right).
An individual B cell produces a single type of antibody, but because of the large 
number of B cells the synthesis of a great variety of antibodies to many different 
antigens is ensured. The diversity of antibodies is not encoded directly in the 
germline but is assembled by random joining of a number of gene segments in 
virgin B cells (V, D, J and C genes for heavy chains (Figure 1) and V, J, and C
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genes for light chains) [1]. Additional diversity results from loss or addition of 
nucleotides at the junctions between these gene segments [2]. Thus, after 
combination of heavy and light chains, an enormous diversity of sequences in the 
variable part of antibody molecules is possible. This is estimated to yield over 1010 
antibody specificities [3]. During the immune response to foreign antigens, B cells 
differentiate into short-lived plasma cells that secrete antibody and long-lived 
memory B cells. Memory B cells undergo somatic hypermutation of the V genes of 
antibodies [4]. This process, known as ‘affinity maturation’, leads to further 
diversity of the antibody repertoire in vivo.
Because of their capacity to specifically interact with an antigen, antibodies are 
useful tools in research, diagnostics and therapy. Since the end of last century, 
antibodies have been obtained from the serum of immunized animals (polyclonal 
antisera). These polyclonal antisera had several disadvantages. Even in serum of a 
well-responding animal, only 10% of the antibodies are specific for the 
immunogen. Moreover, these antibodies are directed to different epitopes of the 
immunogen. As a result of this heterogeneity, polyclonal antisera are often not 
very specific. Furthermore, each antiserum is different from all other antisera, even 
if raised in a genetically identical animal using the identical preparation of antigen 
and the same immunization protocol. Thus, the supply is limited and it is 
impossible to use identical antiserum in an extensive series of experiments or 
clinical tests.
Since the introduction of hybridoma technology 20 years ago, MAb-producing 
hybridomas have become the standard source of antibodies. MAb are characterized 
by recognizing a single antigenic epitope and having a single amino acid sequence 
for the structure of all its molecules. The advantages of MAb-producing 
hybridomas are numerous. For example by culturing MAb-producing hybridomas, 
it is theoretically possible to produce unlimited amounts of MAb which will have 
the same properties. An other advantage is that very specific MAb may be 
identified and produced. In fact, the MAb can be selected on specificity, affinity 
and isotype.
The major techniques for the generation of MAb or MAb fragments are discussed 
below.
PEG-fusion
The history of the generation of MAb goes back to 1975. In that year, George 
Kohler and César Milstein reported the construction of hybridomas by fusion of
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hypoxanthine-guanine-phosphoribosyl-transferase-deficient myeloma cells (P3- 
X63Ag8) with in vivo immunized murine spleen cells, and consecutive selection of 
hybridomas in hypoxanthine, aminopterin, and thymidine (HAT) containing 
medium [5]. These hybridomas combine the capacity of an antigen-activated 
normal B cell to produce and secrete one (and only one) antibody with a given 
specificity, and the ability of unlimited growth of the myeloma cell. Thus, they 
provide an unlimited source of identical antibodies. This discovery had a great 
impact on biomedical sciences as a variety of useful reagents could be made by 
this procedure. It is for this reason that Köhler and Milstein were awarded the 
Nobel Prize for Physiology and Medicine in 1984. The basic fusion procedure has 
changed little over the years, except for the introduction of PEG as a fusing agent 
instead of Sendai virus [6], and the use of other myelomas as fusion partners [7-9]. 
Up till now most MAb are still made by this technique, though the low 
immortalization frequency of B cells (1 : 2x105) can be a drawback in some 
applications.
Electrofusion
An entirely different approach for fusing cells, with a much higher fusion 
frequency, was proposed by Zimmermann et al. [10-12]. In this electrofusion 
technique tight membrane contact between the cells to be fused is obtained by 
exposure to a non-uniform, alternating electric field of low strength. Subsequently, 
reversible electrical breakdown in the membrane contact zone is achieved by a 
short electric field pulse of high intensity which results in the fusion of cells. Later 
on, this technique has been improved by changing the osmolarity and specific 
resistance of the fusion medium [13,14]. Furthermore, the method has been 
adapted for small numbers of B cells by the use of a differently constructed fusion 
chamber [15]. The high fusion frequency (1 : 2000) has meant that electrofusion 
has become increasingly popular during recent years. However, it is still not 
widely used.
Phage display technology
As an alternative for generating antibodies by hybridoma technology (including 
immunization), antibody fragments have been generated by phage display 
technology. Natural [16,17] or in vitro assembled [18,19] V gene repertoires have 
been cloned and displayed on the surface of filamentous bacteriophages. The 
phages of interest, each displaying a single antibody species, are then selected by
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binding to antigen and finally soluble antibody fragments are obtained from 
infected bacteria. The affinity of the initial selected antibody fragments may be 
further improved by random or directed mutation of the V genes or by chain 
shuffling [20]. In chain shuffling, one chain of a low affinity phage antibody is 
kept constant and displayed in association with a library of the other chain (and/or 
vice versa) in order to create a higher affinity antibody. The larger and more 
diverse the libraries of V genes, the greater the chance of finding antibodies that 
have the desired binding specificity and affinity. Further success of the phage 
display technology depends on the availability of larger libraries of greater 
diversity [21,22]. These can be used as a single source of antibodies against a 
range of different antigens without the need for immunization of animals and 
constructing new libraries every time.
Human monoclonal antibodies
The available rodent MAb have proven to be very useful reagents in basic research 
and diagnostics. However, in most therapeutic applications, rodent MAb have 
yielded disappointing results. They invariably evoked a human anti-mouse 
response (HAMA) [23,24], and due to their altered (non-human) carbohydrate 
structures they were generally ineffective in recruiting effector functions in 
humans, such as Fc receptor-mediated antibody dependent cellular cytotoxicity, 
complement activation and phagocytosis [25,26]. Thus, for repeated therapeutic 
use, human MAb are essential. However, the success in generating murine MAb 
contrasts with the many problems that have been encountered in trying to develop 
human MAb. These are mainly caused by the fact that hyperimmunization of 
human subjects is not possible for obvious ethical reasons and because of technical 
limitations in the immortalization of ‘naturally’ primed human B cells. Figure 2 
outlines the major strategies that have been developed for the generation of human 
MAb. These strategies are discussed in more detail below.
Chimerization and humanization of murine MAb
Recombinant DNA techniques have been applied to construct antibodies that 
resemble human MAb but retain the antigen-binding characteristics of murine 
MAb. The variable genes of the murine MAb have been attached to the constant 
regions of human immunoglobulins and expressed in myeloma cells [27,28]. The 
resulting chimeric MAb maintain the specificity of the murine MAb while 
displaying the effector properties of human antibodies. However, in a number of 
cases these MAb are still immunogenic in humans [29,30]. In order to further
10
I Human j 
V MAb J
Fusion
f Immunized ^ I Immunized ^
I SCID mice J I transgenic mice J
f Phage display j (  Naive human ^
^  technology J I  B cells J
Figure 2: An outline of strategies used in the generation of human MAb.
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reduce the immunogenicity of a murine derived antibody, only the hypervariable 
CDR’s from the mouse MAb are ‘grafted’ into a human antibody framework 
[reviewed 31]. The resulting humanized MAb however often show reduced 
reactivity for antigen. The choice of the framework region in which the CDR’s are 
grafted is very important and additional mutations in these framework regions 
might be required to restore full antigen binding capacity [32-34]. These problems 
might prevent CDR-grafting from becoming a general approach, unless antibody 
engineers can predict interactions between hypervariable and framework regions 
based on reliable 3D-structures of a given antigen-antibody complex.
Fusion and EBV transformation of in vivo primed B cells
The generation of human MAb from in vivo primed B cells is limited to a 
relatively small set of antigens (viz. micro-organisms, tumor cells, alloantigens and 
autoantigens) because deliberate immunizations are usually not allowed for ethical 
reasons. Another drawback is that in most cases only peripheral blood 
lymphocytes (PBL) can be used as the primary source of human B cells.
Many different mouse, human and mouse-human myeloma fusion partners have 
been used for the construction of human antibody secreting hybridomas [reviewed 
in 9, 35-37] but none of them has the excellent properties with respect to cloning 
efficiency, fusion frequency, antibody yield and/or final hybridoma stability as 
their murine counterparts in the generation of murine MAb.
As an alternative, human B cells can be efficiently (frequency 1: 50) immortalized 
by Epstein Barr virus (EBV) transformation [37-39]. This is however a 
cumbersome procedure for the production of human monoclonal antibody 
secreting cell lines. Although most human B cells express receptors for EBV 
(CD21), only a subset of these cells are immortalized yielding predominantly IgM 
producing cell lines [35, 37, 40]. Furthermore, EBV transformants are difficult to 
clone and sometimes grow poorly. For this reason, many investigators have fused 
EBV transformants with myeloma cells to obtain more stable and better growing 
hybridomas.
B-cell expansion followed by immortalization
Besides EBV transformation other ways of B-cell expansion have also been 
described as an intermediate before cell fusion e.g. cultures stimulated with 
pokeweed mitogen (PWM) or lipopolysacharide (LPS).
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Another approach is the expansion of human B cells in the CD40 B-cell culture 
system as an intermediate before cell fusion [41]. In the CD40 system, B cells are 
stimulated to sustained proliferation by crosslinking of their CD40 molecules and 
the addition of IL-4. Crosslinking of CD40 molecules is achieved by anti-CD40 
MAb presented on mouse L-cells transfected with human Fc-receptors 
(FcgRII/CDw32) [42,43]. Proliferation lasted for 10-12 days, but repeated 
stimulation by immobilized anti-CD40 and IL-4 appeared to be possible. Twenty 
to 30% of single B cells could be stimulated to yield 100 to 1000 cells within 5 
weeks. Depending on the nature of extra cytokines added to the system, different 
classes of immunoglobulin were secreted by the B-cell clones [44]. In addition, 
class switching and differentiation to plasma cells were observed [43].
We have used the EL-4 B-cell culture system for expansion of both human [45,46] 
and murine B cells [47] prior to electrofusion. In the EL-4 B-cell culture system 
originally described by Zubler et al., B cells are activated by cell-to-cell contact 
with irradiated mouse thymoma cells (EL-4 B5). Subsequently, the activated B 
cells proliferate in response to IL-1, IL-2 and TNFa added in the form of human T- 
cell supernatant [48-51]. Interaction of CD40 ligand (gp39) on the EL-4 cells with 
CD40 on the B cells plays an important role in this activation step but additional 
interactions are required for full B-cell activation [52]. Proliferation peaked on day
7 to 8 after initiation of the culture and lasted for a maximum of 13 to 15 days. Up 
to 90% of peripheral blood or spleen B cells could be expanded to an average 
clone size of 380 cells secreting a mean amount of 40 ng immunoglobulin [48]. 
Individual B-cell clones generated IgM, IgG, IgA, IgM+IgG and IgM+IgG+IgA. 
The latter indicates that class switching also occurs in this system.
Recently, both the EL-4 and the CD40 system have also been used in combination 
with phage display technology for the cloning and expression of antibody 
fragments [53,54] instead of fusing the expanded cells.
In vitro immunization of naive human B cells
As an alternative for in vivo primed B cells, antigen-specific B cells can be 
obtained by in vitro immunization of naive B cells. In vitro immunization 
procedures for human B cells have been based mostly on the procedure described 
by Borrebaeck et al. [55,56]. In general, starting with freshly isolated peripheral 
blood mononuclear cells (PBMC), lysosyme-rich cells like natural killer (NK) 
cells, monocytes and a subset of CD8+ T cells are inactivated by incubation with 
leucyl-leucine methyl ester and, subsequently the cells are incubated with the
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antigen of interest. The MAb obtained after this in vitro immunization procedure 
were mostly of the IgM class. Recently, the in vitro immunized cells were 
submitted to a secondary stimulation in the CD40 B-cell culture system in order to 
induce isotype switching to IgG [57,58]. However, further research is necessary to 
establish the conditions of antigen presentation, T-cell help, lymphokine help and 
timing of a secondary stimulation before in vitro immunization can be widely used.
Mice producing human immunoglobulin
More promising but still an immature concept is the in vivo expression of a human 
immunoglobulin repertoire, such as severe combined immunodeficiency (SCID) 
mice repopulated with B cells, or human immunoglobulin transgenic mice.
SCID mice have no functional rearrangements in their T-cell receptor and 
immunoglobulin variable (diversity) and joining genes due to a recombinase defect 
[59-61]. As a consequence the mice are severely deficient in functional B- and T 
cells. Such mice can be engrafted with normal human lymphoid tissue (then called 
SCIDhu mice) resulting in polyclonal human immunoglobulin secretion [62] and 
the ability to develop a specific antibody response upon immunization with antigen 
[63,64]. The B cells of these mice have been successfully used for the generation 
of human MAb to both foreign and human self antigens using hybridoma 
technology [65-67], EBV transformation [68] and phage display technology [69]. 
Human immunoglobulin transgenic mice carry human immunoglobulin-gene loci 
in germline configuration. These mice are able to express a repertoire of human 
antibodies. Immunization of such mice in combination with murine hybridoma 
technology enables the generation of human MAb [reviewed in 70]. The feasibility 
of this approach was first shown by Bruggemann et al., who introduced the human 
JH cluster and C  region linked to two VH and four D segments into the mouse [71]. 
They showed that the introduced minilocus underwent rearrangement and that the 
mice produced a small amount of immunoglobulins carrying the human ^ chain 
together with a large amount of endogenous immunoglobulin. Recently, this 
approach has been further improved by Lonberg et al. [72,73] and by Jakobovits et 
al. [74]. They have introduced a much larger part of the human immunoglobulin 
genes (including k light chain) and part of the mouse immunoglobulin genes have 
been knocked out. The human immunoglobulin genes in these mice undergo 
rearrangement, heavy-chain class switching and somatic mutation to generate a 
wide repertoire of human immunoglobulins. In addition, after immunization human 
MAb producing hybridomas were generated. Despite the rather limited number of
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human V genes in these mice, the repertoire has been sufficiently diverse to obtain 
MAb with relatively high affinities [72,75]. A next step will be the generation of 
mice with a greater number of human V genes and further silencing of the mouse 
immunoglobulin genes. Furthermore, the human immunoglobulin genes should be 
placed under the control of mouse immunoglobulin regulatory sequences in order 
to obtain higher expression levels of human immunoglobulins.
T-cell modulation
T-cell antigen recognition and activation
Antigenic peptide recognition by T cells occurs through the TCR, which is 
composed of two disulfide-linked polymorphic chains, the a- and the b-chain 
[76,77] (or the g- and 5-chain). The genes encoding the TCR are organized in a 
similar way as the genes encoding antibody (Figure 1). During T-cell development, 
diversity is obtained by rearrangement of the germline V, D, J and C genes for the 
b-chain and V, D and C genes for the a-chain. During recombination, further 
diversity is achieved by addition of non-germline encoded nucleotides and removal 
of nucleotides at the junctions between the gene segments [77,78]. This 
mechanism assures that a large repertoire of T-cell receptors for many different 
antigens is generated.
The TCR only recognizes an antigen as a processed peptide (8-16 amino acids) in 
the context of self major histocompatibility complex (MHC) molecules on the 
surface of antigen presenting cells (APC) [79,80]. Within the TCR variable 
regions, domains of hypervariability can be discerned, called complementarity 
determining regions (CDR1, 2 and 3). The CDR1 and 2 regions are supposed to 
interact with the a-helices of the MHC molecule, while the CDR3 region interacts 
with the peptide presented by the MHC molecule [80-82].
The TCR does not have an intrinsic signaling capacity. For this purpose, the TCR 
is non-covalently associated with the CD3 complex. This complex, consisting of g,
5, e, Z and h chains [76], links the TCR to multiple intracellular signaling 
pathways (Figure 3). However, TCR occupancy by MHC-peptide complexes alone
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APC
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Figure 3: T-cell antigen recognition and activation 
(adapted from: Borel et al. [85])
is not sufficient to induce activation in most normal T cells. Besides the 
TCR/MHC-peptide complex a number of other interactions (e.g. CD28/B7-1 or 
B7-2; LFA-1/ICAM; CD2/LFA-3; CD45/CD22; IL-1R/IL-1, CD4/MHCII or 
CD8/MHCI), are involved in T-cell activation [79,83,84]. The ligands for these 
interactions are provided by APC and/or cytokines and they either enhance the 
signal delivered by the TCR or provide a second signal via a separate signal 
transduction pathway. In the presence of at least one of such costimulatory signals, 
TCR occupancy leads to lymphokine secretion and proliferation (Figure 3).
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Antibodies to T-cell surface markers.
T cells play a pivotal role in the initiation and maintenance of many autoimmune 
diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes and myasthenia 
gravis), allergy and allograft rejection. Thus, T cells may be an important target for 
immunotherapy in these diseases.
General immunosuppressive treatments (e.g. glucocorticoids, azathioprine, 
cyclophosphamide) downregulate the immune system at multiple levels. Hence, 
lack of specificity and adverse side effects limit the effectiveness of these 
treatments. MAb to T-cell surface markers (e.g. CD2, CD3, CD4, CD8, LFA-1, 
CD25, TCR) are a more specific alternative. Interaction of the MAb with the 
surface antigen may directly lead to cell death (T-cell depletion) by the activation 
of complement, by the induction of cell mediated cytotoxicity or by the induction 
of apoptosis. Alternatively, MAb binding may lead to T-cell modulation by 
blocking or downmodulation of the surface molecule or by the induction of anergy. 
There are numerous reports concerning the efficacy of such MAb in treatment of 
autoimmune diseases and allograft rejection in animal models [reviewed in 79]. 
For example, anti-CD3 and anti-CD4 MAb abrogated autoimmune diabetes in 
NOD mice [86,87]; anti-CD2, anti-CD3, anti-CD4 and anti-TCRab have been 
shown to inhibit or prevent allograft rejection in mouse and rat [88-91]; anti-CD2 
and anti-TCRab were successful in suppression, prevention and treatment of EAE 
in rats [92,93]; and anti-CD4 (in combination with anti-TNFa) was able to 
ameliorate established collagen-induced arthritis [94]. The observation that these 
treatment protocols are associated with relatively non-specific attack on all or a 
large subset of T cells, warrants the development of protocols that more 
specifically downregulate disease-relevant T cells. Several investigators have 
reported clonal expansion of T cells and restricted Vb usage in experimental 
models for autoimmune diseases. Thus, MAb directed to Vb-regions have been 
used to either prevent or treat these animal disorders [95-98]. The most specific 
approach involves intervention at the level of TCR recognition by altered peptides 
(discussed in the next section) or by antibodies against the antigen-binding part of 
the TCR. Such antibodies were obtained by three different strategies: 
immunization with TCR CDR3 derived peptides [99,100], the generation of anti­
idiotype antibodies to anti-peptide MAb [101,102] and by the generation of anti­
clonotype MAb [103,104].
Thus far, the use of MAb to T-cell surface markers in the treatment of humans has 
been disappointing. The best results have been obtained with anti-CD3 in the
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prevention of allograft rejection and in the treatment of graft-versus-host disease 
[105,106]. Treatment of autoimmunity is still experimental. Several studies 
demonstrated beneficial effects in initial open studies, but this was not confirmed 
in double-blind, placebo controlled trials [reviewed in 106-109]. An explanation 
for these disappointing results may be that many antibodies were of mouse or 
chimeric origin. Such antibodies have a short half life in humans and often evoked 
a HAMA response. There is limited clinical experience with CDR-grafted MAb 
thus far. Humanized anti-CD3 and anti-CD4 did not show a HAMA response 
[110,111] but there are also reports that humanized MAb may still be 
immunogenic if not the right framework is chosen for humanization [34]. However 
besides immunogenicity, there are several other factors that may influence the 
outcome of MAb therapy: epitope specificity, affinity, isotype (important with 
respect to Fc-receptor and complement binding), dosage and disease stadium at 
onset of therapy.
Anergy induction
Peripheral tolerance to self antigens has been thought to play an important role in 
the regulation of the immune response in humans since autoreactive T cells can be 
isolated from the peripheral blood of healthy individuals [112-114]. Different 
mechanisms are involved in mediating peripheral tolerance including suppression 
by regulatory T cells, clonal deletion by apoptosis and anergy induction [115-117]. 
T-cell anergy or unresponsiveness can be described as a state in which the T cell is 
alive but fails to respond to its antigenic peptide delivered by a professional APC. 
Anergy can result from a number of different situations [reviewed in 118-120]. 
TCR occupancy in the absence of costimulation leads to anergy. This form of 
anergy can be achieved by antigen presentation by costimulatory-deficient or ‘non­
professional’ APC [121-123], antigen presentation by purified MHC molecules in 
planar lipid membranes [124], stimulation of the TCR by anti-CD3 or 
superantigens [125-127], and blocking costimulation by CTLA4-Ig or anti-B7 
MAb [128,129]. The failure to respond is caused by a block in IL-2 production in 
anergic cells. The molecular mechanism underlying this IL-2 transcriptional block 
is not fully understood. Recent work suggests that the transcriptional block results 
from a failure to activate a critical transcription factor for the IL-2 gene, AP-1. In 
addition, increased amounts of a negative regulatory factor (NiL-2a) that blocks 
AP-1 have been found in anergic cells [120]. In this respect, costimulation via 
CD28 in concert with TCR occupancy results in activation of AP-1 via
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phosphorylation of the Jun protein. As a result, IL-2 production and T-cell 
proliferation will be restored.
A different form of anergy can be induced with ‘altered peptide ligands’ (APL). 
Sloan-Lancaster et al. [130-132] have shown that altering the ligand of the TCR by 
using peptide analogues on a functional APC, results in anergy. The peptide 
analogues act as partial agonists for the TCR. Triggering the TCR by these partial 
agonists leads to differences in phosphorylation of ZAP-70, CD3e and Z, as 
compared to stimulation with full agonists. It is unclear how these differences lead 
to the inability to synergize with the CD28 pathway in the activation of IL-2 
transcription and T-cell proliferation.
Another form of anergy is related to oral tolerance induction in vivo. This type of 
anergy is induced by high concentrations of antigenic peptide [117,133,134] and 
appears distinct from the types described above. Differences are: 1) the presence 
of costimulation does not inhibit the induction of anergy [126,135-137] and 2) the 
calcium/calcineurin pathway is blocked rather than the ras/MAP kinase pathway 
[120]. Recently, Kaufman et al. [138] suggested that, following stimulation, the 
net phosphorylation activity of receptor-associated tyrosine kinases will remain 
above background level after removal of the antigen. They propose that this 
residual tyrosine kinase activity is linked to a deficient signal transduction capacity 
of the TCR system to intracellular signaling events.
Recently, Andris et al. [139] described costimulation independent induction of 
anergy with mitogenic anti-CD3 MAb in naive mouse CD4+ cells. These cells had 
become unresponsive for a subsequent stimulation with anti-CD3 due to a 
defective Ca2+ mobilization suggesting a similar mechanism as for the peptide 
induced anergy described above.
One may argue that anti-clonotype MAb may induce anergy in a clonotype specific 
manner. Different mechanisms for such anti-clonotype induced anergy can be 
anticipated. Such MAb may desensitize the TCR like anti-CD3, may partially 
activate the TCR like an altered peptide ligand, may trigger the TCR in the 
absence of costimulation or may mimic MHC/peptide complexes in peptide 
induced anergy.
Scope of this thesis
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The final aim of the research described in this thesis was to generate MAb to the 
clonotype of a human auto-reactive T-cell clone and to investigate whether these 
MAb would be able to modulate the functional properties of this T-cell clone.
Thus far the generation of MAb is hampered by the low immortalization 
frequencies of B cells; approximately 1 : 2x105 for PEG fusion and approximately 
1 : 2000 for electrofusion. Furthermore, a procedure which involves screening of 
randomly fused B cells for the secretion of desired antibodies is rather inefficient 
and requires large amounts of purified antigen. Despite these obstacles, successful 
generation of MAb to a great variety of antigens has shown that this does not need 
to be a problem for the generation of MAb to strong immunogens. However the 
generation of MAb to less immunogenic determinants (e.g. the clonotypic 
determinants of human T-cell receptors) has been very difficult or not possible at 
all. This especially holds true in cases where no purified antigen is available for 
immunization and screening of hybridomas.
To cope with this, a very efficient method for the generation of both human and 
murine MAb has been developed employing a combination of clonal expansion of 
B cells and mini-electrofusion (chapter 2).
In chapter 3, it was investigated if the high efficiency of the B-cell culture/mini­
electrofusion approach described in chapter 2 could be used for the generation of 
MAb from a small number of preselected B cells. Thus large numbers of B cells 
could be submitted to the procedure for the generation of MAb without laborious 
screening procedures.
The B-cell culture/mini-electrofusion approach permits the processing of small 
numbers of B cells and more hybridomas can be generated from one B cell. These 
properties make it particularly useful in the generation of human MAb (chapter 4) 
where limited amounts of donor lymphocytes are available and many hybridomas 
are unstable.
In chapter 5, a method is described for selection of clonotype specific B cells from 
mice immunized with intact T cells. The high potential of the B-cell culture/mini­
electrofusion approach was used for the immortalization of these B cells. 
Furthermore, a fast and sensitive one-step agglutination assay was developed using 
intact T cells for screening of anti-clonotype specific MAb. It was demonstrated 
that the anti-clonotype MAb are able to block antigen-induced T-cell proliferation. 
Further, the MAb can trigger the T cell by its receptor and induce 
unresponsiveness to a subsequent challenge with peptide and APC (chapter 6).
20
These findings may be the basis for the development of a clonotype specific
immunotherapy in T-cell mediated diseases.
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Abstract
A new and very efficient method for the generation of human and murine 
monoclonal antibodies has been developed. The method is based on clonal 
expansion of single B cells in the presence of human T-cell supernatant and 
irradiated murine thymoma helper cells. Subsequently, the clonally expanded B 
cells are immortalized by electric field mediated cell fusion.
The high efficiency of the method allows handling of small numbers of 
lymphocytes e.g. obtained by preselection of specific B cells, small amounts of 
human donor material and murine PBL or lymph node cells. The method may be 
an alternative for the EBV-transformation technique used for the generation of 
human monoclonal antibodies, which immortalizes only a subset of B cells and 
frequently yields poorly growing or unstable cell lines.
This report describes the generation of murine anti-HIV and human anti-rubella 
antibodies combining the clonal expansion of B cells and mini-electrofusion.
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Introduction
Since the introduction of the monoclonal antibody technique by Kohler and 
Milstein (1975) numerous murine monoclonal antibodies (MAb) have been 
developed routinely. However, with average fusion frequencies of 1 out of 2x105, 
the original PEG-fusion technique appeared to be rather inefficient. Therefore, the 
lymphocyte source has been mainly restricted to spleen cells because the low 
numbers of lymphocytes obtained from e.g. peripheral blood lymphocytes (PBL) 
or lymph nodes cannot be handled successfully.
In addition to murine MAb, many investigators have shown an interest in the 
development of human MAb for several reasons. In therapeutic regimes, murine 
MAb have been harmful to patients due to an anti-mouse response (Shawler et al., 
1985; Steis et al., 1990). Human monoclonals are likely to exhibit reduced 
immunogenicity in humans. Furthermore, the human genome represents another 
repertoire of antibodies which may consequently result in monoclonals with other 
specificities. Last but not least, some individuals produce antibodies of interesting 
specificity e.g. immunoinfertile donors, donors with auto-immune diseases and 
donors with anti-tumor antibodies.
A large number of different methods concerning the development of human MAb 
have been reported and are extensively reviewed by James and Bell (1987). These 
methods are mainly based on fusion of lymphocytes with myeloma cells of murine, 
human and murine x human origin or on viral transformation of B cells with 
Epstein-Barr virus (EBV). More recently, methods based on recombinant DNA 
techniques have been reported (Skerra and Pluckthun, 1988; Huse et al., 1989; 
Ward et al., 1989; McCafferty et al., 1990).
Unfortunately, the generation of human MAb is not yet as routine as the generation 
of murine MAb and many technical problems still remain to be solved. A major 
obstacle here is that human immunization is generally not possible for ethical 
reasons. As a consequence only "naturally" occurring human antibodies can be 
developed from human lymphocytes. Moreover, the number of antigen-specific B 
lymphocytes in peripheral blood or lymphoid tissues is usually very low. In vitro 
immunization experiments as reported recently (Borrebaeck et al., 1988; 
Borrebaeck, 1989; Ohlin et al., 1989) may be a solution for the immunization 
problem but the rarity of antigen-specific B cells will still be a problem.
Apart from the lymphocyte source, the development of human MAb producing 
hybridomas is hampered by the low fusion frequency inherent to the PEG-fusion 
technique and the absence of an ideal fusion partner.
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In contradistinction to the low immortalization frequencies in standard PEG-fusion 
techniques, human B lymphocytes are very efficiently immortalized by Epstein- 
Barr virus. In this system, however, immortalization is restricted to a subset of B 
cells and resulting MAb are predominantly of the IgM class. Moreover, the major 
part of EBV-transformants grow poorly and should be subsequently fused with 
myeloma cells in order to obtain stable MAb-producing cell lines.
Thus, there is a need for improved fusion techniques enabling the efficient 
generation of hybridomas. We present here a novel technology combining the 
clonal expansion of murine or human B cells in the presence of human T-cell 
supernatant and irradiated EL-4 helper cells (Wen et al., 1987; Zubler et al., 1987; 
Straub and Zubler, 1989; Zhang et al., 1990), and mini-electrofusion of the 
expanded B cells.
Materials and methods
Reagents
Culture medium DMEM/HAM's F12 was prepared by mixing equal amounts of 
Dulbecco's Modified Eagle Medium (DMEM, Gibco 074-2100) and Nutrient 
mixture F12 (HAM's F12, Gibco 074-1700) and supplementing this mixture with 
2500 mg/l sodium bicarbonate (Baker), 55 mg/l sodium pyruvate (Fluka), 2.3 mg/l 
2-mercaptoethanol (Baker), 1.22 mg/l ethanolamine (Baker), 360 mg/l L-glutamine 
(Merck), 4.5 x 10-4 mg/l sodium selenite (Fluka), 62.5 mg/l sodium penicillin 
(Mycopharm) and 62.5 mg/l streptomycin sulfate (Serva). In fusion experiments, 
the medium was further supplemented with 13.61 mg/l hypoxanthine (Fluka) and 
3.83 mg/l thymidine (Fluka). This medium is referred to as DMEM/HAM's 
F12/HT.
Selection of hybridomas was performed in DMEM/HAM's F12/HT supplemented 
with 1% (v/v) of IL-6 containing supernatant of a human bladder carcinoma cell 
line T24 (T24CM) and 0.4 ^M aminopterin (Flow).
Fusion medium: 280 mM inositol (ICN), 0.1 mM calcium acetate (Baker), 0.5 mM 
magnesium acetate (Baker) and 1 mM histidine (Fluka); specific resistance: 
1.11x104 Wcm. Ingredients were dissolved in Milli-Q water and subsequently the 
conductivity was adjusted to 90 ^S/cm with Milli-Q water or a solution containing 
1 mM calcium acetate and 5 mM magnesium acetate.
Pronase solution was prepared by dissolving 0.5 mg/ml pronase (Calbiochem) in 
DMEM/HAM's F12.
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Percoll density gradient medium (Pharmacia) was made iso-osmotic by the 
addition of one part of 1.5 M NaCl to nine parts of Percoll (100% SIP). This stock 
iso-osmotic Percoll solution was adjusted to lower densities by diluting with 
culture medium.
Cell cultures
Mutant EL-4 thymoma cells, EL-4 B5 (a kindly gift from Dr. R. Zubler, Geneva, 
Switzerland) were routinely cultured in DMEM/HAM's F12 supplemented with 
10% FCS (Bocknek) between cell concentrations of 104 to 106 c/ml as determined 
in a Fuchs-Rosenthal haemocytometer. If cells overgrow 106 c/ml, they may lose 
their B cell stimulating activity.
Murine myeloma cells NS-1 (Köhler et al., 1976), or xenohybrids K6H6B5 (Caroll 
et al., 1986) and PAI-1 were used as fusion partners for murine and human B cells 
respectively. Cells were routinely cultured in DMEM/HAM's F12/HT 
supplemented with 10% FCS in concentrations between 5x104 and 15x105 cells per 
ml. One day before fusion, cultures were split 1:3 to create a log-phase culture at 
the day of fusion.
Preparation of murine spleen cells
After final immunization, the mice were killed and their spleens removed. Cells 
were teased into DMEM/HAM's F12 and clumps disrupted by gentle aspiration 
through a 16 gauge needle. Cell suspensions were centrifuged for 10 min at 2000 
N/kg and the pellets were resuspended in a solution containing 0.16 M NH4Q  and 
0.01 M KHCO3 to lyse the erythrocytes. Cell suspensions were centrifuged again 
and finally resuspended in culture medium.
Isolation of peripheral blood cells
Human leucocytes were isolated by bulging out the erythrocytes in an isotonic 
dextran solution as described by Van Meel (1985). Subsequently the leucocytes 
were suspended in DMEM/HAM's F12 supplemented with 10% FCS and 
incubated for 1 h at 37°C in polystyrene culture flasks to remove monocytes. Then, 
T cells were depleted by two subsequent incubations with paramagnetic 
polystyrene beads coated with anti-CD2 monoclonal antibody (Dynal 111.01). For 
a complete depletion of CD2 positive cells, washed immunobeads and monocyte 
depleted PBL were mixed at a ratio of 40:1. The mixture of beads and cells was 
incubated for 30 min at 2-4°C with gentle mixing every 10 min. Subsequently, 
rosetted cells were isolated by holding a magnetic device against the wall of the 
test tube and removing the supernatant.
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For the isolation of murine PBL, 100 ^l blood were collected by orbital punction 
and immediately thereafter diluted with 100 ^l phosphate-buffered saline (PBS) 
containing 30 IU/ml lithium heparin. Subsequently, the diluted blood was carefully 
layered on 700 ^l Lymphopaque (Nyegaard) in a small capillary. Then, the 
capillary was centrifuged for 30 min at 4000 N/kg and subsequently the interphase 
layer was collected. Finally, platelets were removed by washing the cells twice 
with culture medium.
Preparation of human T-cell/macrophage supernatant (TSN)
Freshly isolated mononuclear cells were centrifuged for 10 min at 2000 N/kg. 
Subsequently, B and T cells were separated according to a modification of the 
method described by Gutierrez et al. (1979). The pellet was resuspended in 5 ml 
100% SIP. Then, a 10 ml layer of 70% SIP followed by a 25 ml layer of 50% SIP 
were layered onto the 100% SIP. The gradient was centrifuged for 10 min at 
25,000 N/kg. The enriched T-cell fraction remaining at the interface between 70% 
and 50% SIP was collected and washed twice with DMEM/HAM's F12 
supplemented with 10% FCS. Washed cells were stimulated for 40-45 h in 
DMEM/HAM's F12 supplemented with 10% FCS, 5 ^g/ml PHA (Wellcome) and
10 ng/ml PMA (Sigma). Finally, supernatant was harvested, filtered through a 0.2 
^m membrane filter and stored in aliquots at -70°C.
EL-4/B-cell cultures
EL-4/B-cell cultures were prepared as described by Zubler et al. (Straub and 
Zubler, 1989; Wen et al., 1989; Zubler et al., 1989; Zhang et al., 1990). Briefly, 
crude or purified B cells were mixed with TSN and 50,000 irradiated (2500 rad) 
EL-4 B5 cells in a final volume of 200 ^l DMEM/HAM's F12 supplemented with 
10% FCS in 96-well flat bottomed tissue culture plates. The optimal amount of 
TSN was established for each batch by titration. Usually 10% TSN was sufficient 
for optimal stimulation of human B cells whereas 20% TSN was usually required 
for murine B cells.
The cultures were incubated at 37°C, with 5% CO2 and 100% humidity. Between 
day 8 and day 12, supernatants were tested for immunoglobulin production.
Mini-electrofusion
The contents of individual EL-4/B-cell cultures were mixed with 106 myeloma 
cells in 2-ml centrifuge tubes. The cells were rendered serum-free by washing once 
with DMEM/HAM's F12/HT. Then, the cell suspension was centrifuged and the
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pellet was resuspended in 1 ml DMEM/HAM's F12/HT at 37°C and 130 ^l 
pronase solution was added. The cell suspension was incubated for 3 min with 
pronase and then the enzyme reaction was stopped by addition of 200 ^l FCS. 
Subsequently, the cells were washed once with fusion medium and resuspended in 
a final volume of 50 ^l fusion medium at room temperature. The complete cell 
suspension was pipetted into the internal space of a fusion chamber. This chamber 
consists of two stainless steel, disc-shaped electrodes embedded in a perspex box. 
The electrodes are separated by a teflon spacer of varying diameter and 0.50 mm 
thickness. Alignment of cells in the fusion chamber was induced by an alternating 
electric field of 2 MHz and 400 V/cm for 30 s. Then, immediately a square, high 
field pulse of 3 kV/cm and 10 ^s duration was applied causing cell membrane 
breakdown. The alternating field was applied again for 30 s in order to allow 
intermingling of cells and resealing of membranes. Finally, the contents of the 
fusion chamber were transferred to 20 ml selection medium and plated into a 96- 
well microculture plate.
At day 14, the cultures were examined for hybridoma growth and the supernatants 
were tested for immunoglobulin production.
Enzyme immunoassays
Measurement of human Ig was performed by a standard sandwich ELISA using 
goat anti-human Ig coated plates and HRP-labeled goat anti-human Ig second 
antibody. Murine Ig was measured with a similar ELISA employing sheep anti­
mouse antibodies. Human IgG and normal mouse serum (Sigma I-4506 and 
M5905) served as positive controls for assessment of assay sensitivity and culture 
medium served as negative control.
For the detection of murine anti-HIV antibodies, plates coated with HIV viral 
lysate were used in combination with HRP-labeled sheep anti-mouse Ig. Human 
anti-rubella antibodies were detected in a double sandwich ELISA with goat anti­
human Ig as the capture antibody and rubella antigen bound to murine monoclonal 
anti-rubella-HRP.
Table I: Outgrowth of murine B cells in the EL-4 B-cell culture system
Cell type Number of Number of Number of Ig-
isolated wells seeded cells per well positive wells
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Spleen 48
48
232
136
144
48
50
50
10
10
2
2
48
45
217
78
74
8
PBL
Spleen
PBL
Spleen
PBL
Murine spleen cells or peripheral blood lymphocytes were inoculated in 96-well 
culture plates in the presence of 50,000 irradiated EL-4 B5 helper cells and 20% 
human T-cell supernatant. Culture supernatants were tested for murine Ig from 
day 8 to 11.
Results
Immortalization of murine B cells
In two independent experiments, B-cell cultures were inoculated with murine 
spleen cells or peripheral blood mononuclear cells at seeding densities of 50, 10 or
2 cells per well. Supernatants of the cultures were tested (day 8-11) for the 
presence of murine Ig, indicating outgrowth of murine B cells. Table I shows that 
outgrowth of B cells had been achieved in approximately 50% of cultures 
inoculated with 2 spleen cells and in approximately 20% of cultures inoculated 
with 2 peripheral blood mononuclear cells.
Twelve individual cultures were submitted to mini-electrofusions with NS-1 
myeloma cells in order to investigate whether it would be possible to generate 
antibody-producing hybridomas from just a small number of B cells present in B- 
cell cultures. Table II shows, that a large number of antibody producing 
hybridomas were generated in 11 out of 12 fusion experiments.
We further investigated whether it would be possible to develop antigen specific 
hybridomas. Therefore, spleen cells and peripheral blood mononuclear cells were 
isolated from mice immunized with HIV viral lysate. At day 9, the cultures were 
examined for cell growth and the supernatants were assayed for murine 
immunoglobulin and murine anti-HIV by ELISA. Table III shows that outgrowth 
of Ig-producing B cells occurred in 52% of cultures inoculated with 2 spleen cells 
and in 35% of cultures inoculated with 4 peripheral blood cells. No anti-HIV
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Table II: Mini-electrofusions of B-cell cultures
Fusion
no.
Origin of 
B-cell culture
Number of 
wells plated 
in fusion
Number of wells 
with hybridoma 
growth
Number of 
Ig-positive 
wells
1 50 spleen cells 48 48 48
2 50 spleen cells 48 48 48
3 50 PBL 48 47 46
4 50 PBL 48 43 42
5 10 spleen cells 48 40 37
6 10 spleen cells 48 47 47
7 10 spleen cells 96 96 96
8 10 PBL 48 48 48
9 10 PBL 48 3 2
10 2 spleen cells 96 94 92
11 2 spleen cells 96 78 78
12 2 spleen cells 96 96 96
Murine B-cell cultures from the experiment described in Table I  were mixed with 
106 NS-1 myeloma cells. Cells were pronase-treated and finally suspended in 
fusion medium. After fusion, cells were seeded in 96-well culture plates in 
selection medium. Nine days after fusion, cultures were examined for hybridoma 
growth and supernatants were tested for murine Ig.
Table III: Outgrowth of anti-HIV specific murine B cells in EL-4 B-cell cultures
Cell type 
isolated
Number of 
wells seeded
Number of 
cells per well
Number of 
Ig-positive wells
Number of 
anti-HIV positive 
wells
Spleen 190 10 n.t. 3
Spleen 190 2 99 0
PBL 190 20 n.t. 4
PBL 190 4 66 0
n.t. = not tested
Murine spleen cells or peripheral blood lymphocytes were inoculated in 96-well 
culture plates in the presence o f50,000 irradiated (2500 rad) EL-4 B5 helper cells 
and 20% human T-cell supernatant. At day 9, culture supernatants were tested for 
murine Ig or murine anti-HIV antibodies.
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Table IV: Mini-electrofusion of individual anti-HIV positive B-cell cultures
Fusion
no.
Number of 
wells seeded
Number of wells 
with hybridoma 
growth
Number of 
Ig-positive 
wells
Number of 
anti-HIV 
positive wells
1 96 96 96 1
2 96 72 65 7
3 96 96 96 3
4 96 42 40 7
5 96 30 n.t 0
6 96 11 11 0
7 96 6 2 2
n.t. = not tested
Murine B-cell cultures from the experiment described in Table III were mixed with 
106 NS-1 myeloma cells. Cells were pronase-treated and finally resuspended in 
fusion medium. After fusion, cells were seeded in 96-well culture plates in 
selection medium. Thirteen days after fusion, cultures were examined for 
hybridoma growth and supernatants were tested for murine Ig and murine anti­
HIV.
positive cultures were found, although in cultures inoculated at higher seeding 
densities, 3 and 4 anti-HIV producing B-cell clones were found in spleen and PBL 
cultures, respectively. All anti-HIV producing cultures were individually submitted 
to mini-electrofusions with NS-1 myeloma cells in order to convert the anti-HIV 
B-cell clones into continuous growing hybridoma cell lines. In five out of seven 
mini-electrofusions at least one antigen-specific hybridoma was generated (Table 
IV).
B-cell clones in cultures inoculated with 2 spleen cells or 4 PBL were expected to 
originate from single B cells. Therefore, two additional mini-electrofusions were 
performed with these cultures to investigate whether it would be possible to 
develop antibody-producing hybridomas from B-cell cultures inoculated with 
single B cells. These fusions resulted in 45 and 75 Ig-producing hybridomas, 
respectively (results not shown).
Immortalization of human B cells
From a donor who had previously suffered a rubella infection, human leucocytes 
were isolated as described in the 'Materials and methods' section. FACS-analysis
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Table V: Outgrowth of human anti-rubella B cells in EL-4 B-cell cultures
Exp. no. Number of 
B cells 
per well
Number of 
wells seeded
Number of Ig 
positive wells
Number of 
anti-rubella 
positive wells
I 90 87 87 3
25 190 190 4
5 190 146 1
1 190 82 0
II 25 508 n.d. 8
2.5 410 361 2
n.d. = not determined
Monocyte and T-cell depleted human leucocytes were inoculated in 96-well 
culture plates in the presence o f50,000 irradiated (2500 rad) EL-4 B5 helper cells 
and 20% human T-cell supernatant. At day 8, culture supernatants were tested for 
human Ig and human anti-rubella antibodies.
Table VI: Mini-electrofusion of individual human B-cell cultures
Fusion
no.
Fusion
partner
Number 
of wells 
seeded
Number of 
wells with 
hybridoma 
growth
Number of 
Ig-positive 
wells
Number of 
anti-rubella 
positive 
wells
1 K6H6B5 96 95 2 0
2 K6H6B5 96 80 1 0
3 K6H6B5 96 75 7 0
4 K6H6B5 96 n.d. 1 0
5 K6H6B5 96 24 0 0
6 PAI-1 96 87 3 0
7 PAI-1 96 n.d. 6 1
8 PAI-1 96 33 0 0
n.d. = not determined
Human B-cell cultures from experiment I  in Table V were mixed with 106 K6H6B5 
or 106 PAI-1 myeloma cells. Cells were pronase-treated and finally resuspended in 
fusion medium. After fusion, cells were seeded in 96-well culture plates in 
selection medium. Fifteen days after fusion, cultures were examined for hybridoma 
growth and supernatants were tested for human Ig and anti-rubella antibodies.
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showed that the final preparation contained approximately 11% B cells, 4% 
monocytes and 1% T cells as determined by staining with anti-CD 19 PE, anti- 
CD14 FITC and anti-CD3 FITC respectively (Becton Dickinson cat. no. 91-0011, 
7493 and 92-0011 respectively). From the scatter pattern it could be deduced that 
the major part of the other cells are probably granulocytes. This cell population 
was used to inoculate B-cell cultures. Cultures were initiated with 850, 250, 50 and 
10 cells per well representing 90, 25, 5 and 1 B cell per well, respectively. Eight 
days after inoculation, human Ig was measured in 43% of cultures, inoculated with 
1 B cell. No anti-rubella positive clones were detected in these cultures but eight 
anti-rubella positive clones were found in cultures inoculated with more B cells 
(Table V, exp. no. I). These cultures were submitted separately to mini­
electrofusions with K6H6B5 or PAI-1 myeloma cells (Table VI). In all fusion 
experiments a large number of hybridomas was generated. However, only a small 
number of these hybridomas produced immunoglobulin. Initially, in two fusions, 
anti-rubella positive hybridomas could be detected. One of these hybridomas was 
successfully scaled up and cloned to a stable anti-rubella IgG producing cell line. 
The others were probably overgrown by non-producing hybridomas.
In a repetition of the experiment described above, EL-4 B-cell cultures were 
initiated with 250 and 25 cells per well by limiting dilution representing 25 and 2.5 
B cells per well, respectively. Table V shows that B cells had grown out in the 
majority of the cultures inoculated with 2.5 B cells per well. Eight anti-rubella 
positive cultures were found in cultures with 25 B cells and two in cultures 
inoculated with 2.5 B cells. Mini-electrofusions of these B-cell cultures with 
K6H6B5 or PAI-1 myeloma cells again resulted in a large number of hybridomas. 
In one fusion with K6H6B5 cells, two anti-rubella IgM hybridomas were found 
which were successfully scaled up and cloned.
Discussion
This report describes a new method for the generation of MAb. The method 
involves clonal outgrowth of individual B cells followed by a mini-electrofusion of 
clonally expanded B cells.
Limiting dilution experiments have shown a very efficient outgrowth of murine B 
cells originating from spleen and peripheral blood in cultures with EL-4 B5 helper 
cells and human T-cell supernatant. Murine Ig production was found in 40-60% of 
cultures inoculated with as little as 2 cells from a crude spleen cell population.
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About a two-fold lower amount of Ig producing cultures was found among cultures 
inoculated with murine PBL which is in agreement with the lower percentage of B 
cells in peripheral blood. Mini-electrofusions of such B-cell cultures, which were 
expected to originate from one B cell, always yielded a large number of antibody 
producing hybridomas.
The method has been applied successfully to the generation of murine anti-HIV 
producing hybridomas. Murine anti-HIV producing B cells were expanded in 
cultures inoculated with 10 spleen cells or 20 PBL. Five out of seven anti-HIV 
producing cultures could be converted into anti-HIV producing hybridomas. The 
two failures may have been due to the presence of a majority of non-specific B 
cells in the oligoclonally expanded B-cell cultures. Unfortunately, no anti-HIV 
producing clones were obtained from clonally expanded B-cell cultures inoculated 
with two spleen cells or four PBL. The latter may have been due to the low 
number of antigen-specific B cells in the crude cell population used in relation to 
the number of wells seeded. It also stresses that the potential of the method can 
only be fully exploited when combined with preselection of antigen-specific B 
cells e.g. by antigen-coated paramagnetic immunobeads (Ossendorp et al., 1989), 
FACS or panning. In addition to its high efficiency, the possibility using small 
numbers of lymphocytes from murine PBL or lymph nodes may give this method a 
particular advantage in the development of murine MAb. Fusion of lymph node 
cells may result in a higher number of sensitized specific B cells and a greater 
spectrum of antibody specificities as was previously shown by Mirza et al. (1987). 
Fusion of PBL obtained from retro-orbital bleeds permits monitoring of the 
immune response for a longer period of time in the same animal at the monoclonal 
level.
As the B-cell culture system can also be used for the expansion of human B cells 
(Wen et al., 1987; Zubler et al., 1987; Straub and Zubler, 1989; Zhang et al., 
1990), we investigated whether this novel method could also be applied to the 
development of human MAb. It appeared that the outgrowth of B cells was again 
very efficient. Mini-electrofusion of individual B-cell cultures resulted in a large 
number of hybridomas, but unfortunately only a small proportion were Ig 
producers. One might argue, that this is due to the instability of hybridomas 
formed from human B cells and the xenohybrid fusion partners (K6H6B5 and PAI-
1). However, there are several indications, that this is not the case. Other 
experiments in our laboratory have shown that the majority of hybridomas from 
EBV-transformed B cells and the xenohybrids were stable antibody producers for
43
more than three months. Furthermore, microscopic examination of B-cell cultures 
inoculated with 10 cells per well of a cell population containing approximately 
11% B cells revealed that cell growth in these wells was not very well correlated 
with Ig production. In some cultures, many cells had grown out and no Ig 
production was detected whereas in other cultures hardly any cells were visible 
between the EL-4 B5 helper cells and a significant amount of Ig was measured. 
Apparently the size of B-cell clones was small and other cells grew in the B-cell 
culture system e.g. NK cells and residual T cells. This may be an explanation for 
large number of non-producing hybridomas (hybridomas from cells other than B 
cells).
Notwithstanding the lower immortalization efficiency of the new method for 
human B cells as compared to murine B cells, two different human anti-rubella 
producing hybridomas from as little as 18 antigen-specific B-cell clones were 
generated. We are now optimizing the B-cell culture system in order to enlarge the 
clone size to a level that would guarantee at least a small number of antigen- 
specific hybridomas from mini-electrofusions.
The method described here may represent an attractive alternative for the 
generation of human MAb. Its high efficiency makes the method superior with 
respect to classical hybridoma technology and permits the use of the small 
numbers of lymphocytes available from human donors. It may also be possible to 
handle small numbers of specific lymphocytes left over from positive selection 
procedures, thereby avoiding laborious screening of negative hybridomas. 
Furthermore, immortalization of B cells by this method may not be restricted to a 
subset of B cells and therefore can result in more IgG producing cell lines than the 
EBV-transformation technique.
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Abstract
This paper reports the generation of monoclonal antibody producing hybridomas 
from a small number of antigen-specific B cells selected by panning on antigen- 
coated dishes and rosetting with antigen-coupled paramagnetic beads. Anti-HIV 
positive B cells from spleen could be recovered by panning with an efficiency of 
5% and a purity of 24%. Immunobead selection of anti-HIV positive B cells from 
the same mice yielded a recovery of 17% and a purity of 7%. Various experimental 
conditions with respect to the selection of specific B cells were investigated, 
leading to an optimized protocol for the isolation of a limited subset of B cells.
The selected cells retained their property to produce immunoglobulins and could 
be clonally expanded in the presence of human T-cell supernatant and irradiated 
murine thymoma helper cells to generate sufficient cells for a mini-electrofusion 
with NS-1 myeloma cells. Up to 78 specific hybridomas could be generated from 
one anti-HIV positive B cell.
An overall efficiency of specific B-cell immortalization of up to 10% was 
obtained.
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Introduction
A random fusion of lymphocytes with myeloma cells yields an excess of irrelevant 
hybridomas and as a consequence laborious screening of large numbers of culture 
supernatants is required to select a few valuable clones. Preselection of antigen- 
specific B cells may circumvent this problem. However, the immortalization 
techniques currently used are not appropriate to process the relatively small 
number of preselected cells. The PEG-fusion technique originally described by 
Köhler and Milstein (1975) has an average fusion efficiency of 5x10-6 whereas by 
electrofusion an improved fusion frequency of 4x10-4 has been reported 
(Zimmermann and Vienken, 1982; Stenger et al., 1988; Schmitt et al., 1989; Van 
Duyn et al., 1989; Zimmermann et al., 1992).
Recently, we described a new approach to generate human and murine monoclonal 
antibodies (Steenbakkers et al., 1992). This approach involves clonal expansion of 
single B cells in the presence of human T-cell supernatant and irradiated murine 
thymoma helper cells. The clonally expanded B cells are subsequently 
immortalized by electrofusion. Approximately 50% of B cells from murine PBL or 
spleen could be converted into antibody producing hybridomas. However, the 
potential of this method can only be fully exploited in combination with 
techniques for selection of antigen-specific B cells prior to clonal expansion.
B cells may be identified on the basis of their surface antigen-receptor phenotype. 
Binding of B cells via this receptor to anti-Ig or hapten immobilized on 
polystyrene dishes (panning), has been used for the isolation of bulk B cells 
(Wysocki and Sato, 1978) and hapten-specific B cells (Alderson et al., 1987). 
More recently, paramagnetic beads coupled with antibodies against cell surface 
molecules have been used for the selection of B cells, T cells and NK cells 
(Kvalheim et al., 1987; Vartdal et al., 1987; Naume et al., 1991). Also, antigen- 
coated beads have been used for the selection of antigen-specific hybridoma cells 
from bulk cultures shortly after fusion (Horton et al., 1989; Ossendorp et al., 
1989).
This article reports on the selection of antigen-specific B cells by panning on 
antigen-coated dishes and by rosetting with antigen-coupled paramagnetic beads. 
In particular we have addressed the question of whether selected B cells could be 
used for clonal expansion and subsequent generation of hybridomas by mini­
electrofusion.
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Materials and methods
The origin of the cell lines used, culture media, reagents and the preparation of T- 
cell/macrophage supernatant (TSN) have recently been described by Steenbakkers 
et al. (1992).
Immunizations and isolation of erythrocyte and monocyte depleted spleen cells 
Six-week-old female BALB/c mice were injected intraperitoneally with 10 ^g HIV 
viral lysate or recombinant BGAL in complete Freund's adjuvant. Two subsequent 
intramuscular injections were given at three weeks intervals with 10 ^g antigen in 
incomplete Freund's adjuvant. Three weeks after the third injection, the mice were 
boosted intraperitoneally with 50 ^g antigen in PBS. Four days after this final 
boost, erythrocyte depleted spleen cells were prepared as described by 
Steenbakkers et al. (1992). Cells were frozen in liquid nitrogen and stored until 
use. In a typical selection experiment, thawed cells were incubated for at least 1 h 
in polystyrene flasks in order to adsorb monocytes. The non-adherent cells were 
used for panning or immunobead selection.
Panning procedure
Six-well culture plates were coated overnight with 4 ml per well of a solution 
containing 2 ^g/ml antigen in 0.05 M sodium carbonate buffer pH 9.6. The wells 
were washed with PBS and directly used for panning experiments. Panning was 
performed by incubating monocyte depleted murine spleen cells (1 - 6x106 cells in 
4 ml) on antigen coated wells for 2 h at 37°C, 5% CO2 and 100% humidity. After 
this incubation, the unattached cells were removed gently by three washes with 
PBS. The remaining B cells were recovered by incubating with 250 ^l PBS 
containing 1.1 mM Na2EDTA and 0.05% trypsin pH 7.5 for 2 min. Trypsin 
treatment was stopped by the addition of 5 ml DMEM/HAM's F12 supplemented 
with 10% FCS. To remove residual attached B cells, the wells were flushed with 
the medium using a Pasteur pipette. Different dilutions of selected cells were used 
to generate B-cell cultures (limiting dilution).
Immunobead selection procedure
Tosylactivated paramagnetic beads (Dynal cat.no. 140.03) were coupled with 
antigen according to the method described by the manufacturer.
Antigen-coated beads and cells were incubated in culture medium (5 - 20x105 
cells/ml) for 1 h at 4°C with occasionally gentle shaking. Alternatively, the 
suspension of beads and cells were centrifuged for 10 min at 2000 N/kg. The 
majority of the supernatant was removed leaving some liquid above the pellet
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(total volume of beads, cells and supernatant approximately 50 ^l). The contents of 
the test tube were then resuspended and incubated for 30 min at 4°C. In both 
protocols, unbound cells were removed gently by three washes with PBS. Beads 
and rosetted cells were plated in a B-cell culture system at different dilutions.
B-cell culture system
B-cell cultures were prepared as described by Zubler et al. (Straub and Zubler, 
1989; Wen et al., 1989; Zubler et al., 1989; Zhang et al., 1990). Briefly, crude or 
selected B cells were mixed with TSN and 50,000 irradiated (2500 rad) EL-4 B5 
cells in a final volume of 200 ^l DMEM/HAM's F12 supplemented with 10% FCS 
in 96-well flat bottomed tissue culture plates. Between day 8 and day 12, 
supernatants were tested for anti-HIV or anti-ßGAL and for total immunoglobulin 
production as described by Steenbakkers et al. (1992).
The recovery of specific B cells was defined as the total number of antigen- 
specific B cells (in the various dilutions of the same cell population) divided by the 
total number of specific B cells in the pool of lymphocytes submitted to the 
selection procedure.
The purity of the B-cell populations was defined as the total number of specific B 
cells in the various dilutions divided by the total number of Ig-producing B cells. 
In cases where more than 60% of the wells were positive the number of specific B 
cells or Ig-producing B cells was calculated from the number of positives in the 
subsequent dilution step.
Mini-electrofusion
Mini-electrofusions were performed as described by Steenbakkers et al. (1992). 
Briefly, the contents of individual B-cell cultures were mixed with 106 NS-1 
myeloma cells (Köhler et al. 1976) and rendered serum-free by washing with 
DMEM/HAM's F12/HT. Then, the cells were treated with pronase solution for 3 
min and subsequently washed with fusion medium. Electrofusion was performed 
in a 50 ^l fusion chamber by an alternating electric field of 30 s, 2 MHz, 400 V/cm 
followed by a square, high field pulse of 10 ^s, 3 kV/cm and again an alternating 
electric field of 30 s, 2 MHz, 400 V/cm. Finally, the contents of the fusion 
chamber were transferred to 20 ml selection medium and plated into a 96-well 
microculture plate. On day 14, the cultures were examined for hybridoma growth 
and the supernatants tested for anti-HIV and total immunoglobulin production as 
described previously.
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Results
Panning
Erythrocyte and monocyte depleted spleen cells from mice immunized with HIV 
viral lysate were submitted to a panning procedure on a HIV viral lysate coated 
culture dish. The selected B cells were plated at various dilutions to allow clonal 
expansion and testing of antibody specificity. The results presented in Table I 
show that an enriched population of anti-HIV specific B cells was obtained after 
panning. Approximately 24% of the selected B cells were specific for the antigen 
(defined as purity). Before selection 0.15% of the B cells were found to be specific 
for HIV. This figure, however, is only based on one antigen-specific B-cell clone. 
A better estimate of the number of anti-HIV specific B cells before selection can 
be deduced from the unbound cell population. In this population, 7 anti-HIV 
specific B cells were found in 285 cultures inoculated with 50 cells/well (14,250 
cells). With a plating efficiency of 11% (21 Ig-positive B-cell cultures from 190 
spleen cells) it can be calculated that this cell population contains approximately 
0.44% anti-HIV specific B cells. Since only a minor part of the specific B cells 
were selected, the purity of the unselected cell population can only be slightly 
higher. For this reason, the number of antigen-specific B cells prior to panning was 
also assumed to be 0.44%. Thus, starting panning with 1.7x106 cells and taking 
into account a plating efficiency of 11%, at least 823 cells should be antigen 
specific. From these, 41 (5%) were recovered after panning.
Immunobeads
Antigen-coupled paramagnetic beads were investigated as an alternative for 
selection by panning. An advantage of this procedure is that rosettes formed 
between antigen-coupled beads and specific B cells can be used directly for clonal 
expansion of B cells without prior trypsinization. Several conditions for the 
incubation of beads and cells were studied in order to improve recovery and purity 
of selected B cells i.e. bead to cell ratio, incubation volume and addition of 
uncoated beads during the wash steps.
Bead to cell ratio. Lymphocytes from mice immunized with BGAL were 
submitted to a selection procedure with BGAL-coupled paramagnetic beads using 
two different bead to cell ratios. After incubation and removal of unbound cells, 
beads containing the selected cells were collected in culture medium and plated in 
a B-cell culture system at various dilutions. On day 11, culture supernatants were 
tested for total immunoglobulin and anti-BGAL. An example of such an 
experiment is shown in Table II. With an increased bead to cell ratio, a larger
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Table I: Panning of anti-HIV specific B cells
Cell population Number of 
wells 
inoculated
Number of 
cells per 
well
Number of Ig- 
positive wells
Number of 
anti-HIV pos. 
wells
Recovery Purity
Unselected cells 95 50 95 1
95 10 95 0 0.15%
95 2 21 0
Unbound cells 285 50 285 7 0.44%
Selected cells 95 n 85 24
95 l/3n 37 10 5%* 24%
95 l/6n 23 7
1.7xl(f lymphocytes were submitted to a panning procedure on a HIV viral lysate coated dish. The selected cells 
were expanded in a B-cell culture system and on day 8 culture supernatants were tested for total 
immunoglobulin and anti-HIV. Unselected and unbound cells were used as controls.
: based on the number of positive B cells in the unbound cell population, 
n: a number of selected cells that could not be determined.
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Table II: Influence of bead to cell ratio and incubation volume on immunobead selection of antigen-specific B cells
Conditions Bead:cell
ration
Number of 
wells 
inoculated
Number of 
cells per well
Number of 
Ig-positive 
wells
Number of anti- 
BGAL pos. 
wells
Recovery Purity
No 95 50 95 16
selection 95 10 79 4 2.3%
95 2 29 1
Selection; 1:0.6 48 l/16n 48 20 3.7% 15%
beads and 1:0.6 47 l/64n 39 10
cells in 1:4 48 l/16n 46 8 0.7% 14%
large volume 1:4 47 l/64n 13 1
Selection; 1:0.6 48 l/16n n.d. 48 >20%
beads and 1:0.6 47 l/64n 47 41
cells in 1:4 48 l/16n n.d. 47 14%
pellet 1:4 47 l/64n 47 29
3.6x1 ( f lymphocytes were submitted to the immunobead selection procedure using two different bead to cell ratios. For 
each bead to cell ratio, cells and beads were incubated either in a volume of 3.6 ml or in approximately 50 \il. The 
selected cells were expanded in a B-cell culture system and on day 11 culture supernatants were tested for total 
immunoglobulin and anti-BGAL. Unselected cells were used as a control, 
n: a number of selected cells that could not be determined.
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number of anti-BGAL positive B cells were obtained. Approximately 14% of 
selected B cells were antigen-specific. This figure was independent of the bead to 
cell ratio.
Incubation volume. The results of the effect of the incubation volume are 
presented in Table II. A 5 to 20-fold higher yield of anti-BGAL specific B cells 
was obtained when beads and cells were incubated in approximately 50 ^l 
compared to 3.6 ml.
Addition of uncoated beads during wash steps. Even in animals showing a good 
response, only a minor part of the lymphocytes are able to produce antibodies of 
the desired specificity. Therefore, in immunobead selections with antigen coated 
beads, a large excess of beads over target cells was always present. Theoretically, 
it should be possible to reduce the amount of beads without affecting the 
efficiency of the selection. However, the experiment described above showed that 
less B cells were recovered upon reduction of the number of beads. This might be 
due to a loss of beads during the wash steps, the consequences of which may be 
reduced by the addition of uncoated beads during the washes. Table III shows an 
experiment to test this possibility. Lymphocytes (5.8x105 cells) from the same 
mice as in the panning experiment were incubated with HIV viral lysate coated 
beads using a bead:cell ratio of 2:1 and 1:4. Beads and cells were incubated in a 
pellet of approximately 50 ^l. After this incubation, uncoated beads were added to 
the tube with a bead:cell ratio of 1:4 until the total amount of beads was equal to 
the number of beads in the tube with a ratio of 2:1. Subsequently, unbound cells 
were removed by washing and the beads containing the bound cells were plated in 
a B-cell culture system at various dilutions in order to determine the number of 
selected anti-HIV specific B cells in comparison to the total amount of B cells.
The results presented in Table III show that both the yield and frequency of anti­
HIV specific B cells were the same in both selection procedures. A recovery of 
17% was obtained with a purity of 7%.
Mini-electrofusion of clonally expanded, anti-HIV specific B cells 
The experiments described above show that trypsin-treated B cells as well as B 
cells bound to paramagnetic immunobeads could be clonally expanded. Mini­
electrofusions were performed with these B-cell cultures in order to investigate 
whether sufficient specific B cells were obtained for the generation of monoclonal 
antibody producing hybridomas.
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Table III: Influence of addition of uncoated beads during the wash steps in immunobead selection of antigen-specific B 
cells
Cell
population
Ratio
coated beads: 
uncoated beads: 
cells
Number of 
wells 
inoculated
Number 
of cells 
per well
Number of 
Ig-positive 
wells
Number of 
anti-HIV 
positive wells
Recovery Purity
Unselected 95 50 95 4
cells 95 10 76 0 0.36%
95 2 44 0
Selected 8:0:4 95 n 95 43
cells 8:0:4 95 l/4n 66 10 14% 7.1%
8:0:4 95 l/16n 36 1
1:7:4 95 n 95 58
1:7:4 95 l/4n 79 8 17% 7.4%
1:7:4 95 l/16n 43 1
5.8x1 ( f lymphocytes were submitted to an immunobead selection procedure using a bead:cell ratio o f 2:1 and 1:4. During 
the wash steps the proportion of beads in the tube with a bead:cell ratio o f 1:4 was adjusted to a ratio o f 2:1 with uncoated 
beads. The selected cells were expanded in a B-cell culture system and on day 11 culture supernatants were tested for total 
immunoglobulin and anti-HIV. Unselected cells were used as a control, 
n: a number of selected cells that could not be determined.
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Table IV shows the results of two experiments on mini-electrofusions with 106 
NS-1 myeloma cells and individual B-cell cultures from 'panned' and immunobead- 
selected B cells, respectively. In 13 out of 14 fusions anti-HIV producing 
hybridomas could be generated. Up to 78 anti-HIV producing hybridomas were 
generated from one anti-HIV positive B cell.
Table IV: Mini-electrofusion of individual antigen specific B-cell cultures
Selection
procedure
Fusion
no.
Number 
of wells 
seeded
Number of 
wells with 
hybridoma 
growth
Number of 
Ig-positive 
wells
Number of 
anti-HIV 
positive 
wells
Panning I 95 23 20 5
II 95 13 12 6
II 95 2 2 1
IV 95 3 1 1
V 95 0 - -
VI 95 1 1 1
Paramagnetic I 95 n.d. 95 78
immunobeads II 95 n.d. 95 2
III 95 n.d. 92 62
IV 95 n.d. 72 1
V 95 n.d. 94 37
VI 95 n.d. 92 10
VII 95 n.d. 37 36
VIII 95 n.d. 95 39
Murine anti-HIV positive B-cell cultures from 'panned' or immunobead-selected B 
cells were mixed with 1 0  NS-1 myeloma cells. Cells were pronase-treated and 
finally resuspended in fusion medium. After fusion, the cells were seeded in 96- 
well culture plates in selection medium. Ten days after fusion, cultures were 
examined for hybridoma growth and supernatants were tested for total 
immunoglobulin and anti-HIV. 
n.d. = not determined
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Discussion
We have recently reported an efficient method for the generation of antibody 
producing hybridomas from a small number of B cells (Steenbakkers et al., 1992). 
Using a combination of clonal expansion and mini-electrofusion, up to 50% of B 
cells could be immortalized. However, the benefit of this method may only be fully 
exploited when antigen-specific B cells can be used.
This report shows that panning on antigen-coated dishes as well as selection with 
antigen-coupled paramagnetic beads can be used for the isolation of antigen- 
specific B cells from a crude spleen cell population. B cells obtained from both 
selection procedures can be activated to proliferate in a B-cell culture system. 
Moreover, it has been shown that expanded cells originating from a single selected 
B cell can be fused with NS-1 myeloma cells, yielding continuously growing and 
antibody-producing hybridomas of predefined specificity.
The number of Ig producing hybridomas obtained by mini-electrofusion did not 
always correspond with the number of anti-HIV producing hybridomas indicating 
that the original B-cell cultures were not monoclonal. However, it is reasonable to 
assume that these cultures were monoclonal for anti-HIV B cells since the number 
of anti-HIV positive cultures was small with respect to the total number of B-cell 
cultures inoculated. Nevertheless, the relevant hybridomas could readily be 
subcloned.
In selection experiments with paramagnetic beads, a recovery of more than 20% 
was obtained with BGAL-coupled beads and a recovery of up to 17% with HIV- 
coupled beads. Considering that plasma cells cannot be bound since they lack 
surface Ig receptor and probably a proportion of memory B cells cannot be bound 
because they have low affinity antigen receptors, this value is rather high. In the 
present study, spleens were taken four days after the last boost. This was shown to 
be favourable for fusion without prior selection and clonal expansion since more 
plasma cells are present (Eshar, 1985). It is possible that the recovery in selection 
can be improved by taking the spleens several weeks after the final immunization 
since at this stage more memory cells are probably present.
The purity of antigen-specific B cells after selection in a number of experiments 
varied from 7 to 58% (not all data shown). This means that an enrichment-factor of 
20 to 50 was obtained for anti-HIV positive B cells and 6 to 40 for anti-BGAL 
specific B cells.
Both of the methods described for the selection of specific B cells are simple and 
convenient. Selection with paramagnetic beads has the advantage that rosetted
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cells can be used directly (no trypsin treatment) for the expansion in the B-cell 
culture system. As cell-cell contact between the B cell and EL-4 helper cells is 
required for activation and subsequent proliferation in the B-cell culture (Zhang et 
al., 1990), the B cells apparently detach from the beads during culturing or are not 
fully shielded with beads so that cell-cell contact is still possible.
In summary, this report describes a specific B-cell selection efficiency of 20%, 
half of which can be expanded in a B-cell culture system. Of all B-cell cultures, 
100% can be converted into hybridomas by mini-electrofusion. Hence, it can be 
concluded that the overall efficiency of specific B-cell immortalization is 10%. 
This is approximately 250 times better than direct electrofusion and 20,000 times 
better than classical PEG-fusion (Van Duyn et al., 1989). Moreover, only a limited 
number of supernatants need to be tested due to enrichment of specific B cells by 
the selection procedure. Only cells from antigen-specific B-cell cultures require 
mini-electrofusion.
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Abstract
Human anti-cytomegalovirus (CMV) specific B cells were enriched to a purity of 
up to 38% on CMV coated dishes and subsequently clonally expanded in the 
presence of human T-cell supernatant and irradiated murine thymoma helper cells. 
The expanded cells were immortalized by a mini-electrofusion with K6H6B5 
myeloma cells. Twenty-two anti-CMV positive B-cell clones could be obtained 
from as little as 1.5 ml donor blood. The majority of these clones produced anti- 
CMV antibodies of the IgG class.
Ten anti-CMV positive B-cell clones were submitted to separate mini­
electrofusions yielding stable, human anti-CMV IgG producing hybridomas in six 
out of ten fusions. These antibodies recognized different proteins of the CMV 
virus, as deduced from the immunofluorescence staining pattern on infected human 
fibroblasts.
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Introduction
Human monoclonal antibodies (MAbs) are desired for several reasons. The 
humoral response to complex molecules such as viral proteins is different in 
human and mice (1). Therefore, the generation of human MAbs may yield 
antibodies of other epitope-specificities and allows an analysis of the human B-cell 
repertoire in response to such antigens. Furthermore, therapeutic administration of 
mouse immunoglobulin in humans results in the elicitation of human anti-mouse 
antibodies (HAMA) and consequently a short half-life of the administered 
antibody and sometimes harmful side-effects (2,3). Finally, several antibody- 
mediated effector functions e.g. complement fixation and Fc binding to monocytes, 
macrophages and NK cells are dependent on the Fc part of immunoglobulin (1,4). 
Several methods for the generation of human MAbs have been described (5,6). 
These methods are mainly based on transformation of B lymphocytes with 
Epstein-Barr virus (EBV) or fusion of B lymphocytes with myeloma cells of 
murine, human or murine-human origin. However, development of therapeutic 
human MAbs by these techniques or a combination thereof is limited. EBV- 
transformation yields predominantly antibodies of the IgM class. On the other 
hand, fusion is hampered by a low frequency of immortalization, which is 
especially disadvantageous in the development of human MAbs, where limited 
amounts of donor lymphocytes are available and the number of antigen-specific B 
cells usually is very low because active immunizations are generally not possible 
for ethical reasons. These problems may be overcome in part by the use of SCID 
mice (7) or by antibodies obtained via recombinant DNA techniques (8-11). 
However, these methods are not yet routine and a number of technical problems 
remain to be solved.
We have recently described another approach for the generation of monoclonal 
antibodies (12). This approach also is an attractive alternative for the generation of 
human MAbs for several reasons: i) because of its high efficiency (up to 50% of 
murine B cells could be immortalized), processing of small amounts of donor 
lymphocytes is possible, ii) different hybridomas may be generated originating 
from a single B cell, which enhances the chance for finding a well-growing, stable 
hybridoma, and iii) antibodies of the IgG class can be made.
Here the generation and preliminary characterization of human anti­
cytomegalovirus (CMV) MAbs of the IgG class is described using this approach. 
Anti-CMV specific human B cells were selected by panning on antigen-coated 
dishes and subsequently clonally expanded in cultures with murine thymoma
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helper cells and human T-cell supernatant as a source of cytokines. Finally, 
antibody producing hybridomas are made by mini-electrofusion.
CMV is a member of the herpesvirus group that infects a large fraction of the 
human population. After primary infection the virus remains latently present 
within its host. However, serious disease and even death can result when infection 
or reactivation of latent virus occurs in immunocompromised individuals such as 
organ transplant recipients (13). Snydman et al. (14) reported a protective effect of 
CMV hyperimmune globulin when given prophylactically to renal transplant 
patients during the first 4 months after transplantation. Instead of hyperimmune 
globulin, human MAbs against the virus may be used for disease therapy and 
prophylaxis. Such antibodies can also be used for the study of the human immune 
response against CMV at a monoclonal level.
Methods and materials
Reagents
Culture medium DMEM/HAM's F12 was prepared as previously described by 
Steenbakkers et al. (12). In fusion experiments, the medium was supplemented 
with 13.61 mg/l hypoxanthine (Fluka, Buchs, Germany) and 3.83 mg/l thymidine 
(Fluka). This medium is referred to as DMEM/HAM's F12/HT. Selection of 
hybridomas was performed in DMEM/HAM's F12/HT supplemented with 1% 
(v/v) of IL-6 containing supernatant of a human bladder carcinoma cell line T24 
(T24CM) and 0.4 ^M aminopterin (Flow Laboratories, Irvine, Scotland).
Fusion medium: 280 mM inositol (ICN Biomedicals, Costa Mesa, CA, USA), 0.1 
mM calcium acetate (Baker Chemical, Phillipsburg, NJ, USA), 0.5 mM 
magnesium acetate (Baker) and 1 mM histidine (Fluka); specific resistance:
1.11x104 Wcm. Ingredients were dissolved in Milli-Q water, and subsequently the 
conductivity was adjusted to 90 ^S/cm with Milli-Q water or a solution containing 
1 mM calcium acetate and 5 mM magnesium acetate.
Pronase solution was prepared by dissolving 0.5 mg/ml pronase (Calbiochem, La 
Jolla, CA, USA) in DMEM/HAM's F12.
For the preparation of human T-cell/macrophage supernatant (TSN), peripheral 
blood mononuclear cells were isolated from fresh buffy coats on a Ficoll-paque 
density gradient. Subsequently, T cells were separated from B cells as described 
by Steenbakkers et al. (12). The enriched T cells were stimulated for 40-45 h in 
DMEM/HAM's F12 supplemented with 10% FCS, 5 ^g/ml PHA (Wellcome,
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Dartford, England) and 10 ng/ml PMA (Sigma Chemical Co., St. Louis, MO, 
USA). Finally, supernatant was harvested, filtered through a 0.2 ^m membrane 
filter and stored in aliquots at -70°C.
Cell cultures
Mutant EL-4 thymoma cells, EL-4 B5 (a gift from Dr. R. Zubler, Geneva, 
Switzerland), were routinely cultured in DMEM/HAM's F12 supplemented with 
10% FCS (Hyclone Laboratories, Logan, UT, USA) at cell concentrations of 1x104 
to 1x106 cells/ml as determined in a Fuchs-Rosenthal haemocytometer. If cells 
overgrow 1x106 cells/ml, they may lose their B-cell stimulating activity. Mouse- 
human xenohybrid K6H6B5 (15) was used as fusion partner for B cells. Cells were 
routinely cultured in DMEM/HAM's F12/HT supplemented with 10% FCS at 
concentrations between 5x104 and 15x105 cells per ml. One day before fusion, the 
cultures were split 1:3 to create a log-phase culture at the day of fusion.
Human peripheral blood mononuclear cells (MNCs) from fresh heparinized blood 
were isolated on a Ficoll-paque density gradient. Cells were frozen in liquid 
nitrogen or used directly. Before using the cells in a selection experiment, they 
were incubated for at least 1 h in DMEM/HAM's F12 supplemented with 10% 
FCS in polystyrene culture flasks. Thus, monocytes adhere to the culture flasks 
and the nonadherent cells were used for panning.
Panning procedure
CMV antigen (strain AD-169) was prepared by sonification of partially purified 
nuclei from infected human diploid lung fibroblasts (HFFG) as described by Van 
Loon et al. (16). For panning, six-well culture plates were incubated overnight 
with 4 ml/well of a solution containing 400-fold diluted CMV antigen in 0.05 M 
sodium carbonate buffer pH=9.6. Subsequently, the wells were washed with PBS 
and directly used for panning experiments.
Panning was performed by incubating monocyte depleted mononuclear cells (5 to 
20x105 cells in 4 ml) on antigen-coated wells for 75-90 min at 37°C, 5% CO2 and 
100% humidity. After this incubation, the unattached cells were removed gently by 
three subsequent washes with PBS. Then, the antigen-bound, specific B cells were 
recovered by incubating each well with 250 ^l PBS containing 1.1 mM Na2EDTA 
and 0.05% trypsin (Flow; 16-893-49), pH=7.5, for 2-5 min. Trypsin treatment was 
stopped by addition of 5 ml DMEM/HAM's F12 supplemented with 10% FCS. 
Finally, the entire surface of the wells was flushed with the medium using a 
Pasteur pipette in order to remove residual attached B cells mechanically.
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Different dilutions of selected cells were used to inoculate EL-4/B-cell cultures 
(limiting dilution).
For control B-cell cultures of unselected B cells, T cells and NK cells were 
removed to avoid outgrowth of these cells. Monocyte-depleted MNCs were 
incubated with a mixture of anti-CD2 paramagnetic beads (111.01; Dynal, Wirral, 
UK) and anti-CD16 paramagnetic beads (4716N; Advanced Magnetics, 
Cambridge, MA, USA). For a complete depletion of CD2 and CD16 positive cells, 
washed immunobeads and monocyte-depleted MNCs were mixed at a ratio of 
40:1. The mixture of beads and cells was incubated for 30 min at 2-4°C with gentle 
mixing every 10 min. Subsequently, rosetted cells were isolated by holding a 
magnetic device against the wall of the test tube and removing the supernatant.
EL-4/B-cell cultures
EL-4/B-cell cultures were inoculated as described by Zubler et al. (17-20). Briefly, 
crude or purified B cells were mixed with TSN and 100,000 irradiated (75,000 in 
experiment II; 2500 rad) EL-4 B5 cells in a final volume of 200 ^l DMEM/HAM's 
F12 supplemented with 10% FCS in 96-well flat-bottomed tissue culture plates. 
The optimal amount of TSN was established for each batch by titration. Usually 
10% TSN was sufficient for optimal stimulation of human B cells. The cultures 
were incubated at 37°C, with 5% CO2 and 100% humidity. Between day 8 and day
12, supernatants were tested for immunoglobulin production.
The recovery after selection was calculated from the number of specific B cells 
found after selection and the number of specific B cells that were submitted to the 
selection procedure. The purity was calculated from the number of antigen-specific 
B cells and the total number of B cells that had grown out. The number of the 
antigen-specific B cells, used for calculation of the recovery and purity, was 
determined by addition of the individual numbers found in separate dilutions from 
a cell population. In cases where more than one B cell had grown out in a well (all 
wells positive), the total number of B cells was calculated from the number of B 
cells grown out in the highest dilution and the dilution factor.
Mini-electrofusion
Mini-electrofusions were performed as described by Steenbakkers et al. (12). 
Briefly, the contents of individual B-cell cultures were mixed with 106 myeloma 
cells and rendered serum-free by washing with DMEM/HAM's F12/HT. Then, the 
cells were treated with pronase solution for 3 min and subsequently washed with 
fusion medium. Electrofusion was performed in a 50 ^l fusion chamber by an 
alternating electric field of 30 s, 2 MHz, 400 V/cm followed by a square, high field
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pulse of 10 ^s, 3 kV/cm and again an alternating electric field of 30 s, 2 MHz, 400 
V/cm. Finally, the contents of the fusion chamber were transferred to 20 ml 
selection medium and plated into a 96-well microculture plate. At day 14, the 
cultures were examined for hybridoma growth and the supernatants were tested for 
immunoglobulin production.
Enzyme immunoassays
Measurement of human immunoglobulin was performed by a standard sandwich­
ELISA using goat anti-human immunoglobulin coated plates and HRP-labeled 
goat anti-human immunoglobulin second antibody. Human IgG (I-4506; Sigma) 
served as positive control for the assessment of assay sensitivity, and culture 
medium served as a negative control. For the detection of human anti-CMV 
antibodies, plates coated with CMV nuclear antigen were used in combination 
with HRP-labeled goat anti-human immunoglobulin. This conjugate was replaced 
by HRP-labeled goat anti-human IgG(Fc) or HRP-labeled goat anti-human 
IgM(Fc) for determination of the immunoglobulin class of anti-CMV specific 
antibodies.
In order to establish whether human MAbs were directed against CMV antigens 
pp65 or gB, an antigen capture ELISA was performed in which these proteins were 
captured by specific MAbs (21). Briefly, murine MAb C10, which recognizes the 
lower matrix protein pp65 (22), or murine MAb C40, which reacts with a 
membrane antigen of an apparent molecular weight of 58 kD that shows homology 
with gB of herpes simplex (23), was coated on ELISA plates. Subsequently, the 
antigen of interest was allowed to bind from a detergent extract of CMV-infected 
cells in the late stage of infection. Then, the human anti-CMV MAbs were 
incubated in twofold dilutions starting with 1:4. Bound antibody was detected by 
peroxidase-labeled second antibody against human IgG (De Beer Medicals, 
Hilvarenbeek, Netherlands).
Immunofluorescence staining
Membrane immunofluorescence was performed on human embryonic lung 
fibroblasts as described by Middeldorp et al. (24). Subconfluent monolayers were 
infected with CMV AD-169 at 2 pfu/cell and infected cells were used for staining
3 days after infection. Uninfected fibroblasts were used as control. The whole 
staining procedure was performed on ice and precooled solutions were used. 
Dilutions of the human MAbs (1:5) were made in RPMI 1640 (Gibco, Uxbridge, 
UK) with 2% FCS. After the cells were washed three times, FITC-labeled second 
antibodies (dilution 1:250; De Beer) were added. After 1 h incubation, the cells
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were washed again, subsequently fixed in methanol at -20°C for 20 min, and air 
dried. Glass slides were mounted in 50% glycerol-PBS, pH 8.0, sealed with nail 
polish and kept at 4°C.
For immunofluorescent staining of intracellular structures, fibroblasts were seeded 
on 12 well Cooke slides (Nutacon, Schiphol, Netherlands). Slides to be used for 
staining of late antigens were used 4 days after infection, and slides to be used for 
immediate early antigens were prepared after infection and subsequent treatment 
with cycloheximide and actinomycine D for 3 h. Incubation with human MAbs 
was performed as described above except that PBS was used as a buffer and the 
slides were fixed with acetone before staining.
Immunoblot procedure
Immunoblotting was performed as described by Van Zanten et al.(25) Briefly, an 
extract of CMV-infected fibroblasts was applied on a 8% gel. SDS-PAGE was 
then performed as described by Laemmli (26). The separated polypeptides were 
electrophoretically transferred to a nitrocellulose membrane (BA 85, Schleicher 
and Schuell Inc. Keene, NH, USA) by a semi-dry electroblotter (Ancos, 
Copenhagen, Denmark). After the blot was blocked with 3% BSA, the human 
MAbs (diluted 1:8) were incubated for 90 min. After the blot was washed, AP- 
conjugated goat anti-human IgG serum (Sigma) was added. The blot was 
developed with nitroblue tetrazolium (Sigma) and 5-bromo-4-chloro-3- 
indolylphosphate (Sigma).
Immunoprecipitation
Immunoprecipitation was performed as described by Grefte et al. (22). In short, 
CMV-infected cell extract that had been precleared with a human serum obtained 
from a CMV-negative individual was incubated overnight with the human MAbs 
and protein A-Sepharose beads CL-4B (Pharmacia, Uppsala, Sweden). After 
washing the beads, layering them on a 20% sucrose cushion, and pelleting by high­
speed centrifugation, we analyzed the immunoprecipitated material by SDS-PAGE 
and immunoblotting. The antigens immunoprecipitated by the human MAbs were 
detected by a human serum with high levels of anti-CMV antibodies.
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Table I: Panning of human anti-CMV positive B cells
Donor Cell population No. of 
wells 
inoculated
No. of 
cells/well
No. of 
immunoglobulin 
positive wells
No. of 
anti-CMV 
positive wells
Recovery 
(%) ”
Purity
(%)
Cells before selection 95 450 n.d. 19
Donor A 95 75 n.d. 4 <0.9%
Exp. I 95 15 76 1
Selected cells 95 a 10 4 4.4% 38%
95 l/5a 6 2
Cells before selection 95 450 n.d. 3
Donor B 95 75 n.d. 2 <0.2%
Exp. I 95 15 60 0
Selected cells 95 a 15 1 4.0% 5.6%
95 l/5a 3 0
Donor A Cells before selection 570 31 444 14 <3%
Exp. II Selected cells 190 a 92 22 13% 24%
Monocyte depleted MNCs (exp. I, donor A: 18x10s cells; exp. I, donor B: 10x1 ( f cells; exp. II, donor A: 9xl(f cells) were 
submitted to a panning procedure on a CMV coated dish. Then, selected cells were used to inoculate B-cell cultures in 96-well 
culture plates. The same monocyte depleted MNCs (exp. I, donor A: 3.2x1 ( f cells; exp. I, donor B: 2x1 ( f  cells; exp. II, donor A:
0.75x1 ( f cells) were incubated with anti-CD2 and anti-CD 16paramagnetic immunobeads to remove T cells and NK cells. B- 
cell cultures were inoculated with the unrosetted cells in order to determine the number o f anti-CMV specific B cells and the 
total number of B cells before selection. At day 12 and day 9 (exp. I  and exp. II, respectively), culture supernatants were tested 
for human immunoglobulin and human anti-CMV. 
a: not determined number of selected cells. n.d.: not determined.
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Results
Selection and proliferation of anti-CMV positive B cells
Human MNCs were isolated 11 weeks after a primary CMV infection (donor A) or 
16 weeks after a secondary CMV infection (donor B). Then, the monocytes were 
removed and the lymphocytes were submitted to a panning procedure on a CMV 
antigen-coated culture dish. After harvesting the selected cells from the culture 
dish, limiting diluted B-cell cultures were inoculated in order to clonally expand 
the selected B cells and measure their specificity. To determine the number of 
specific B cells in the cell population before selection, control B-cell cultures were 
inoculated with cells that were depleted for monocytes, T cells and NK cells. At 
day 12 and day 9 (exp. I and exp. II respectively), culture supernatants were tested 
for human immunoglobulin and anti-CMV. Table I shows the results of two 
independent panning experiments with lymphocytes from donor A and one 
experiment with donor B. In all experiments, a relatively pure B-cell population 
was obtained after selection ranging from 5.6% for donor B up to 38% for donor 
A. Before selection, these purities were less than 0.2% and 0.9%, respectively. 
Further, it could be calculated that approximately 4% and 13% of specific B cells 
were recovered after panning in experiments I and experiment II, respectively. 
Moreover, 36 anti-CMV immunoglobulin positive cultures were tested in an 
ELISA for anti-CMV IgG and anti-CMV IgM. Specific responses of IgG, IgM and 
IgG plus IgM occurred at a ratio of 34:1:1.
Mini-electrofusion of clonally expanded specific B cells
Nine days after inoculation of the B-cell cultures, ten individual anti-CMV 
positive B-cell cultures from donor A were submitted to a mini-electrofusion with 
106 K6H6B5 myeloma cells in order to generate continuously growing, human 
anti-CMV producing cell lines. At day 19 after fusion, cultures were examined for 
hybridoma growth. Supernatants were tested for human immunoglobulin and anti- 
CMV antibodies. Table II shows the results of well-growing hybridomas at day 19. 
Initially, approximately twofold more hybridomas were found, but these are not 
included in the table as they grew very slowly or stopped growing at an early stage 
after cell fusion. Human anti-CMV positive hybridomas were grown and followed 
for the production of anti-CMV for more than 2 months. At day 19, 1 to 3 anti- 
CMV positive hybridomas were found in 7 out of 10 fusions. A few hybridomas 
lost their antibody production on prolonged culture, but ultimately at least one 
hybridoma appeared to be stable in 6 out of 10 fusions. From each of these six 
fusions, one hybridoma was subcloned by limiting dilution. The results of these
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Table II: Mini-electrofusions of individual anti-CMV positive B-cell cultures
Fusion
number
No. of 
wells 
seeded
No. of wells with 
hybridoma growth 
(day 19)
No. of immunoglobulin 
positive hybridomas 
(day 19)
Number of human anti-CMV positive 
hybridomas 
Day 19 Day 27 >2 months
I 48 12 3 2 2 2
II 48 4 3 3 2 1
III 48 6 6 3 2 1
IV 48 1 1 1 1 1
V 48 2 2 0 0 0
VI 48 1 1 1 0 0
VII 48 10 9 0 0 0
VIII 48 22 3 2 2 2
IX 48 1 1 1 1 1
X 48 1 1 0 0 0
Individual human anti-CMV positive B-cell cultures from experiment II in Table I  were mixed with I f f  K6H6B5 myeloma 
cells. Cells were pronase-treated and resuspended in fusion medium. After fusion, cells were seeded in 96-well culture 
plates in selection medium. Nineteen days after fusion, cultures were examined for hybridoma growth and supernatants 
were tested for human immunoglobulin and human anti-CMV antibodies. Anti-CMV positive hybridomas were scaled up, 
cloned and followed for the production of anti-CMV for more than two months.
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cloning experiments (data not shown) indicate that 5 out of 6 hybridomas were 
already stable before subcloning. It was confirmed that all six anti-CMV clones 
were of the IgG class.
Characterization of MAbs
The six stable human anti-CMV MAbs were characterized by indirect 
immunofluorescence, immunoblotting, immunoprecipitation, and in an antigen 
capture ELISA. After staining of intracellular structures on infected human 
embryonic fibroblasts, three different staining patterns could be identified. 
Antibodies CMVHU.02, CMVHU.05 and CMVHU.06 reacted with nuclear 
inclusion bodies present in the late stage of CMV infection (Figure 1A). Nuclear 
staining in the immediate early phase of CMV infection and a cytoplasmatic, dot­
like staining in the late stage of infection were observed with CMVHU.03 and 
CMVHU.07 (Figures 1B and 1C). Antibody CMVHU.04 showed staining of the 
Golgi apparatus region and a weak reaction with nuclear inclusion bodies. None of 
the six antibodies showed any reaction with uninfected fibroblasts or with 
membrane antigens on infected fibroblasts.
In the immunoblotting study using an extract of CMV-infected fibroblasts 
prepared at 4 days after infection, no reactivity was found with all six antibodies. 
Reactivity of the antibodies with CMV antigens under nondenaturating conditions 
was investigated in an immunoprecipitation experiment. Figure 2 shows that 
antibodies CMVHU.03 and CMVHU.07 precipitated a 65 kD protein. No 
reactivity was found with antibodies CMVHU.04, CMVHU.05 and CMVHU.06. 
Here, the only band seen is the heavy chain of the IgG molecule.
Antibodies CMVHU.03 and CMVHU.07 were also positive in an antigen capture 
ELISA in which lower matrix protein pp65 was bound via murine MAb C10. None 
of the six human MAbs showed any reaction in the anti-gB capture ELISA.
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Figure 1: (A) Antibodies CMVHU.02, CMVHU.05 and CMVHU.06 showed 
reactivity with nuclear inclusion bodies present in the late stage of infection. (B) 
Antibodies CMVHU.03, CMVHU.07 gave a nuclear staining in the immediate 
early phase of CMV infection and (C) a cytoplasmatic, dot-like pattern in the late 
stage of infection.
A B C  D E F
Figure 2: CMV proteins immunoprecipitated from late-infected cell extracts with 
the human MAb. Lane A, control precipitation without antibody; lanes B to F, 
immunoprecipitations with antibodies CMVHU.03 to CMVHU.07, respectively
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Discussion
This report describes an alternative strategy for the generation of human MAbs. 
Six stable human anti-CMV MAbs were developed by directed clonal expansion 
of anti-CMV specific B cells obtained from panning and subsequent 
immortalization of the expanded cells by a mini-electrofusion with K6H6B5 
myeloma cells.
After panning, the purity of anti-CMV specific B cells varied from 5.6% for donor 
B with less than 0.2% anti-CMV specific cells in the starting population, to 38% 
for donor A with less than 0.9% antigen-specific precursor cells in the starting 
population. The recovery of antigen-specific B cells after panning ranges from 4% 
in experiment I to 13% in experiment II, which is rather high considering that 
probably a number of memory B cells will not bind strongly enough because of 
their low affinity antigen receptors.
The immunofluorescence staining pattern on infected human fibroblasts showed 
that at least three different specificities could be distinguished among these six 
antibodies, viz. antibodies reacting with proteins that appear in the immediate early 
phase of infection, antibodies reacting with nuclear inclusion bodies that appear in 
the late stage of infection, and an antibody that recognizes a structure in the Golgi 
apparatus at late the stage of infection. No reactivity was found in Western blot 
studies under reducing conditions, indicating that the antibodies probably 
recognize a conformational epitope of the virus proteins. From 
immunoprecipitation studies and an antigen capture ELISA, it could be established 
that two antibodies were directed against the pp65 lower matrix protein. This is a 
phosphoprotein that is abundantly present in CMV-infected fibroblasts. It covers 
approximately 95% of the protein mass in dense bodies, a noninfectious particle. 
The fine specificity of the other antibodies should be further established.
The approach to the development of human MAbs followed here is attractive 
compared to EBV transformation or direct fusion of human donor lymphocytes for 
several reasons. The major part of antibodies produced by EBV transformation are 
of the IgM class, which are unwanted because they usually show a low affinity and 
have a large size and a shorter half life than IgG (27). Of 36 anti-CMV positive B- 
cell cultures analyzed in our experiments 34 were of the IgG class. Only one B-cell 
clone was IgM, and in one well both anti-CMV IgG and anti-CMV IgM was found. 
The latter indicates that class switch may occur in the B-cell culture. It is very 
unlikely that one specific IgG B cell and one specific IgM B cell were inoculated 
in the same well because of the low frequency of IgM clones and the low
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frequency of anti-CMV clones with respect to the number of wells seeded. Similar 
results were reported by Zubler et al. (18,20), who found single cell clones of 
IgM:IgG:IgM+IgG in a ratio of 6:1:3. Contrary to our results, in this study a 
majority of IgM clones was found, which might be explained by the fact that the 
total B-cell population was examined. In the present study, preselected anti-CMV 
specific B cells were used, which are primed in vivo by CMV and which are 
possibly enriched for high affinity binding cells by panning.
Direct PEG fusion or electrofusion of human lymphocytes is characterized by a 
low immortalization frequency, which is a serious drawback because the major 
part of B cells from mostly limited amounts of human donor material are lost in 
these fusions. The immortalization frequency of the method described in this 
report depends on the combined efficiencies of the three steps used, viz. panning, 
clonal expansion of B cells, and mini-electrofusion. An overall immortalization 
frequency of specific B cells of 2 to 6% was obtained.
It was previously shown (12,18,20) that 40 to 90% of human B cells could be 
clonally expanded in the B-cell culture system. This indicates not only that small 
amounts of human donor lymphocytes are sufficient but also that small numbers of 
specific B cells obtained after preselection procedures can be processed. Although 
the exact cloning efficiency of B cells in these experiments could not be 
established, the potency of the method described is clearly shown. For example, 
the 22 anti-CMV positive B-cell clones (exp. II) obtained after panning and clonal 
expansion of the B cells were derived from as little as 1.5 ml donor blood. Ten of 
these B-cell clones were submitted to separate mini-electrofusions, and six of these 
fusions yielded stable human anti-CMV MAbs.
An additional advantage of the combination of clonal expansion of B cells and 
mini-electrofusion is that more hybridomas could be generated from a single B 
cell. Loss of hybridomas due to instability or growth problems is fatal in direct 
fusion procedures but may be without consequence in case there are more 
hybridomas from one B cell.
79
References
1. Foung SKH, Bradshaw PA, Emanual D. Use of human monoclonal antibodies to 
human cytomegalovirus and varicella zoster virus. In: Borrebaeck CAK, Larrick JW, 
eds. Therapeutic monoclonal antibodies. New York: Stockton Press, 1990.
2. Shawler D L, Bartholomew RM, Smith LM , Dillman RD. Human immune response 
to multiple injections of murine IgG. J. Immunol. 1985; 135: 1530.
3. Steis RG, Carrasquillo JA , McCabe R, Bookman MA, Reynolds JC, Larson SM, 
Smith JW, Clark JW, Dailey V , Del Vecchio S, Shuke N, Pinsky CM, Urba WJ, 
Haspel M. Toxicity, immunogenicity, and tumor radioimmunodetecting ability of 
two human monoclonal antibodies in patients with metastatic colorectal carcinoma. 
J. Clin. Oncol. 1990; 8: 476.
4. Nose M, Wigzell H. Biological significance of carbohydrate chains on monoclonal 
antibodies. Proc. Natl. Acad. Sci USA 1983; 80: 6632.
5. Van Meel FCM, Steenbakkers PGA, Oomen JCH. Human and chimpanzee 
monoclonal antibodies. J. Immunol. Methods 1985; 80: 267.6. James K , Bell GT. Human monoclonal antibodies; current status and future 
prospects. J. Immunol. Methods 1987; 100: 5.
7. Carlsson R, Martensson C, Kalliomaki S, Ohlin M, Borrebaeck CAK. Human 
peripheral blood lymphocytes transplanted into SCID mice; constitute an in vivo 
culture system exhibiting several parameters found in a normal humoral immune 
response and are a source of immunocytes for the production of human monoclonal 
antibodies. J. Immunol. 1992; 148: 1065.8. Burton DR, Barbas CF, Persson MAA, Koenig S, Chanock RM, Lerner RA. A large 
array of human monoclonal antibodies to type 1 human immunodeficiency virus 
from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. 
Acad. Sci USA 1991; 88: 10134.
9. Ward ES , Gussow D, Griffiths AS, Jones PT, Winter G. Binding activities of a 
repertoire of single immunoglobulin variable domains secreted from E. coli. Nature 
1989; 341: 544.
10. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous 
phage displaying antibody variable domains. Nature 1990; 348: 552.
11. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. 
By-passing immunization: Human antibodies from V-gene libraries displayed on 
phage. J. Mol. Biol. 1991; 222: 581.
12. Steenbakkers PGA, Van Meel FCM, Olijve W. A new approach to the generation of 
human or murine antibody producing hybridomas. J. Immunol. Methods 1992; 152: 
69.
13. Myers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after 
human marrow transplantation. J. Infect. Dis. 1986; 153: 478.
14. Snydman DR, Werner BG , Heinze-Lacey B , Berardy VP, Tilney NL, Levey AS, 
Strom TB , Carpenter LB , Levey RH, Harmon WE, Zimmerman CE, Shapiro M E, 
Steinman T , LoGerfo F, Idelson B , Schroter PJ, Levin MJ, McIver J, Leszczynski J, 
Grady GF. Use of cytomegalovirus immune globulin to prevent cytomegalovirus 
disease in renal transplantation recipients. N. Engl. J. Med. 1987; 317: 1049.
15. Caroll W L, Thielemans K , Dilley J, Levy R. Mouse x human heterohybridomas as 
fusion partners with human B cell tumors. J. Immunol. Methods 1986; 89: 61.
80
16. Van Loon AM, Heessen FW A, Van der Logt JTM , Van der Veen J. Direct enzyme- 
linked immunosorbent assay that uses peroxidase-labeled antigen for determination 
of immunoglobulin M antibody to cytomegalovirus. J. Clin. Microbiol. 1981; 13: 
416.
17. Straub C, Zubler RH. Immortalization of EBV-infected B cells is not influenced by 
exogenous signals acting on B cell proliferation. J. Immunol. 1989; 142: 87.
18. Wen L , Hanvanich M, Werner-Favre W, Brouwers N, Perrin LH , Zubler RH. 
Limiting dilution assay for human B cells based on their activation by mutant EL-4 
thymoma cells: total and anti-malaria responder B cell frequencies. Eur. J. Immunol. 
1987; 17: 887.
19. Zhang X , Hauser C, Zubler RH. Soluble factor-independent stimulation of human B 
cell response by mouse thymoma cells. J. Immunol. 1990; 144: 2955.
20. Zubler RH, Werner-Favre C, Wen L , Sekita K , Straub C. Theoretical and practical 
aspects of B cell activation: Murine and human systems. Immunol. Rev. 1987; 99: 
281.
21. Van der Voort LHM , Van Zanten J, De Leij LFM H, The TH. Determination of 
human antibodies to specific antigens of cytomegalovirus using an antigen capture 
immunoassay. J. Immunol. Methods 1989; 121: 95.
22. Grefte JMM, Van der Gun B TF , Schmolke S, Van der Giessen M, Van Son WJ, 
Jahn G, The TH. The lower matrix protein pp65 is the principal viral antigen present 
in peripheral blood leukocytes during an active cytomegalovirus (CM V) infection. J. 
Gen. Virol. In press.
23. Van der Voort LHM , De Leij LFHM , The TH. Characterization of membrane 
antigens on human cytomegalovirus infected fibroblasts recogniezed by human 
antibodies. J. Virol. 1989; 63: 1485.
24. Middeldorp JM, Jongsma J, The TH. Immunofluorescence for the detection of 
antibodies against cytomegalovirus induced membrane antigens. J. Clin. Microbiol. 
1986; 24: 405.
25. Van Zanten J, Van der Giessen M, Van Son WJ, The TH. Antibody responses to 
human cytomegalovirus specific polypeptides studied by immunoblotting in relation 
to viral load during cytomegalovirus infection. J. Med. Virol. In press.
26. Laemmli U K. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 1970; 227: 680.
27. Waldmann TA , Strober W, Blaese RM. Variations in the metabolism of 
immunoglobulins measured by turnover rates. In: Merler E , ed. Immunoglobulins: 
Biologic aspects and clinical uses. National Academy of Sciences: Washington 
1970: 33.
81
S2
Chapter 5
Generation and functional characterization of anti­
clonotype antibodies to human T-cell receptors
Peter G.A. Steenbakkers, Annemieke M. H. Boots 
and Antonius W.M. Rijnders
Department of Immunology, N.V.Organon, Oss, The Netherlands
Submitted
83
Summary
Monoclonal antibodies directed to the clonotypic structure of the TCR may be 
useful reagents in the study and therapy of T-cell-mediated diseases. In contrast to 
several reports concerning the generation of anti-clonotype mAb to mouse TCR, 
only a very limited number of anti-clonotype mAb to human TCR has been 
described. So far, a suitable method for the generation of anti-clonotype mAb to a 
given TCR is lacking. In this report, we describe a novel strategy for the 
generation of such mAb. Mice were immunized with intact human T cells. Then, 
spleen cell populations were precleared from B cells reactive to CD3 and the 
constant region of the TCR by adsorption to TCR/CD3 complexes derived from an 
irrelevant T-cell clone. Subsequently, clonotype-specific B cells were selected 
with TCR/CD3 complexes from the T-cell clone of interest. The small number of 
B cells resulting from this selection were clonally expanded in a B-cell culture 
system and then immortalized by a mini-electrofusion.
Ten clonotype-specific mAb were generated against a DRB 1*0401-restricted T- 
cell clone recognizing an epitope of the Human Cartilage glycoprotein 39, which 
was recently found to be a candidate autoantigen in rheumatoid arthritis. All mAb 
immunoprecipitated the same heterodimeric molecule having a molecular mass of 
approximately 85 kD under non-reducing conditions. Under reducing conditions, 
this molecule resolved in two major peptides of 40 and 50 kD which is consistent 
with the disulfide-linked a- and b-chain of the TCR. Absolute specificity was 
demonstrated in a T-cell agglutination test with the T-cell clone of interest 
compared to a set of 16 defined, irrelevant T-cell clones or lines.
In functional assays, the mAb were found to inhibit or block antigen-specific T- 
cell stimulation. In addition, crosslinked mAb were found to stimulate 
proliferation of the specific clone in the absence of antigen and APC. The 
functional assays suggest that at least three different clonotypic determinants on 
the autoreactive T-cell clone are recognized by the mAb. Such mAb may have 
clinical relevance in deleting or modulating autoreactive T cells in a clonotype 
specific manner.
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Introduction
T lymphocytes recognize antigenic peptides bound to MHC molecules by virtue of 
their antigen receptor. This TCR consists of two different chains, usually a  and b, 
associated with a CD3 multimeric complex. Each chain contains a constant (C) 
region and a variable (V) region. Antibodies against the TCR may be useful in the 
intervention of T cell-related disorders such as autoimmune diseases, allergy and 
allograft rejection [1, 2]. Such therapeutic regimes will not be very specific if anti­
C region antibodies are used. However, several investigators have reported the 
clonal expansion of T cells and restricted Vb gene usage in clinical disease [3-7] 
and in experimental autoimmune disease models [8-11]. In the latter situation, Vb 
region-specific mAb have been shown to either prevent or treat these diseases [9­
11]. More specifically, mAb against the antigen-binding region of the TCR (anti­
clonotype mAb) may be used to intervene in T-cell mediated autoimmune disease. 
[12, 13]. In addition, these mAb may serve as useful reagents in studying the 
distribution of clonotypic determinants in clinical diseases.
Thus far, the generation of such clonotype-specific mAb has proven to be difficult. 
This is for a great deal related to the difficulty of obtaining a significant amount of 
purified TCR for immunization and subsequent testing of hybridoma specificity. 
As an alternative source of antigen, T-cell lysate or intact T cells may be used. The 
use of intact T cells proved to be successful in the generation of anti-clonotype 
mAb to the mouse TCR [14-17]. This is explained by the notion that immunization 
of mice with syngeneic T cells will lead to reactivity to the clonotypic 
determinants only.
One may appreciate that generation of such antibodies to clonotypic determinants 
on human TCR is more difficult. So far, reports are limited to a few cases where 
undefined T-cell clones [18] or Jurkat leukemia cells were used [19]. To our 
knowledge, there are no reports of anti-clonotype mAb to antigen-specific human 
T-cell clones. This lack of success is explained by the observation that mice 
immunized with intact human T cells will build an immune response to a broad 
spectrum of determinants due to the species difference. Consequently, it is hard to 
select the mAb of interest using the standard hybridoma technology.
We have previously reported the generation of mAb from a small number of 
preselected antigen-specific B cells [20, 21]. Selected B cells are first expanded 
under limiting dilution conditions in the presence of human T-cell supernatant and 
irradiated murine thymoma cells. Subsequently, the clonally expanded B cells are 
immortalized by electrofusion. In the present study, this technology was used for
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the generation of anti-clonotype mAb to an autoreactive T-cell clone specific for 
an epitope of Human Cartilage glycoprotein 39 (HC gp-39). This antigen was 
recently found to be a candidate autoantigen in rheumatoid arthritis [Verheijden et 
al.; submitted]. Our method does not require purified TCR for immunization and 
subsequent testing since we have devised a powerful selection method for 
clonotype-specific B cells and a fast one-step agglutination assay using intact T 
cells for screening of hybridoma specificity.
Materials and methods
Reagents
Culture medium DMEM/HAM's F12 was prepared as previously described by 
Steenbakkers et al. [22]. Selection of hybridomas was performed in standard HAT 
selection medium supplemented with 1% (v/v) of IL-6 containing supernatant of a 
human bladder carcinoma cell line T24.
Fusion medium: 280 mM inositol, 0.1 mM calcium acetate, 0.5 mM magnesium 
acetate and 1 mM histidine; specific resistance:1.11 x 104 Wcm. Ingredients were 
dissolved in Milli-Q water and subsequently the conductivity was adjusted to 90 
^S/cm with Milli-Q water or a solution containing 1 mM calcium acetate and 5 
mM magnesium acetate.
Cell cultures
The influenza haemagglutinin-specific T-cell clone H.258 was isolated from 
peripheral blood mononuclear cells (PBMC) upon stimulation with peptide 
HA307-319 Y®F (PKFVKQNTLKLAT). This Va2,Vb3-positive T-cell clone 
recognizes the epitope in the context of DRB1*0401.
The autoreactive T-cell clone H.243 was isolated from peptide-stimulated PBMC 
derived from a rheumatoid arthritis patient as described by Verheijden et al. 
[Human Cartilage gp-39 is a candidate autoantigen in rheumatoid arthritis; 
submitted for publication]. This Th1-like clone recognizes epitope 
RSFTLASSETGV from HC gp-39 in the context of DRB 1*0401 by virtue of a 
Va8,Vb9-positive TCR.
In addition, we selected a set of 15 different, defined T-cell clones or lines as a 
control for the agglutination assay (see Table III). This set was generated from 
human PBMC or synovial tissue following antigen-specific stimulation, 
stimulation with anti-Vb9, PHA or IL-2. The V a  and Vb usage of these clones 
was determined by RT-PCR using V a  and Vb family-specific primers.
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All T cells were routinely cultured in DMEM/HAM’s F12, 10% FCS, 20 U/ml IL-
2, 5 U/ml IL-4 and periodically restimulated with antigen and histocompatible 
APC or with PHA and feeder cells. For proliferation assays, FCS was replaced by 
Normal Human Serum (NHS).
Preparation of T-cell lysate and loading beads with TCR/CD3 complexes 
Ten to 14 days after restimulation, T cells were washed with PBS and solubilized 
by incubating (30 min, 0oC) at a concentration of 108 cells/ml in extraction buffer 
according to Oettgen et al. [23] (10 mM triethanolamine, 150 mM NaCl, 1 mM 
Na2EDTA, 1% digitonin, 10 ^g/ml leupeptin, 10 ^g/ml aprotinin, 1 ^g/ml 
pepstatin, 1 mM AEBSF and 1.8 mg/ml iodoacetamide pH 7.8). The mild 
detergent digitonin allows extraction of intact TCR/CD3 complexes. Nuclear and 
cellular debris were removed by centrifugation at 16,000 g for 15 min at 4oC and 
the supernatant was stored in aliquots at -20oC until use for selection of B cells or 
immunoprecipitation.
For selection of specific B cells, paramagnetic beads were loaded with TCR/CD3 
complexes. Briefly, 100 ^l Sheep anti-mouse Ig (SAM) coupled paramagnetic 
beads (Dynal 110.02, Oslo, Norway) were incubated (overnight, 4oC) with 22 ^g 
anti-CD3 (OKT3) in PBS, 0.1% BSA. After washing the beads with PBS/BSA, 1.4 
x 108 cell equivalents of T-cell lysate and an equal volume (1.4 ml) PBS/BSA with 
1% normal mouse serum were added. The latter was added to prevent binding of B 
cells to free SAM binding sites on the beads. The bead suspension was incubated 
for 2 to 4 h at 4oC and washed with PBS/BSA before use.
Establishing the optimal immunization protocol
In order to establish the most efficient immunization protocol for the generation of 
clonotype-specific antibodies, four different routes of immunization were 
evaluated (see Table I). For this purpose, we used the influenza haemagglutinin- 
specific H.258 clone. When the H.243 clone became available, we applied the 
most efficient procedure to obtain mAb against clonotypic determinants of this 
autoreactive T-cell clone.
Six-week old female BALB/c mice were immunized at 3- to 7 week intervals with 
either 5 x 106 intact T cells or paramagnetic beads loaded with TCR/CD3 
complexes from 5 x 107 cell equivalents. Where adjuvant was used, the first 
immunization was done with complete Freund’s adjuvant, subsequent boosts were 
given in incomplete Freund’s adjuvant and the final boost was given without 
adjuvant.
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Generation of clonotype-specific mAb
Mice were injected intraperitoneally 4 times at 3- to 7-week intervals, with 5 x 106 
resting T cells in PBS. Five days after the final injection, mice were sacrificed and 
erythrocyte- and monocyte-depleted spleen cell populations were prepared as 
described previously [21, 24].
To preclear these spleen cell populations for B cells reactive to human CD3 or the 
constant region of TCRab, 3 x 107 ‘immune’ spleen cells were incubated twice 
with 20 pl SAM beads loaded with TCR/CD3 complexes derived from an 
irrelevant T-cell clone. Subsequently, B cells specific for the variable region of the 
TCR were selected by incubating the resulting cell suspension with SAM beads 
loaded with the TCR/CD3 complexes of the T-cell clone of interest. Each 
incubation was performed for 90 min at room temperature in DMEM/HAM’s F12, 
10% Calf Serum (Hyclone, Logan, UT, USA), 0.2% normal mouse serum. During 
these incubations, the suspension was homogenized every 5 min. After the final 
incubation, the beads were carefully washed five times with DMEM/HAM’s F12, 
10% Calf Serum and resuspended in the same medium.
Monoclonal antibody producing hybridomas were generated from these selected B 
cells by clonal expansion and mini-electrofusion as described previously [24]. 
Briefly, selected B cells were mixed with T-cell supernatant and 50,000 irradiated 
(2500 rad) EL-4 B5 cells at a final volume of 200 pl DMEM/HAM's F12, 10% 
FCS in 96-well flat bottomed tissue culture plates. On day 8, supernatants were 
tested in a one-step T-cell agglutination assay as described below using either the 
T-cell clone of interest or an irrelevant T-cell clone. B-cell cultures producing 
discriminating mAb were submitted to a mini-electrofusion procedure. The 
specific B-cells from these cultures were mixed with 106 NS-1 myeloma cells [25] 
and serum was removed by washing with DMEM/HAM's F12. Next, the cells 
were treated with pronase solution for 3 min and subsequently washed with fusion 
medium. Electrofusion was performed in a 50 pl fusion chamber by an alternating 
electric field of 30 s, 2 MHz, 400 V/cm followed by a square, high field pulse of 
10 ps, 3 kV/cm and again an alternating electric field of 30 s, 2 MHz, 400 V/cm. 
Finally, the contents of the fusion chamber were transferred to 20 ml selection 
medium and plated into a 96-well microtiter plate. On day 8 after fusion, the 
cultures were examined for hybridoma growth and screened in the one-step T-cell 
agglutination assay again.
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T-cell agglutination assay
For fast screening of hybridoma- and B-cell cultures on anti-clonotype antibodies, 
we devised a one-step agglutination assay. Comparing reactivity of the T-cell clone 
of interest and an irrelevant T-cell clone or line, this assay presented a rapid 
method to discriminate between reactivity to clonotypic determinants or reactivity 
to common T-cell markers. We found the agglutination assay to be more sensitive 
than an ELISA with intact cells and less laborious than FACS analysis. For 
example, up to 2000 supernatants could be screened in less than 4 hours.
Using half-area microtiter plates, 50 pl of hybridoma supernatant was mixed with 
20 pl bead/cell suspension containing 2 x 105 paramagnetic SAM-beads and 5 x 
104 T cells in DMEM/HAM’s F12. After 2 to 3 h of incubation at 37oC, 
agglutination was examined under a microscope. It was found that no wash steps 
are required at mAb concentrations between 50 ng/ml and 5 pg/ml which is within 
the limits usually found in hybridoma- and B-cell cultures.
Immunoprecipitation and Western blot
Ten to 14 days after restimulation, T cells were washed and cell surface proteins 
were labeled with biotin. Briefly, T cells were incubated at a concentration of 5 x 
106 cells/ml with 0.5 mg/ml sulfo-NHS-biotin in PBS for 30 min at room 
temperature. Subsequently, the cells were washed again and solubilized as 
described above. Before use in an immunoprecipitation experiment, the cell lysate 
was precleared once by incubating with SAM-paramagnetic beads. 
Immunoprecipitation was performed by incubating 107 cell equivalents of 
precleared lysate for 3-4 h with 15 pl SAM-paramagnetic beads preloaded with 
mAb (1 ml hybridoma supernatant). Then, immunoprecipitates were washed three 
times with PBS, boiled in sample buffer and submitted to SDS-PAGE on a 10% 
gel either under reducing conditions or non-reducing conditions. Immunoblotting 
was performed using PVDF membranes and streptavidine-alkaline phosphatase for 
detection. The blots were developed with BCIP and NBT as a chromogenic 
substrate.
For Western blot studies, paramagnetic SAM-beads were loaded with TCR/CD3 
complexes as described above using OKT3 as the immunoprecipitating antibody 
and non-biotinylated T-cell lysate. After SDS-PAGE on a 10% gel under reducing 
or non-reducing conditions, the blots were incubated with 2.5 ml hybridoma 
supernatant. Bound antibodies were detected using alkaline phosphatase- 
conjugated goat anti-mouse Ig and BCIP/NBT as substrate.
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Antibody mediated inhibition ofantigen-induced T-cell proliferation 
Twenty pl hybridoma supernatant, 2 x 104 resting T cells and 1 x 105 DRB1*0401- 
matched PBMC were added to flat-bottomed microtiter wells in 150 pl 
DMEM/HAM’s F12, 10% NHS. After 3 h incubation at 37oC, 50 pl of peptide 
FGRSFTLASSETGVG (16 pg/ml) was added to the cultures. After two days of 
incubation at 37oC, the cells were pulsed with 0.5 pCi [3H]-thymidine for another 
16 to 18 h. Finally, the cells were harvested onto glass fiber filters and [3H]- 
thymidine incorporation was measured by gasscintillation on a Matrix 96 
(Packard, Meriden, CT, USA). Each variable was tested in quadruplicate.
Antibody mediated T-cell proliferation
Flat-bottomed microtiter wells were coated (overnight, room temperature) with 
100 pl Sheep anti-mouse Ig at 40 pg/ml in PBS. The wells were washed once and 
then incubated with 100 pl mAb at a concentration of 2 pg/ml in PBS for 2 h. 
Excess of free mAb was removed by washing and 2.5 x 104 resting T cells were 
added in 200 pl DMEM/HAM’s F12, 10% NHS. The cultures were incubated for 
two days at 37oC and [3H]-thymidine incorporation was determined as described 
above. Each variable was tested in quadruplicate.
Results
Establishing the optimal immunization protocol
Initially, two different immunization strategies were performed. In the first 
strategy, we aimed at obtaining a TCR-specific immune response by using 
immuno-adsorbed TCR/CD3 complexes. As only very small amounts of TCR/CD3 
complexes can be isolated, paramagnetic beads were used as a carrier and in 
addition to conventional immunization routes, an intrasplenic immunization was 
performed. Intrasplenic immunization was previously found to be successful for 
minute amounts of antigen [26, 27]. Using SDS/PAGE and silver staining it was 
estimated that per immunization with 5 x 107 cell equivalents of TCR/CD3 
complexes, approximately 250 ng of TCR was injected (not shown). Alternatively, 
immunization was performed with intact T cells. In this case only a minor part of 
the immune response is expected to be directed against the TCR and therefore 
successful generation of clonotype-specific mAb depends on a powerful method 
for the selection of specific B cells, and on fast sensitive screening procedures. 
Table I shows the different immunization schedules used with T-cell clone H.258.
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Table I: Immunization schedules and characterization of sera
Immun.
group
antigen adjuvant route agglutination/FAC S 
H.258* SCR0.08A* 
(immun.) (irrelevant)
inhibition of 
Ag-driven 
proliferation*
Western
blot
I T cells none ip (5x) +++ +++ ++ -
II T cells; TCR/CD3 yes ip;im;im;im;ip +++ +++ ++ -
III TCR/CD3 yes sc;sc;sc;ip - - - -
IV TCR/CD3 none is (5x) + +/- - -
Normal Mouse Serum - - - -
Four groups of each two BALB/c mice were immunized with either intact T cells or immuno-adsorbed TCRJCD3 
complexes bound to paramagnetic beads. Immunizations were performed in the absence or presence of adjuvant as 
indicated. Different routes o f immunization were followed namely: ip = intraperitoneal; im = intramuscular; sc = 
subcutaneous; is = intrasplenic.
Sera from the mice were characterized for binding in a T-cell agglutination assay, FACS-staining and Western blot. 
Functional characterization was performed using a test for antibody-mediated inhibition of antigen-driven T-cell 
proliferation.
H.258= T-cell clone used for immunization; SCR0.08A= irrelevant T-cell clone.
* + means inhibition of T-cell proliferation.
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Sera of immunized mice were characterized in 3 different tests. First, the binding 
of antibodies to H.258 was tested and compared to an irrelevant, Va3V^14 
positive T-cell clone (SCRO.08A) by FACS and in an agglutination assay. Second, 
sera were tested for inhibition of antigen-induced proliferation of clone H.258 and 
third, sera were tested for staining of the specific TCR in a Western blot. High 
titers (>1:1200) were obtained in mice immunized with intact T cells as 
determined by both FACS staining and agglutination tests (Group I and II). As 
expected these sera did not discriminate in binding between the two different T- 
cell clones due to the great similarity of antigens on these T cells. No reactivity 
was found in Western blots with these sera. Further, these sera completely 
inhibited antigen-driven proliferation. This finding as such does not indicate 
reactivity to the TCR only, as the result can also be explained by reactivity to 
adhesion molecules or costimulatory molecules. On the other hand, mice 
immunized with purified TCR/CD3 complexes by a conventional route (group III) 
did not show any reactivity in these tests. Mice immunized with TCR/CD3 
complexes by the intrasplenic route (group IV) showed a low-titered response 
(1:100 in the agglutination assay). Moreover, a discrimination in binding to clone 
H.258 compared to clone SCRO.08A was found in both FACS staining and 
agglutination, thereby suggesting specificity for the variable region of the H.258 
TCR. However, no inhibition of antigen-driven proliferation was observed nor any 
reactivity was found in a Western blot.
The spleen cells from the mice in group I, II, en IV were submitted to the 
procedure for the generation of anti-clonotype mAb. Such mAb, however, were 
obtained only from the mice in group I as described in more detail below. Some 
anti-T cell reactive mAb were obtained from the mice in group II and IV, but the 
antibodies were not able to discriminate between the T-cell clone of interest and 
the irrelevant T-cell clone. The difference in results obtained from group I and 
group II suggests that the use of Freund’s adjuvant has an adverse effect on the 
generation of anti-clonotype antibodies.
Generation of anti-clonotype mAb
After we had established the optimal immunization schedule with T-cell clone 
H.258, we applied the same schedule for the HC gp-3 9-specific T-cell clone, 
H.243. Spleen cells from mice immunized according to schedule I (Table I) were 
depleted for erythrocytes and monocytes. Then, the cells were incubated with 
paramagnetic beads loaded with TCR/CD3 complexes from the irrelevant, 
Va3Vb14-positive clone SCRO.08A. After this incubation, a large number of
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Table II: Outgrowth o f  anti-T cell specific B cells in EL-4 B-cell cultures
Number of 
wells 
inoculated
Plating
density
Number of wells 
with B-cell 
outgrowth
Agglutination 
with H.243
Agglutination 
with H.258
384 x 384 68 40
192 1/6 x 171 13 7
192 1/36 x 81 3 1
28 x  1 0  lymphocytes were submitted to an immunobead selection procedure for 
the selection of anti-clonotype specific B cells. The selected B cells were expanded 
at different plating densities in an EL-4 B-cell culture system and on day 8, 
supernatants were tested for agglutinating antibodies with the T cells o f interest 
(H.243) and irrelevant T cells (H.258).
x: undetermined number of selected cells; number of cells was too low for 
counting.
rosetted cells were visible indicating a successful removal of B cells reactive to 
common determinants on CD3 and TC R ab In a second round of preclear, very 
few rosettes were observed. In order to select B cells specific for the clonotype of 
interest, the resulting cell suspension was incubated with paramagnetic beads 
loaded with TCR/CD3 complexes from clone H.243. Following this incubation we 
did not observe any rosettes, which is explained by the low number of these 
specific B cells. Nevertheless, collected beads were plated at 3 serial dilutions in a 
B-cell culture system to create limiting dilution conditions for clonal outgrowth of 
B cells. After an incubation period of 8 days, the B-cell supernatants were tested in 
an agglutination assay with clone H.243 and an irrelevant clone H.258 (Va2,V^3). 
Supernatants from 36 B-cell cultures were found to agglutinate H.243 cells but not 
H.258 cells (Table II). Supernatants from 48 B-cell cultures agglutinated both 
clones indicating that these B cells had escaped from the preclear procedures. 
Eighteen B-cell cultures specific for the H.243 clone, were submitted to a mini­
electrofusion. Some fusions did not result in T-cell specific hybridomas and some 
others could not be cloned to stable cell lines. Ultimately, stable hybridomas were 
obtained from 11 out of 18 mini-electrofusions. The isotypes of these mAb are 
shown in Table III.
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Specificity o f mAb
To investigate the fine specificity of these 11 mAb, we first used an extended T- 
cell agglutination test to further discriminate between reactivity for clone H.243 
and other defined T-cell clones or lines. Second, we characterized the nature of the 
molecules recognized by the mAb using immunoprecipitation. In addition, the 
reactivity of the mAb in Western blots was determined.
Fine specificity of the mAb for T-cell clone H.243 was determined in an 
agglutination test with clone H.243, another six V^9-positive T-cell lines or 
clones, two Va8 positive T-cell clones and eight T-cell clones expressing other 
Va's and V b’s (Table III). The results show that mAb TCR 74 is Vp9-specific as it 
agglutinates exclusively all V^9-positive T-cell lines. All other TCR antibodies 
agglutinated clone H.243 only, thereby excluding reactivity to Va8, V^9, the 
constant region of TCRab, CD3 and other common T-cell surface molecules. 
Thus, it is very likely that these antibodies are directed against the antigen-binding 
part of the H.243 TCR.
Next, we addressed the question whether the mAb are indeed directed to the TCR 
and not to another unique molecule on H.243. SDS/PAGE under non-reducing 
conditions shows that all mAb are able to immunoprecipitate a major band of 
approximately 85 kD and a minor band of 21 kD from a digitonin lysate of T-cell 
clone H.243. This is consistent with the molecular weight of the TCRa^-complex 
and of CD3 chains e/5 respectively. Under reducing conditions the 85 kD band 
dissociates into two bands of 40 and 50 kD which is consistent with the size of the 
TCR a- and b chains respectively. The immunoblot of one of the anti-H.243 
specific mAb is shown in Figure 1, together with OKT3 as a positive control and 
an irrelevant mAb as a negative control.
In addition, all anti-clonotype antibodies stained the TCR (85 kD band) in a 
Western blot run under non-reducing conditions. (Figure 2). Staining of the IgM 
mAb (TCR 72, TCR 78 and TCR 83) was less pronounced which is probably due 
to the fact that the anti-Ig conjugate does not react equally well with IgM. The 
non-specific, high molecular weight bands at the top of the blot originate from the 
immunoprecipitating antibodies SAM and OKT3. No staining with the anti­
clonotype mAb was seen in a Western blot run under reducing conditions (not 
shown). These data suggest that the mAb recognize a conformational epitope 
formed by the intact TCRab complex.
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Table III: Agglutination of different T-cell clones or lines with anti-TCRmAb.
T cell Stimul. Va,Vß clone TCR TCR TCR TCR TCR TCR TCR TCR TCR TCR TCR BMA
usage or line 64 66 69 70 72 73 74 76 78 79 83 031
IgG2a IgGl IgGl IgG2a IgM IgGl n.d. IgG2a IgM IgGl IgM IgG2b
H.243 antigen Va8,Vß9 clone + + + + + + + + + + + +
H.258 antigen Va2,Vß3 clone - - - - - - - - - - - +
H.156.VB09 anti-V(39 Vß9 line - - - - - - + - - - - +
H.183.VB09 anti-V(39 Vß9 line - - - - - - + - - - - +
H.222.VB09 anti-V(39 Vß9 line - - - - - - + - - - - +
H.236.VB09 anti-V(39 Vß9 line - - - - - - +/- - - - - +
H.276.VB09 anti-V(39 Vß9 line - - - - - - + - - - - +
VB09 IL-2 Vß9 clone - - - - - - + - - - - +
SCR0.08B PHA Va8,Vß4 clone - - - - - - - - - - - +
SCR0.08C PHA Va8,Vß24 clone - - - - - - - - - - - +
SCR0.08A PHA V a3,Vßl4 clone - - - - - - - - - - - +
H.261.001 antigen n.d. clone - - - - - - - - - - - +
H.263.001 antigen Vßl3 clone - - - - - - - - - - - +
MTHUT.07C antigen n.d. clone - - - - - - - - - - - +
H.258 A9A antigen Vßl3 clone - - - - - - - - - - - +
VB03 IL-2 Vß3 clone - - - - - - - - - - - +
JURKAT - Vß8 clone - - - - - - - - - - - +
Fifty ¡il ofhybridoma supernatant was mixed with 20 ¡il bead/cell suspension containing 2 x  l ( f  paramagnetic 
SAM-beads and 5 x  101 T cells as indicated. After incubation at 37°C, agglutination was examined.
+: strong agglutination; +/-: moderate agglutination; no agglutination.
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Figure 1: Identification of H.243 T-cell surface molecules immunoprecipitated by 
MAb directed against H.243.
SDS/PAGE was performed under non-reducing conditions (lane 2, 3 and 4) or 
under reducing conditions (lane 5, 6 and 7) in a 10 % gel. Lane 1: 10 kD ladder 
marker; lane 2 and 5: control MAb; lane 3 and 6: TCR 83; lane 4 and 7: anti- 
CD3, OKT3.
85 kD —►
1 2 3 4 5 6 7 8 9 10 11 12 13
Figure 2: Anti-clonotype MAb recognize TCRaB in Western blotting.
Anti-CD3 immunoprecipitated TCR/CD3 complexes of H.243 were resolved on a 
10% SDS-PAGE gel under non-reducing conditions and subsequently transferred 
to PVDF membranes. The membranes were incubated with MAb and finally the 
bound MAb were detected by using an alkaline phosphatase-conjugated goat anti­
mouse Ig second antibody. Lane 1: 10 kD ladder marker, lane 2: TCR 64, lane 3: 
TCR 66, lane 4: TCR 69, lane 5: TCR 70, lane 6: TCR 72, lane 7: TCR 73, lane 8: 
TCR 76, lane 9: TCR 78, lane 10: TCR 79, lane 11: TCR 83, lane 12: control 
MAb, lane 13: medium control.
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Antibody mediated inhibition ofantigen-induced T-cell proliferation 
After we had established the specificity of the mAb for the TCR of H.243, we 
investigated whether the mAb could inhibit antigen-driven proliferation of this T- 
cell clone. In this experiment, mAb were pre-incubated with T cells and APC and 
3 hours later, pulsed with different concentrations of peptide. All mAb were found 
to inhibit antigen-driven proliferation of clone H.243, as compared to a set of 
control mAb (mAb1 to mAb4) (Figure 3a). More specifically, the IgG2a subclass 
mAb (TCR 64, TCR 70, TCR 76), and two IgM mAb (TCR 78 and TCR 83) 
almost completely blocked antigen-driven proliferation, whereas inhibition by the 
IgG1 mAb (TCR 66, TCR 69, TCR 73, TCR 79) and one IgM mAb (TCR 72) was 
less pronounced. As expected, an anti-clonotype mAb specific for an irrelevant 
clone prepared by the same procedure (TCR 44 directed against clone H.258) did 
not have an effect on antigen recognition by clone H.243. The inhibition patterns 
were not dependent on suboptimal or saturating concentrations of peptide (results 
not shown).
Inhibition of antigen-recognition was then assessed at different concentrations of 
mAb (Figure 3b). Dose response curves of TCR 64, TCR 70 and TCR 83 show 
that maximal inhibition could be obtained with as little as 100 ng/ml. For 
comparison, TCR 78 was approximately tenfold less potent.
Antibody induced T-cell proliferation
We next addressed the question whether the clonotype-specific mAb can trigger 
the H.243 clone by its receptor and thereby induce proliferation. For this purpose, 
mAb were immobilized on flat-bottomed microtiter plates and incubated with
H.243 T cells. Figure 4 shows that all specific mAb induced proliferation of H.243 
cells in this assay. The magnitude of the response obtained with TCR 64, TCR 66, 
TCR 70, TCR 73, TCR 76 and TCR 79 was comparable to the response of anti- 
CD3 (OKT3). TCR 69 and TCR 78 were only weakly mitogenic (< 500 cp5m) 
whereas TCR 72 and TCR 83 induced an intermediate response. No proliferation 
was induced by the set of control mAb (mAb 1 to-4) and the irrelevant anti­
clonotype mAb TCR44.
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Figure 3: Pre-incubation with anti-TCR mAb inhibits or blocks antigen-driven proliferation 
of human T-cell clone H.243.
a) Inhibition by mAb directed against H.243 (TCR 64 to TCR 83) was compared to control 
mAb as indicated and to TCR 44, an anti-clonotype mAb specific for clone H258. Each 
value represents the mean counts per 5 min of quadruplicate cultures + standard deviation.
b) dose response curves of strong inhibiting mAb; TCR 64 (open circles), TCR 70 (closed 
triangles), TCR 78 (open squares), TCR 83 (closed squares) and control mAb 1 (closed 
circles). Each value represents the mean counts per 5 min of triplicate cultures.
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Figure 4: Immobilized anti-TCR mAb stimulate proliferation of human T-cell clone
H.243.
Proliferation induced by mAb directed against H.243 (TCR 64 to TCR 83) was 
compared to control mAb as indicated and to TCR 44 which is an anti-clonotype 
mAb directed against another TCR. Each value represents the mean counts per 5 
min of quadruplicate cultures + standard deviation.
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Discussion
Until now, the generation of clonotype-specific mAb for human T-cell clones has 
met with little success. This paper describes a new strategy for the generation of 
anti-clonotype mAb directed against human T-cell receptors. The strategy can be 
used for any TCR of interest and does not require large numbers of T cells or 
purified TCR. It comprises the following sequence of steps:
1) immunization of mice with intact human T cells without adjuvant,
2) isolation of splenic lymphocytes and depletion of B cells specific for CD3 
or the constant region of the TCR,
3) positive selection of anti-clonotype specific B cells,
4) clonal expansion of selected B cells,
5) double screening of B-cell culture supernatants in a one-step agglutination 
assay using the T-cell clone of interest and an irrelevant T-cell clone,
6) mini-electrofusion of B-cell cultures producing antibodies specific for the 
T-cell clone of interest
7) retesting of hybridomas and cloning to stability.
We have shown here by two different examples that this strategy was successful 
for the generation of mAb to clonotypic determinants on TCR. A similar strategy 
may be followed for the generation of mAb to other cell surface molecules or for 
the generation of anti-idiotypic antibodies. The approach followed here may be an 
attractive alternative for recombinant DNA procedures in which soluble TCR are 
generated or in which the TCR is expressed on syngeneic mouse cells which are 
then used for immunizations.
We have evaluated different routes of immunization to evoke an immune response 
to a given TCR. One strategy involved immunization with small amounts of 
purified, immuno-adsorbed TCR/CD3 complexes coupled to paramagnetic beads. 
The advantage of such strategy is that predominantly antibodies to TCR and CD3 
will be induced. From mice injected with purified TCR/CD3 complexes, however, 
no anti-clonotype mAb were obtained. Apparently, the amount of antigen equal to
5 x 107 cell equivalents is not sufficient to induce the required response. 
Intrasplenic immunization with purified TCR/CD3 complexes did not overcome 
this problem. The second strategy, involving immunization with whole T cells 
proved to be more successful. Suprisingly, only the immunization without 
Freund’s adjuvant led to the generation of clonotype-specific mAb. One may argue 
that the oil in the adjuvant changes the structure of the TCR in a way that the 
resulting antibodies can no longer recognize the native clonotype. Following
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immunization of mice with intact human T cells, the ensuing response is expected 
to be directed to a multitude of antigenic determinants on the T cells due to the 
species difference. Success will therefore depend on a superior selection method 
for clonotype-specific B-cells and a proper assay for screening on anti-clonotype 
mAb. In order to accomplish this, we have combined preselection of specific B- 
cells with a cell agglutination assay enabling fast screening on anti-TCR reactivity. 
The one-step agglutination assay using intact T cells as the source of antigen was 
designed to circumvent the fact that purified TCR is not readily available. The 
assay involves mixing of mAb sample, T cells and paramagnetic beads. Reactivity 
of the antibody results in agglutination of beads and cells. To discriminate between 
antibodies directed against the variable region of the TCR and antibodies to 
common T-cell determinants including the constant region of the TCR, two 
agglutination assays were performed viz. with the T-cell clone of interest and with 
an irrelevant T-cell clone.
In this report, a set of 11 mAb was generated with specificity for the TCR of the 
autoreactive, HC gp-39-specific T-cell clone. One of these mAb was specific for a 
common determinant on V^9, whereas ten mAb were specific for the antigen- 
binding part of the H.243 TCR. This was exemplified by immunoprecipitation of 
the TCR, staining of the TCRab chains in a Western blot and in agglutination tests 
in which the reactivity of the mAb to H.243 was compared with a set of 16 Va- 
and Vb-characterized T-cell clones or lines against unrelated antigens.
All anti-clonotype mAb appeared to inhibit or block antigen-driven proliferation of 
clone H.243. In an assay using DR-matched PBMC as APC, up to 98% inhibition 
of proliferation was observed. This inhibition was independent of the amount of 
antigen added. Possibly the antibodies bind so strong to the TCR that no 
competition with relatively weak binding MHC/peptide complexes [28] takes 
place. One may argue that all antibodies are able to completely block 
MHC/peptide binding. The residual proliferation (limited inhibition) observed 
with some antibodies can then be explained as antibody induced proliferation 
instead of antigen induced proliferation. In this case cross-linking of the mAb is 
not obtained by binding to the plastic surface of culture plates but by Fc-receptors 
on the APC added. Especially the four IgG1 antibodies showed relatively high 
proliferation compared to the IgG2a which may be explained by a better binding of 
mouse IgG1 to human Fc-receptors. The IgM antibodies can not be cross-linked in 
this experimental set up (no Fc-p receptors are available) but this pentameric 
molecule may be able to crosslink by itself.
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Indeed, when crosslinked on plastic surface, all anti-clonotypic mAb were found to 
induce proliferation of clone H.243. However, the magnitude of the proliferative 
response differed. Some mAb induced strong proliferation comparable to 
proliferation induced by OKT3 whereas others were only weakly mitogenic.
The functional data suggest that different epitopes are recognized on the same 
clonotypic structure. It is likely that the three IgM antibodies recognize three 
different clonotypic determinants. TCR 78 and TCR 83 strongly inhibit antigen- 
induced proliferation. TCR 78, however, is tenfold less potent in its inhibiting 
capacity than TCR 83. Both mAb induce only weak proliferation of H.243 as 
opposed to the third IgM (TCR 72), which is strongly mitogenic for H.243. With 
respect to the IgG1 subclass mAb it can be remarked that TCR 69 is different from 
the others (TCR 66, TCR 73 and TCR 79) because it is less mitogenic. The three 
IgG2a mAb show a similar behavior in both functional assays and therefore may 
be directed to a single clonotypic determinant.
We have generated and characterized a set of mAb specific for at least three 
different clonotypic determinants on the autoreactive TCR of clone H.243. The 
finding that these mAb can block or conversely, trigger the T cell by its receptor 
suggests that such mAb may be used in the deletion or modulation of T cells in a 
clonotype specific manner. It is anticipated that such mAb may be used to 
manipulate the autoantigen-specific response in T-cell mediated autoimmune 
diseases such as rheumatoid arthritis.
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T-cell anergy induced by clonotype-specific antibodies: 
Modulation of an autoreactive human T-cell clone in vitro
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Summary
Monoclonal antibodies specific for the clonotype of an autoreactive T cell may be 
useful reagents in the modulation of autoimmune disease. We have previously 
reported the generation of a set of MAb specific for the clonotypic structure of a 
human T-cell clone recognizing an epitope of Human Cartilage gp-39, which was 
recently identified as a candidate autoantigen in rheumatoid arthritis.
Here, we demonstrate that small amounts of immobilized anti-clonotype MAb can 
induce anergy in the autoreactive clone. Following the anergic stimulus, T cells 
failed to proliferate upon restimulation as a result of a lack of IL-2 gene 
transcription. In addition, a diminished IFNg production was found. Our data 
indicate that anergy was not a result of TCR downmodulation or the absence of 
free TCR.
The anergic state was induced independent of costimulation or the presence of IL- 
2 and no protein synthesis was required for the induction of anergy. Anti­
clonotype MAb induced anergy was prevented by cyclosporin A, suggesting that 
active signaling via the calcium/calcineurin pathway was required for the 
induction of anergy. In coculture experiments, anergic T cells were found to 
suppress the response of reactive cells from the same clone. This bystander 
suppression led to 90% inhibition of proliferation. Our data are the first 
demonstration of the anergizing potential of clonotype-specific antibodies in vitro. 
Such MAb can be used for the induction and maintenance of antigen-specific T- 
cell tolerance in rheumatoid arthritis.
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Introduction
Current therapies for autoimmune diseases are often non-specific and suffer from 
major side effects. The induction of antigen-specific peripheral tolerance is 
therefore considered an attractive approach for treatment of autoimmune diseases. 
One of the mechanisms underlying peripheral tolerance is T-cell anergy or 
unresponsiveness [1], which is defined as a state in which the T cell is alive but 
fails to respond to its antigen presented by functional antigen presenting cells 
(APC). Failure of such cells to proliferate is caused by a defective IL-2 production 
as a result of an IL-2 transcriptional block [2].
Several models of T-cell anergy have been reported [reviewed in 2-4]. Anergy has 
been described as a result of TCR occupancy in the absence of costimulation. 
Anergy has also been obtained by partial triggering of TCR mediated by peptide 
analogues of an immunogenic peptide (APL) presented on a functional APC. In 
another model, anergy has been obtained by stimulation of human T-cell clones in 
the presence of high concentrations of peptide.
Monoclonal antibodies (MAb) directed to the clonotypic structure of relevant T 
cells may be used to manipulate autoantigen specific T-cell responses and hence 
treat autoimmune diseases in a specific manner. These T cells may be identified on 
the basis of their antigen specificity or from dominant TCR rearrangement at the 
site of the lesions. An example of the latter are the TCR expressed in the brains of 
multiple sclerosis (MS) patients that show a restricted usage of CDR3 motifs [5]. 
Similar motifs are present in myelin basic protein-specific T-cell clones derived 
from MS patients and encephalitogenic T-cell clones from Lewis rats [6]. 
Clonotype specific MAb may exert their immunosuppressive effect by depletion of 
the autoreactive T cells or blocking of antigen induced proliferation. Another 
possible mechanism of action for the MAb may be modulation of T cells by the 
induction of anergy as has already been shown in a non-specific manner for anti- 
CD3 MAb [7-9]. In addition to the high specificity and the high affinity of anti­
clonotype MAb, an antibody approach offers the possibility to manipulate the 
therapeutic effect by the molecular design. The construction of single chain MAb 
or specific human Fc-regions coupled to high affinity anti-clonotypic MAb can 
provide for a low dose effect with good pharmacokinetics [9-11], and at the same 
time minimize the risk of inadvertent T-cell stimulation. Moreover, anti-clonotype 
MAb can be used in case clonally expanded T cells are isolated from patients and 
the antigen is not known.
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We have previously reported the identification of Human Cartilage gp-39 (HC gp- 
39) as a candidate autoantigen in rheumatoid arthritis [12]. Peptides encompassing 
amino acids 263-27S of this protein are recognized by 3G to 40% of rheumatoid 
arthritis patients. Furthermore, we have isolated a Thl clone recognizing epitope 
HC g p ^ 263-2”  in the context of DRB1*0401 and generated a set of MAb directed 
against the clonotype of this autoreactive human T-cell clone. The MAb were 
found to block antigen-induced proliferation of the autoreactive T-cell clone. In 
addition, the MAb were able to trigger the T-cell by its receptor [Steenbakkers et 
al.; submitted]. In the present study, we show that these MAb can modulate the 
response of the T-cell clone by the induction of anergy in vitro. The mechanism 
underlying this type of anergy was investigated and related to other models of T- 
cell anergy.
Materials and methods
Reagents
The medium used in all culture experiments was DMEM/HAM’s F12 modified 
(Gibco BRL, Paisley, UK, cat. no. 041-9182S).
Mouse anti-clonotype MAb to human T-cell clone H.243 were generated as 
described by Steenbakkers et al. [Generation and functional characterization of 
anti-clonotype antibodies to human T-cell receptors; submitted for publication]. 
TCR 64, TCR 7G and TCR 76 are of the IgG2a class. TCR 66, TCR 69, TCR 73 
and TCR 79 are of the IgGl class. TCR 72, TCR 78 and TCR 83 are IgM. In 
functional assays, these MAb were found to inhibit or block antigen-driven T-cell 
proliferation. In addition, cross-linked MAb were found to stimulate proliferation 
of the H.243 clone. MAb ZP 7A directed to zona pellucida was used as a control 
antibody [provided by Dr. M. van Duin, Organon, Oss, The Netherlands].
Peptide HC gp-3926l-27S (FGRSFTLASSETGVG) and HC gp-3 9262"277 
(GRSFTLASSETGVGAP) were synthesized by solid phase peptide synthesis 
using an automated Milligen 9GSG synthesizer and purified by reverse phase 
HPLC.
Primers were synthesized using a DNA synthesizer (Applied Biosystems 394) 
according to the manufacturer’s instructions. IL-2 S’ primer 
AACTCCTGTCTTGCATTGCA was synthesized according to the sequence 
reported by Sorg et al. [13] and IL-2 3’ primer TGTTTCAGATCCCTTTAGTTC 
was deduced from the EMBL data bank (fragment length 3SG bp). Glyceraldehyde-
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3-phosphate dehydrogenase (GAPDH) 5’ primer
CCCTTCATTGACCTCAACTACATGG and GAPDH 3’ primer 
GGTCCACCACCCTGTTGCTGTAGCC were deduced from the sequence in the 
EMBL data bank (fragment length 874 bp).
T-cell clone
T-cell clone H.243 was derived from a rheumatoid arthritis patient as described by 
Verheijden et al. [12]. This Th1-like T-cell clone recognizes epitope 
RSFTLASSETGV from HC gp-39 in the context of HLA-DRB 1*0401. Upon 
antigen-specific stimulation the clone was found to produce IL-2 and large 
amounts of IFNg as opposed to small amounts of IL-4. The TCR of this clone is 
characterized as Va8 and V^9. Cells were routinely cultured in DMEM/HAM’s 
F12, 10% NHS, 20 U/ml rIL-2, 5 U/ml IL-4, and periodically restimulated with 
antigen and histocompatible APC, or with PHA and feeder cells.
Induction of anergy using clonotype-specific MAb
Twenty-four well culture plates were coated (overnight, room temperature) with 1 
ml Sheep anti-mouse Ig at 40 pg/ml in PBS. The wells were washed once and then 
incubated with 1 ml MAb at a concentration of 2 pg/ml in PBS for 2 h. Excess of 
free MAb was removed by washing and 2 x 106 washed, resting T cells were added 
in 2 ml DMEM/HAM’s F12, 10% NHS. Where indicated cyclosporin A (Sandoz, 
Bazel Switzerland), rIL-2, cycloheximide (Sigma, St Louis, MO, USA) or HLA- 
DRB1*0401 matched APC (3000 rad irradiated) were added at the time of culture 
initiation. After overnight incubation, the plates were chilled on ice and the T cells 
were resuspended by pipetting. The cells were washed once with complete culture 
medium and used for a T-cell proliferation assay, cytokine analysis and FACS 
analysis as described below.
T-cell proliferation assay
The antigen-specific proliferative response of T cells was assessed in flat- 
bottomed microwell cultures containing 2 x 104 T cells, 1 x 105 HLA-DRB1*0401 
matched, irradiated (3000 rad) PBMC and variable antigen concentrations in 200 
pl DMEM/HAM’s F12, 10 % NHS. After two days incubation at 37 oC, the cells 
were pulsed with 0.5 pCi [3H]-thymidine and incubated for another 16-18 hours. 
Finally, the cells were harvested onto glass fiber filters and [3H]-thymidine 
incorporation was measured by gasscintillation on a Matrix 96 (Packard, Meriden, 
CT, USA). Each variable was tested in triplicate. Control cultures were stimulated
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with either 2.5 pg/ml PHA or blank medium. The proliferative response to IL-2 
was assessed by incubating T cells with 20 U/ml rIL-2 in the absence of APC.
FACS analysis
In order to determine the number of free TCR after anergy induction, four different 
stainings were performed. First, non-anergic H.243 T cells obtained from an 
incubation with control MAb ZP 7A, were stained with GaM-FITC (Beckton & 
Dickinson). The fluorescence-intensity of these cells reflects the background 
fluorescence level. Second, anergic H.243 cells obtained from incubation with 
anti-clonotype MAb were stained with GaM-FITC. The fluorescence-intensity of 
these cells reflects the amount of anti-clonotype MAb left on the cells from the 
anergic stimulus. Third, anergic H.243 cells were first incubated with an excess of 
the same anti-clonotype MAb that was used for anergy induction and then stained 
with GaM-FITC. This fluorescence reflects the total amount of TCR present on 
these anergic cells. The difference in fluorescence between the third and the 
second staining reflects the amount of free TCR present on anergic cells. Fourth, 
non-anergic H.243 cells were indirectly stained with the anti-clonotype MAb as 
the primary antibody and GaM-FITC as the secondary antibody. The fluorescence 
of these cells reflects the total amount of TCR present on non-anergic cells. The 
difference in fluorescence between the fourth and the third staining reflects 
downmodulation of TCR during the induction of anergy.
IL-2 receptor expression was determined by staining with anti-CD25/FITC 
(Beckton & Dickinson). All stained cells were analyzed with the FACScan 
(Beckton & Dickinson). In all cases, forward and side scatter analysis was applied 
to eliminate dead cells and debris from further analysis.
Cytokine analysis
For cytokine analysis, wells of 24-well culture plates were inoculated with 5 x 105 
T cells, 2.5 x 106 DRB1*0401-matched PBMC (3000 rad irradiated) and variable 
antigen concentrations in 750 pl DMEM/HAM’s F12, 10 % NHS. Control cultures 
were performed with either 2.5 pg/ml PHA or blank medium.
After 4 h incubation at 37 oC, the cells were harvested for IL-2 mRNA analysis by 
RT-PCR. Briefly, cells were washed once with PBS and RNA was extracted using 
the RNAzoltm B method (Campro Scientific, Veenendaal, The Netherlands). Then, 
cDNA was prepared with Superscript II reverse transcriptase. Finally PCR 
amplification was performed using specific primer sets for IL-2 and for a 
housekeeping enzyme, GAPDH. cDNAs were amplified for 30 cycles, each one 
performed at 94 oC for 30 s, 55 oC for 30 s and 72 oC for 1 min. The PCR products
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were loaded on an agarose gel containing 1 % agarose and 0.5 pg/ml ethidium 
bromide and electrophoresed at 120 V for approximately 1 h. Fragments of DNA 
were visualized under UV light. The 100 bp DNA ladder marker (Gibco) was used 
to determine the fragment length of each PCR fragment.
From duplicate cultures, supernatants were harvested after 24 h of culture and 
tested for IFNg in a specific capture ELISA. Anti-IFNg (M700A; Endogen, 
Cambridge, MA, USA) was used as the capture antibody and anti-IFNg (M701; 
Endogen) conjugated to HRP was used for detection. Recombinant human IFNg 
(Campro Scientific) was used as a standard.
Results
Anti-clonotype MAb induce unresponsiveness o f human T-cell clone H.243 to 
subsequent stimulation with antigen and APC
T-cell receptor occupancy in the absence of costimulation is known to induce 
anergy. Previously we had found that immobilized anti-clonotype MAb to H.243 
can functionally trigger the TCR of this clone [Steenbakkers et al.; submitted]. 
Therefore, it was interesting to investigate whether the same antibodies could 
induce anergy. For this purpose, 10 different anti-clonotype MAb were 
immobilized on 24-well plates and incubated overnight with H.243 T cells to give 
the anergic stimulus. Then, T cells were removed from the plates and it was tested 
whether they could respond to increasing concentrations of HC gp-3 9262-277 
presented by irradiated, DRB 1*0401 -matched APC. Figure 1 shows that this 
response was completely abrogated by 8 out of 10 MAb whereas H.243 cells 
incubated with a control MAb (ZP 7A) still responded well to peptide presented by 
APC. The response of T cells incubated with TCR 69 and TCR 83 was 
significantly reduced but not completely abrogated at higher peptide 
concentrations.
Unresponsiveness is not due to poor cell viability or lack of free TCR 
In the next experiment, the properties of the unresponsive T cells obtained from 
incubation with anti-clonotype MAb were characterized in more detail. Anergy 
was induced by immobilized TCR 76 (anergic cells) and compared with an 
immobilized control MAb, ZP 7A (non-anergic cells). Following the induction 
phase, T cells were stimulated with increasing concentrations of HC gp-39261-275 or 
PHA and irradiated, DRB 1*0401-matched APC. In addition, the T cells were
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Figure 1: Anti-clonotype MAb induce anergy in human Th1-clone H.243. 
Immobilized anti-clonotype MAb or control MAb, ZP 7A, were incubated 
overnight with H.243 T cells. After removal o f the cells from the anergic stimulus, 
the cells were given a full stimulus of increasing concentrations o f peptide and 
DRB1 *0401 matched APC. Proliferation was assessed by 3H-thymidine 
incorporation. Each value represents the mean counts per 5 min of triplicate 
cultures +/- standard deviation.
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Figure 2: Induction ofanergy by anti-clonotype MAb TCR 76.
a) Unresponsiveness is not due to cell-death or apoptosis.
Immobilized TCR 76 (anergic cells) or control MAb, ZP 7A, (non-anergic cells) 
were incubated overnight with H.243 T cells. After removal o f the cells from the 
anergic stimulus, the cells were given a full stimulus o f DRB1*0401 matched APC 
and PHA or increasing concentrations o f peptide. In addition, T cells were 
incubated with IL-2 in the absence of APC. Proliferation was assessed by 3H- 
thymidine incorporation. Each value represents the mean counts per 5 min of 
triplicate cultures + standard deviation.
b) Unresponsiveness is not due to TCR blockade or downmodulation.
Non-anergic H.243 T cells resulting from incubation with immobilized ZP 7A 
(histograms 1 and 4) or anergic T cells resulting from incubation with immobilized 
TCR 76 (histograms 2 and 3) were stained directly with GaM-FITC (histograms 1 
and 2) or indirectly with TCR 76 and GaM-FITC (histograms 3 and 4). Histogram 
1 reflects background fluorescence level, histogram 2 reflects the number of TCR 
molecules occupied with anti-clonotype MAb after removal from the anti­
clonotype MAb coated plates, histogram 3 reflects the total number of TCR 
molecules on anergic cells and histogram 4 reflects the total number of TCR 
molecules on non-anergic cells. The difference in fluorescence between histograms
1 and 2 represents the amount o f TCR 76 antibody left on the cells from the 
anergic stimulus. The difference in fluorescence between histograms 2 and 3 
represents the amount o f free TCR molecules present on anergic cells. The 
difference between histograms 3 and 4 represents TCR downmodulation from the 
anergic stimulus.
c) and d) represent similar experiments performed with free TCR 76 instead of 
immobilized TCR 76.
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stimulated with IL-2 in the absence of APC. HC gp-39261"275 was used in this 
experiment instead of HC gp-3 9262-277 because this peptide is superior in 
stimulating T-cell clone H.243. As shown in Figure 2a, approximately 90% 
reduction of the proliferative response was observed after incubation with anti­
clonotype MAb, whereas the cells responded normally to PHA indicating cell 
viability. In addition, anergic cells were found to respond to IL-2 as opposed to 
non-anergic cells. This is in agreement with an increased level of CD25 expression 
on anergic cells (data not shown).
Next, we investigated the availability of free TCR molecules after the anergic 
stimulus. For this purpose, four different stainings were performed on the cells 
from the experiment described above. Non-anergic cells were either directly 
stained with GAM-FITC or indirectly with TCR 76 and GAM-FITC (Figure 2b, 
histogram 1 and 4 respectively). Anergic cells were also directly stained with 
GAM-FITC or indirectly with TCR 76 and GAM-FITC (Figure 2b, histogram 2 
and 3 respectively). The difference in fluorescence between histogram 1 and 2 
reveals that a small amount of anti-clonotype MAb was still bound to the T cells 
after removal from the anergic stimulus. Apparently, some MAb was detached 
from the plastic surface together with the T cells. Although TCR 76 itself is 
mitogenic at higher concentrations (> 0,5 pg/ml), the small amount of MAb left on 
the cells did not lead to proliferation (Figure 2a, no antigen added). Further, from 
the difference between histogram 4 and 3, it can be deduced that TCR expression 
is slightly downmodulated on the T cells after the overnight anergy-induction 
phase. However, the difference in fluorescence intensity between the histograms 3 
and 2 reveals that the majority of TCR molecules are still freely available on 
anergic cells, suggesting that TCR blocking or downmodulation are not 
responsible for the anergic state. Note that the x-axis scale is logarithmic. Similar 
results were obtained with two other anti-clonotype MAb, TCR 66 and TCR 70 
(results not shown).
To provide further evidence that T-cell anergy is not due to the residual amount of 
MAb left on the cells after the anergic stimulus or to TCR downmodulation, the 
experiment was repeated with free TCR 76 instead of immobilized TCR 76 (Figure 
2c and 2d). TCR 76 was previously shown to block antigen-induced proliferation 
of H.243 in this experimental setting (Steenbakkers et al. submitted). Comparing 
Figure 2d with Figure 2b, it can be deduced that more TCR molecules are 
occupied after incubation with free TCR 76 and that the same level of TCR 
downmodulation was achieved. As a consequence only a few free TCR molecules
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were available on the cells incubated with free TCR 76 (Figure 2d, difference 
between histogram 3 and 2). Despite these observations, the cells responded to 
antigen and APC. These observations support that neither TCR blocking by MAb 
left on the cells after the anergic stimulus nor TCR downmodulation as observed in 
Figure 2b are responsible for the unresponsiveness of H.243 incubated with 
immobilized TCR 76 (Figure 2a). Moreover, the number of free TCR molecules 
after incubation of H.243 with immobilized TCR 76 (Figure 2b, difference 
between histogram 3 and 2) appears enough to give a response.
Unresponsive H.243 cells show a reduced level o f IL-2 gene transcription and 
diminished IFNg production
It has previously been shown that T-cell anergy may result from IL-2 gene 
transcription blockade [2]. Thus, we investigated whether the same holds true for 
unresponsiveness induced by anti-clonotype MAb TCR 76. Instead of measuring 
proliferation, cells were harvested 4 h after restimulation for the detection of IL-2 
mRNA by RT-PCR. PCR for housekeeping enzyme GAPDH was performed on the 
same cDNA samples as an internal control for RNA isolation and cDNA synthesis. 
It was found that using equal amounts of RNA, IL-2 gene transcription in anergic 
cells was significantly reduced after stimulation with 25 or 5 pg/ml peptide, or 
nearly absent after stimulation with 1 pg/ml peptide, compared to IL-2 
transcription of non-anergic cells (Figure 3a).
Next, we investigated the effect of T-cell unresponsiveness on the level of IFNg- 
production. Cultures were set up as for the study of IL-2 gene transcription, but 
instead of harvesting the cells after 4 h, supernatants were harvested after 24 h. 
The amount of IFNg in the supernatants was determined in a sandwich ELISA 
using IFNg-specific antibodies. It was found that anergic cells produced a 
significantly lower amount of IFNg compared to non-anergic cells (Figure 3b).
Cyclosporin A prevents the induction of anergy by anti-clonotype MAb, whereas 
IL-2 or cycloheximide does not prevent anergy
Different effects of cyclosporin A (CsA) and IL-2 on the induction of anergy have 
been reported depending on the way anergy was induced [7, 14-18]. Further, it has 
been reported that cycloheximide prevents the induction of anergy [19]. Therefore, 
we investigated the effect of these compounds on the induction of anergy by anti­
clonotype MAb. The experiments were performed as described above using TCR 
76 as the anergy inducing MAb and ZP 7A as the control MAb. During the 
induction phase either 1 pg/ml CsA, or 500 U/ml rIL-2 or 3 pg/ml cycloheximide
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Figure 3: Analysis o f cytokine production of anergic H.243 T cells.
a) IL-2 transcription is blocked in anergic cells.
T-cell clone H.243 was treated either with anergy-inducing anti-clonotype MAb, 
TCR 76, or control MAb, ZP 7A. After treatment with MAb, the cells were 
stimulated with increasing concentrations o f peptide and DRB1*0401-matched 
APC for 4 h, and RNA was isolated from the cells. RT-PCR’s for IL-2 (upper gel) 
and a housekeeping enzyme GAPDH (lower gel) were performed on RNA isolated 
from anergic T cells (lanes 2-6) and non-anergic T cells (lanes 7-11). Lane 1 and 
13: 100 bp DNA ladder marker, lane 2 and 7: 25 ¡Jg/ml peptide, lane 3 and 8: 5 
jjg/ml peptide, lane 4 and 9: 1 Jg/ml peptide, lane 5 and 10: medium control, lane
6 and 11: PHA control, lane 12: PCR control without template.
b) Interferon-gproduction is diminished in anergic cells.
H.243 was treated either with anergy-inducing anti-clonotype MAb, TCR 76, or a 
control MAb, ZP 7A. After treatment with MAb, the cells were stimulated with 
increasing concentrations of peptide (or PHA) and APC for 24 h. Then, IFNg w^ as 
determined in the supernatants using a specific sandwich ELISA.
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Figure 4: Effects o f CsA, IL-2 and cycloheximide on the induction of anergy by 
anti-clonotype MAb to H.243.
a) CsA prevents the induction of anergy. H.243 cells were incubated overnight 
with immobilized anti-clonotype MAb, TCR 76, either in the presence or absence 
of 1 Jg/ml CsA, or with control MAb, ZP 7A. Subsequently, the cells were 
restimulated with increasing concentrations of peptide or PHA and APC. In 
addition, T cells were incubated with IL-2 in the absence of APC. Proliferation 
was assessed by 3H-thymidine incorporation. Each value represents the mean 
counts per 5 min of triplicate cultures + standard deviation.
b) Interleukin-2 and cycloheximide does not prevent the induction of anergy by 
anti-clonotype MAb TCR 76. This experiment was performed under the same 
conditions as the experiment described in a) except that 500 U/ml rIL-2 or 3 Jg/ml 
cycloheximide were used instead of CsA.
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was added to the cultures. These compounds were washed out before initiation of 
the proliferation assay.
The calcineurin inhibitor CsA prevented the induction of anergy by TCR 76 
suggesting that an active signal via the calcium/calcineurin pathway is required for 
the induction of anergy (Figure 4a). The addition of IL-2 during the induction 
phase had no effect (Figure 4b) indicating that lack of IL-2 production during the 
induction phase is not the reason for anergy. Further, cycloheximide did not 
prevent the induction of anergy indicating that protein synthesis is not required to 
obtain anergy. Similar results were obtained with two other anti-clonotype MAb, 
TCR 66 and TCR 70 (results not shown).
Induction of anergy by anti-clonotype MAb is costimulation independent 
Triggering the TCR in the absence of costimulation can induce anergy in T cells. 
However, anergy can also be induced in the presence of costimulation using 
altered peptide ligands (APL) or high concentrations of soluble peptides [2]. 
Apparently, the role of costimulators may vary with the nature of the anergizing 
stimulus. To gain more insight into the mechanism of anergy induction by anti­
clonotype MAb, we investigated the influence of costimulation. In this experiment,
2 x 105 T cells and 5 x 105 irradiated, DR-matched APC were added to wells 
coated with anti-clonotype MAb, TCR 66 or TCR 70. Control cultures with MAb 
in the absence of APC were performed as described above. After overnight 
incubation, the cells were collected, washed and restimulated in a T-cell 
proliferation assay with peptide HC gp-39261-275 and fresh irradiated, DR-matched 
APC from the same donor as the APC used during the induction phase. The results 
show that the induction of anergy by TCR 66 and TCR 70 was independent of 
costimulation (Figure 5).
Anergic cells suppress the response of non-anergic cells
Recently, it was suggested that anergic T cells may have a role in bystander 
suppression [20-22]. Thus, we investigated whether anergic H.243 cells were able 
to suppress the response of non-anergic H.243 cells. Anergy was induced with 
TCR 76 and non-anergic cells were obtained from incubation with control MAb 
ZP 7A. Subsequently, proliferation assays were performed using different T-cell 
populations viz. 2 x 104 anergic T cells per well, 2 x 104 non-anergic T cells per 
well or mixtures of decreasing concentrations of anergic T cells (4 x 104, 2 x 104, 1 
x 104 and 0.5 x 104) and 2 x 104 non-anergic T cells per well. The response of non- 
anergic cells was significantly reduced in a dose related fashion by the addition of 
anergic cells (Figure 6a). Approximately 90% reduction of proliferation was
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obtained at an antigen concentration of 1 pg/ml and a ratio anergic cells versus 
non-anergic cells of 2:1. At higher antigen concentrations less reduction of 
proliferation was observed (72% at 5 pg/ml and 39% at 25 pg/ml). A two-fold 
increase in APC concentration in the proliferation assay had no effect on this 
bystander suppression at an antigen concentration of 1 pg/ml and only slightly 
increased the response at higher antigen concentrations (Figure 6b). This suggest 
that the suppressive effect is not due to competition for MHC/peptide complexes. 
Also competition for antigen is not likely to be an explanation for the reduced 
reactivity because a five fold increase in antigen concentration still does not give a 
maximal response.
petide conc. (^g/ml)
Figure 5: Induction of anergy in T-cell clone H.243 by anti-clonotype MAb is 
costimulation independent
Immobilized TCR 66, TCR 70, or control MAb ZP 7A were incubated overnight 
with H.243 T cells either in the presence or absence of DRB1*0401-matched APC. 
Subsequently, the cells were restimulated with increasing concentrations of 
peptide and APC from the same donor as used during the induction phase. 
Proliferation was assessed by 3H-thymidine incorporation. Each value represents 
the mean counts per 5 min of triplicate cultures +/- standard deviation.
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Figure 6: Anergic H.243 Tcells suppress the response of non-anergic H.243 Tcells.
a) Immobilized TCR 76 or control MAb, ZP 7A, were incubated overnight with 
H.243 T cells. Then, both T-cellpopulations were used in a proliferation assay with 
increasing concentrations o f peptide (or PHA) and APC using 2 x  104 T cells per 
well. In addition, variable amounts o f anergic cells resulting from incubation with 
TCR 76 were mixed with 2 x  104 non-anergic cells resulting from incubation with 
ZP 7A,, and a proliferation assay was performed. A/N: ratio o f anergic cells versus 
non-anergic cells; 1= 2 x  104 cells. Proliferation was assessed by 3H-thymidine 
incorporation. Each value represents the mean counts per 5 min of triplicate 
cultures + standard deviation.
b) Equal amounts (2 x  104 cells) o f anergic and non-anergic cells were mixed and 
proliferation was assessed in a proliferation assay using 1 x  1C5 and 2 x  1C5 APC 
per well.
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Discussion
In the present study, we have shown that anti-clonotype MAb are able to modulate 
the response of an autoreactive DRB1*0401-restricted T-cell clone specific for an 
epitope on HC gp-39. Anergy was induced by presentation of immobilized anti­
clonotype MAb to this T-cell clone. After removal of the anergic stimulus, the 
clone could not be stimulated with antigen presented on DRB 1*0401-matched 
APC. Anergy seems to be a result of defective IL-2 gene transcription upon 
re stimulation. Besides a defective IL-2 gene transcription, the anergic cells also 
showed a diminished IFNg production.
Cell death or apoptosis did not account for T-cell unresponsiveness as anergic cells 
retained the ability to respond to PHA and exogenous IL-2. Compared to non- 
anergic cells, anergic cells displayed a slightly reduced number of freely accessible 
TCR molecules at the cell surface as a consequence of TCR downmodulation and 
the presence of a residual amount of anti-clonotype MAb on the cells after the 
anergic stimulus. However, it is unlikely that the small reduction of TCR was 
responsible for anergy because i) only a very small number of TCR are required 
for T-cell activation [23] and ii) our own data (Figure 2c and 2d) show that only a 
few free TCR molecules are required for a response.
Previously, we have demonstrated that immobilized anti-clonotype MAb are able 
to trigger the TCR of the specific T-cell clone leading to proliferation. However, 
the same stimulus does not lead to proliferation if the T cells are removed from the 
antibody coated plates because no background proliferation was observed after 
restimulation of the cells. From the latter observation, it can also be concluded that 
the residual amount of MAb left on the cells after the anergic stimulus does not 
lead to proliferation, which is in agreement with our findings that low amounts of 
anti-clonotype MAb (<100 ng/ml; data not shown) are not mitogenic. Further, we 
conclude that continuous presence of a small amount of anti-clonotype MAb on 
the cells was not responsible for the anergic effect because incubation with free 
anti-clonotype MAb resulted in a larger amount of antibody on the T cells and did 
not result in the same level of unresponsiveness (Figure 2c and 2d).
It appeared that very small amounts of anti-clonotype MAb are required for anergy 
induction. Coating wells with as little as 50 ng/ml antibody was sufficient to 
induce anergy (results not shown). The high affinity of MAb for the TCR (nM 
range) may account for this quantitative effect in vitro. In vivo, the prolonged 
bioavailability of antibodies may be an additional benefit. This makes antibodies 
an attractive candidate for the induction of anergy in autoimmune disease.
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The anti-clonotype MAb induced anergy was prevented by CsA, suggesting a role 
for the calcium/calcineurin pathway [24, 25]. Furthermore, the induction of anergy 
was not prevented by accessory cells indicating that this model of T-cell anergy is 
independent of costimulation. We further conclude that the induction of anergy 
was not due to lack of IL-2 production during the initial culture with MAb. In fact, 
IL-2 is produced by the T cells after incubation with weakly mitogenic anti­
clonotype MAb. Furthermore, addition of supraoptimal concentrations of IL-2 
(500 U/ml) during the induction phase did not prevent anergy. Finally, we found 
that protein synthesis was not required for the induction of anergy.
The anti-clonotype induced anergy described in this study is clearly distinct from 
T-cell anergy induced by TCR occupancy in the absence of costimulation since in 
the latter model, anergy induction is prevented by costimulation or IL-2 [2, 26] and 
requires protein synthesis [19].
One may argue that anti-clonotype MAb behave like APL. Thus, partial triggering 
the TCR by anti-clonotype MAb might lead to the induction of anergy. Indeed 
anti-clonotype MAb induced anergy resembles APL induced anergy in murine T- 
cell clones in that anergy is prevented by CsA [15] and is not prevented by the 
presence of costimulation [2]. However, recently it was reported [18] that APL 
induced anergy could be rescued by addition of IL-2 during the induction phase, 
which is in contradistinction to our findings with clonotype specific MAb.
The same holds true for anergy induced by high concentrations of peptide. 
Cyclosporin A and costimulation added during the induction of this form of anergy 
has similar effects as we have found for the induction of anergy by anti-clonotype 
MAb [2, 27]. However, Essery et al. [16] reported that high concentrations of IL-2 
(300 to 1000 U/ml) prevented the induction of anergy, whereas in our experiments 
anergy was not prevented by as much as 500 U/ml IL-2.
Further, several investigators have used anti-CD3 for the induction of anergy. 
Anti-CD3 induced anergy in naive CD4+ mouse T cells [8] and in human resting T 
cells [28] differs from the anti-clonotype MAb induced anergy reported here, 
because in these experiments anergy could not be prevented by CsA [28, F. 
Andris; personal communication]. Anti-CD3 induced anergy in murine Th1 clones 
[7] also differs from our model because it was prevented in the presence of 
accessory cells. In this respect, it is worth noting that triggering the TCR/CD3 
complex by anti-CD3 may be different from triggering the TCR/CD3 complex by 
anti-TCR as was recently reported by Kishimoto et al. [29]. Thus, we believe that 
the anti-clonotype MAb induced anergy model presented in this study is different
122
from previously reported models. Though it should be remarked that it is difficult 
to compare the great variety of anergy data in the literature because of many 
differences in experimental conditions and T-cell sources (naive T cells, T-cell 
clones and different species).
Peripheral tolerance is an important mechanism for generating unresponsiveness 
against both self and external antigens. It is mediated by T cells using at least three 
nonmutally exclusive mechanisms: suppression, apoptosis and anergy [1, 30, 31]. 
It was reported that tolerance can by induced by epitopes of the antigen even if 
they are different from the autoreactive epitope [32]. Recently, it was also found 
that anergic T cells are able to transfer unresponsiveness to a separate population 
of antigen responsive T cells [20-22] and it was suggested that this phenomenon 
called infectious anergy might be responsible for T-cell mediated suppression in 
oral tolerance [21]. In this report, we have shown that anergic T cells can inhibit 
the response of non-anergic cells from the same T-cell clone in a dose related 
fashion. Up to 90% inhibition was found at a nearly saturating concentrations of 
antigen. At higher antigen concentrations, less inhibition was observed but these 
high concentrations are not likely to reflect a physiological situation. To date, we 
have not extensively investigated the mechanism underlying this form of bystander 
suppression. Our preliminary data suggest that competition for APC surface or 
antigen is not responsible for this suppressive effect. Further, it seems unlikely that 
the reduced proliferation is due to competition for locally produced IL-2 as 
proposed by Lombardi et al. [20] since anergic cells also respond to IL-2 and the 
net result would be proliferation as well. The anergic cells may exert their 
suppressive effect by secretion of soluble factors or another as yet undefined 
mechanism.
We have previously shown that the anti-clonotype MAb used in this study were 
able to inhibit antigen-driven proliferation of the HC gp-39 specific Th1 clone. In 
this report, we have shown that small amounts of these MAb can induce anergy in 
this autoreactive T-cell clone which is at the same time the first demonstration of 
human T-cell anergy by clonotype specific antibodies. Together, these findings 
suggest that clonotype specific antibodies may be interesting tools for modulation 
of T-cell mediated diseases in common and for the modulation of the autoreactive 
response to HC gp-39 in rheumatoid arthritis patients in this particular case.
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Chapter 7: General discussion and conclusion
B-cell culture/mini-electrofusion approach for the generation of MAb 
This thesis describes a novel approach for the generation of human or murine MAb 
producing hybridomas. The approach is based on expansion of B cells in the 
presence of human T-cell supernatant and irradiated murine thymoma cells, 
followed by immortalization of individual cultures of expanded B cells in a mini­
electrofusion procedure (B-cell culture/mini-electrofusion approach). Following 
such a protocol, a very high immortalization frequency of B cells was achieved. 
Approximately 50% of murine B cells and 30% of human B cells could be 
immortalized. This is at least 1000-fold more efficient than a standard 
electrofusion procedure, and more than 100,000-fold more efficient than the 
classical PEG-fusion technique (Table I) [1-3].
Table I: Immortalization frequency of the B-cell culture/mini-electrofusion 
approach compared to other immortalization approaches.
murine B cells human B cells
B-cell culture/mini-electrofusion
3fcino 3fcono
PEG fusion 5 x 10-6 [1] 1 x 10-6 [2]
electrofusion 4 x 10-4 [1] 1 x 10-4 [2]
EBV -transformation not possible 2 x 10-2 [3]
# Chapter 2
The PEG fusion technique has proven to be successful in the generation of MAb 
against (mostly) immunodominant antigens or epitopes. However, it has been 
difficult to generate MAb against rare or weakly immunogenic antigens/epitopes in 
the presence of immunodominant ones. These immunogens do not generate many 
antibody-producing cells. Therefore, MAb were only obtained after screening of 
thousands of hybridomas, or were not generated at all. This particularly holds true 
for the generation of MAb to cell surface antigens that constitute only a minor part 
of the cellular proteins and are often difficult to purify in sufficient amounts for 
immunization.
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Several strategies have been followed to solve this problem. In some cases, the 
immunogen was purified free from other abundant or highly antigenic molecules 
[4]. To obtain a response to the very small amounts of immunogens resulting from 
such purification procedures, intrasplenic immunizations were performed 
[reviewed in 5]. Immunosuppression or tolerization of mice has been used to 
suppress undesired antigenic components [6-8]. Other strategies such as 
immunologic masking by antibodies have also been used [9,10]. Cell surface 
molecules have been expressed by recombinant DNA procedures, either as soluble 
molecules or on the surface of syngenic mouse cells. Expression as soluble 
molecules simplifies purification. Expression on syngenic mouse cells means that 
upon immunization of mice only the newly expressed surface molecules will be 
recognized [11-15].
Besides these attempts to improve the immune response, the fusion frequency of B 
cells has been enhanced by electrofusion [1,16-18]. Generating more hybridomas 
increases the chance of finding rare MAb. However, such an approach involves an 
increased screening effort and requires large amounts of antigen for screening. On 
the other hand, the immortalization frequency of B cells in electrofusion is still not 
sufficiently high to immortalize a low number of preselected antigen-specific B 
cells. Note that with an immortalization frequency of 1 : 2000, still 99,95% of the 
B cells are lost.
None of the methods described above have become a general strategy for the 
generation of MAb to minor antigenic determinants. Therefore, there is a need for 
higher immortalization frequencies enabling immortalization of B cells in 
combination with proper selection techniques for antigen-specific B cells.
In the generation of human MAb, the use of hybridoma technology has been 
mainly limited to a few antigens for which vaccination is allowed or human donors 
were naturally primed. Furthermore, only small amounts of human donor material 
are available and the source is often limited to peripheral blood cells. The number 
of specific B cells in peripheral blood is relatively small and fusion frequencies of 
these cells are 5- to 10-fold lower than for mouse spleen cells. The latter is due to 
the fact that these B cells are usually not activated by an immunization procedure, 
and the lack of suitable fusion partners for human B cells [2,19-21]. Alternatively, 
human B cells can be immortalized by EBV-transformation. Though EBV- 
transformation is a relatively efficient procedure (Table I), only a subset of human 
B cells are immortalized yielding predominantly IgM antibodies. The resulting 
EBV-transformed B cells are difficult to grow and to clone by limiting dilution
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culture [3,19,22,23]. These drawbacks warrant the development of an improved 
technology for the generation of human MAb.
Most of the limitations of PEG fusion, electrofusion and EBV-transformation has 
been circumvented by the B-cell culture/mini-electrofusion approach.
The EL-4 B-cell culture system supports the outgrowth of both human and murine 
B cells. Limiting dilution studies with human B cells showed that up to 90 % of B 
cells could be expanded (in our hands 25 to 75 % of human or murine B cells 
could be grown out). One human B cell generated on average a clone of 380 cells. 
Data on the outgrowth of single murine B cells have not been reported. In theory, 
380 B cells are not enough to generate hybridomas by the electrofusion technique 
that immortalizes 1:2500 murine spleen B cells and 1:10,000 human peripheral 
blood B cells. However, from electrofusion experiments with EBV-transformed 
human B cells we have learned that activated B cells can be fused with a frequency 
up to 1:50. This offers the opportunity for successful immortalization of B cells 
expanded in the EL-4 B-cell culture system as these cells are also activated. As 
shown in Chapter 4, 60 % of antigen-specific human B-cells cultures could indeed 
be immortalized by electrofusion with K6H6B5 myeloma cells. Together with a 
mean outgrowth value of 50 % of human B cells in the B-cell culture system, an 
overall immortalization efficiency of 0,3 (30 %) was achieved for human B cells 
(Table I). Applying the B-cell culture/mini-electrofusion approach to murine B 
cells, 100 % of B-cell cultures originating from a single B cell can be 
immortalized. This implies that the outgrowth of murine B cells (mean of 50 %) in 
the EL-4 B-cell culture system, and not the efficiency of electrofusion of these 
cultures, determines the overall immortalization frequency of murine B cells 
(Table I). Up to 700 hybridomas could be generated from 1 mouse B cell. This 
large number suggests that much more than 380 B cells are obtained in cultures of 
murine B cells. This was confirmed by microscopic observation of these cultures. 
The mini-electrofusion procedure that we have performed was adapted from 
standard electrofusion protocols. Besides some minor technical differences, our 
protocol differs in the myeloma to B cell ratio that was used. Usually, myeloma:B 
cell ratios of 1:1 to 10:1 have been used by other investigators. We have used a 
100 to 1000-fold excess of myeloma cells. This has the advantage that every B 
cells is in contact with a myeloma cell during the fusion procedure. Moreover, it 
supplies a workable amount of cell mass.
The high frequency of the B-cell culture/mini-electrofusion approach enables the 
immortalization of small numbers of B cells obtained from antigen-specific
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selection procedures (Chapter 3 and 5). In fact, for the generation of murine MAb, 
our approach is only advantageous if selection of antigen-specific B cells can be 
achieved. Without a preselection more than 5 x 107 hybridomas can be generated 
from one spleen. Of course, it is not possible to screen such a large number of 
hybridomas. We have demonstrated that antigen-specific B cells selected by 
panning on antigen-coated dishes or rosetting with antigen-coupled paramagnetic 
beads, can be immortalized. Thus, many antigen-specific hybridomas were 
generated without laborious screening of large numbers of irrelevant hybridomas. 
This was also the basis for a subtractive selection strategy used for the generation 
of antibodies to the clonotypic structure of human T cells. In this strategy, spleen 
cells from mice immunized with whole T cells were first depleted for B cells 
reactive to the monomorphic part of the TCR (negative selection). Then, B cells 
reactive to the polymorphic part of the TCR were selected (positive selection). The 
small number of B cells obtained after such an elaborate selection procedure (less 
than 100 specific B cells were selected starting from 3 x 107 spleen cells) could be 
immortalized (Chapter 5, discussed below). A similar strategy was successfully 
applied for a number of recombinant fusion proteins by which preclears were 
performed with the carrier protein and positive selections were done with the 
recombinant fusion protein (data not shown).
The B-cell culture/mini-electrofusion approach also enables processing and 
immortalization of B cells from small amounts of human donor material (Chapter
4), murine blood samples (Chapter 2) or murine lymph nodes. The efficiency of 
the approach for generation of human MAb was demonstrated by the generation of 
22 human anti-CMV producing B-cell clones from as little as 1.5 ml human donor 
blood. These B-cell clones were predominantly of the IgG class. Sixty percent of 
such B-cell clones could be immortalized successfully in a mini-electrofusion 
procedure. Our approach still requires sensitized B cells and hence does not 
circumvent the problem that deliberate immunizations are not allowed in humans. 
Therefore, it would be attractive to combine the high immortalization frequency of 
the B-cell culture/mini-electrofusion approach with recently developed methods 
for the sensitization of naive human B cells (in vitro immunization, SCIDhu mice 
and human Ig transgenics) in which the number of antigen-specific B cells are 
usually low [24-29; Jacobovitz personal communication].
An additional advantage is that more hybridomas can be generated from a single B 
cell. Though in theory these hybridomas secrete the same antibody, they may be 
genetically different. Thus, it enables selection of the hybridoma with the optimal
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properties regarding growth, stability and antibody production. The latter is 
particularly important for the generation of human MAb where many hybridomas 
lose antibody production or suffer from growth problems.
Anti-clonotype MAb
The newly developed B-cell culture/mini-electrofusion approach was applied for 
the generation of MAb to the clonotype of human T-cell clones.
T cells play an important role in the initiation and maintenance of many 
autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, diabetes and 
myasthenia gravis. Antibodies directed against the clonotypic structures of T cells 
involved may be used as therapeutic reagents. However, to date there are no 
reports about the generation of such antibodies to a given antigen-specific T-cell 
clone, which is likely due to a lack of sufficient amounts of purified TCR for 
immunization of mice and screening of hybridomas. Moreover, the clonotypic 
structure represents only a part of the TCR molecule and upon immunization with 
the TCR of interest, antibodies are also evoked to the constant part, which is 
similar to other TCR.
Therefore, we have developed a strategy for the generation of anti-clonotype MAb 
that does not require large numbers of T cells or purified TCR and enables rapid 
and simple discrimination between anti-clonotype MAb and MAb directed to other 
epitopes on the T cell. This strategy comprises the following sequence of steps:
1) immunization of mice with intact human T cells without adjuvant,
2) isolation of splenic lymphocytes and depletion of B cells specific for CD3 
or the constant region of the TCR,
3) positive selection of anti-clonotype specific B cells,
4) clonal expansion of selected B cells,
5) double screening of B-cell culture supernatants in a one-step agglutination 
assay using the T-cell clone of interest and an irrelevant T-cell clone,
6) mini-electrofusion of B-cell cultures producing antibodies specific for the 
T-cell clone of interest,
7) retesting of hybridomas and cloning to stability.
In this thesis, the strategy was successfully applied for two different clonotypes. A 
similar strategy may also be used for the generation of anti-idiotype MAb or 
antibodies against other cell surface molecules. The method may be particular 
useful in case antibodies are desired against one member of a family of structurally
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related cell surface receptors, like for example the TNF receptor family or the 
cytokine receptor family.
Ten clonotype-specific MAb were generated to a HLA DRB1*0401-restricted T- 
cell clone recognizing an epitope of the Human Cartilage glycoprotein 39 (HC gp- 
39), which was recently found to be a candidate autoantigen in rheumatoid arthritis 
[30]. In a functional assay, the MAb were found to inhibit or block antigen- 
induced proliferation of the autoreactive T-cell clone. On the other hand, 
immobilized MAb were weakly mitogenic for the autoreactive T-cell clone, thus 
indicating that they could functionally trigger the T cell by its receptor. 
Crosslinking of the TCR by the anti-clonotype MAb also leads to 
unresponsiveness of the T-cell clone to subsequent stimulation by antigen and 
DRB1*0401 matched APC. The mechanism of this anti-clonotype MAb induced 
anergy was investigated and compared to previously reported models of T-cell 
anergy. The anti-clonotype MAb induced anergy model presented in our study 
seems different from other models (Chapter 6). Though, it should be remarked that 
it is difficult to compare the great variety of anergy data in the literature because of 
many differences in experimental conditions and T-cell sources (naive T cells, T- 
cell clones and different species).
The in vitro functional properties of anti-clonotype MAb (inhibition of antigen- 
driven proliferation and induction of T-cell anergy) makes them interesting 
reagents for treatment of autoimmune diseases in a clonotype specific manner. In a 
potential therapeutic regime, such MAb may exert disease modulating activity by 
T-cell depletion, TCR blocking or the induction of T-cell anergy depending on the 
nature of the applied antibody (e.g. isotype, Fab fragments, F(ab’)2 fragments, 
dose, crosslinking). Such MAb may offer an alternative for conventional 
immunosuppressive drugs which lack specificity and often show adverse side 
effects, or for more specific therapies involving T-cell surface markers, for 
example anti-CD4 MAb. The latter has proven to be successful in animal models, 
[31-33] however clinical experience with depleting antibodies has shown that 
treatment of humans was less successful due to a persistent severe lymphopenia, 
which could result in generalized immunosuppression [34]. Recent studies with 
non-depleting anti-CD4 antibodies seems to be more successful though there are 
only a very limited number of clinical data up till now [Abstracts 35,36].
These observations warrant the development of a more specific therapy based on 
the clonotypic structure of disease relevant T cells. However, before anti­
clonotype MAb can be brought to the clinic, there are still several hurdles to
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overcome. An absolute requisite for the success of such an approach is that the 
population of disease-inducing T cells must display TCR of limited intra- and 
inter-individual heterogeneity, as is the case in some animal models of 
autoimmunity [37-40]. A number of investigators have described restricted V^- 
gene usage in certain autoimmune diseases, but others found no indication at all 
for restricted use [41-44]. Studies of the TCR expressed in the brains of multiple 
sclerosis (MS) patients have revealed a restricted usage of CDR3 motifs [45]. 
Similar motifs were found in myelin basic protein-specific T-cell clones derived 
from MS patients and encephalitogenic T-cell clones from Lewis rats [46]. 
However, thus far there are insufficient data concerning conserved CDR3 usage to 
form a definite conclusion about the occurrence of a restricted number of 
clonotypes [44]. Therefore, application of TCR family- or clonotype-specific 
antibodies in treatment of human autoimmune diseases awaits the identification of 
disease-relevant T cells that bear a particular TCR.
With respect to rheumatoid arthritis (RA), we have recently found that peptides 
encompassing amino acids 263-275 of HC gp-39 are recognized in approximately 
30% of the patients (unpublished data). The anti-clonotype MAb described in this 
thesis are directed to a Th1 clone recognizing this epitope. Preliminary results in 
the study of the occurrence of T cells with similar clonotypic structures in the 
synovium of RA patients have shown that such T cells were present in the patient 
from which the Th1 clone was derived, but not in 3 other patients. More patients 
have to be tested for a definite conclusion.
For a prolonged treatment in humans, it would be necessary to humanize the 
interesting anti-clonotype MAb. Otherwise, the strategy for the generation of anti­
clonotype MAb as described above can be applied on SCID-hu mice or human 
immunoglobulin transgenic mice that are immunized with the T-cell clone of 
interest.
Finally, one may argue that the anti-clonotype MAb approach for treatment of 
autoimmune disease is too specific because the antibodies attack only one TCR, 
reactive with only one epitope of the antigen. However, a broader therapeutic 
effect may be anticipated as well. For example, the antibody combining site 
(idiotype) of anti-clonotype MAb may represent a mirror image of the structure of 
the MHC/peptide complex. Thus, they may recognize different TCR reactive with 
the same MHC/peptide complex. We were not able to test this possibility for our 
MAb since we did not have a second T-cell clone specific for the same epitope. 
Alternatively, such antibodies can be obtained by the generation of anti-idiotype
135
antibodies (i.e. antibodies directed to the combining site of another antibody) 
against antibodies directed to the T-cell epitope. Such anti-idiotype antibodies may 
act as agonists, antagonists or partial agonists for the TCR. A similar approach has 
already been shown for antibodies to the thyroid-stimulating hormone (TSH) 
receptor [47,48] and for the A1 adenosine receptor [49]. An example relevant for 
autoimmune disease has been reported by Zhou and Whitaker, who were able to 
treat experimental allergic encephalomyelitis (EAE) in mice by anti-idiotype 
antibodies to a T-cell epitope from myelin basic protein [50]. Another reason for a 
more widespread therapeutic effect of anergy inducing MAb comes from the 
observation that anergic T-cell clones can suppress the response of non-anergic T- 
cell clones of other specificity [51-53]. Our own experiments had already shown 
that following the induction of anergy by anti-clonotype MAb, anergic cells could 
suppress the response of reactive cells from the same clone in vitro (Chapter 6). 
However, the problem of the control of T-cell function in vivo may be more 
complex.
In conclusion, MAb to the clonotypic structure of autoreactive T cells may be 
suitable reagents for the physical elimination or functional inactivation of these T 
cells in autoimmune diseases. However, before starting therapeutic development of 
such MAb, it will be necessary to establish the presence of a limited set of clonal 
or oligoclonal expanded T cells with identical clonotypic structures at the 
inflammatory sites in autoimmune diseases. Anti-clonotype MAb may be helpful 
in performing these studies.
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Samenvatting
T-cellen spelen een centrale rol bij het initiëren en in stand houden van een aantal 
auto-immuunziekten zoals bijvoorbeeld reumatoïde artritis, multiple sclerose en 
diabetes mellitus. Zij hebben specifieke receptoren (TCR) op het celoppervlak die 
auto-antigenen herkennen in de context van MHC-moleculen op een antigeen- 
presenterende cel (APC). Behalve deze antigene stimulus heeft een T-cel ook co- 
stimulerende signalen nodig om te worden aangezet tot proliferatie en cytokine- 
produktie.
De huidige behandeling van auto-immuunziekten is meestal gebaseerd op 
onderdrukking van de algemene immuunrespons met immuunsuppressieve 
middelen. Deze hebben echter soms ernstige bijwerkingen en zijn bovendien niet 
specifiek omdat ze ook de noodzakelijke normale afweer onderdrukken. 
Specifieker zijn de experimentele antistof-therapieën waarbij een co-stimulerend 
signaal dat nodig is voor T-cel activatie wordt geblokkeerd of gemoduleerd, of T- 
cellen worden verwijderd op grond van het bezit van een receptor voor een co- 
stimulerend molecuul. Bij een dergelijke benadering worden echter niet alleen de 
pathogene T-cellen aangepakt, maar ook T-cellen die nodig zijn voor het goed 
functioneren van de immuunrespons.
Een therapie met minimale bijwerkingen is alleen gericht op de pathogene T-cel. 
Verschillende onderzoekers hebben een klonale uitgroei van een beperkte 
diversiteit aan T-cellen waargenomen op de plaats van ontsteking bij auto- 
immuunziekten. Er zijn ook rapporten over een beperkt gebruik van TCR V-genen 
en CDR3-motieven. Monoklonale antistoffen (MAb) tegen het antigeen-bindende 
gedeelte (clonotype) van zulke pathogene T-cellen bieden een mogelijkheid voor 
specifieke immunotherapie, en voor het bestuderen van het ziekteverloop. Tot nu 
toe zijn er echter geen methoden voorhanden om zulke anti-clonotype MAb te 
genereren. Het onderzoek beschreven in dit proefschrift is bedoeld om MAb te 
genereren tegen het clonotype van een humane autoreactieve T-cel kloon en om te 
onderzoeken of deze MAb in staat zijn tot modulatie van de functionele respons 
van deze T-cel kloon. Hiertoe is allereerst een nieuwe methode ontwikkeld voor 
een zeer efficiënte immortalisatie van kleine hoeveelheden antigeen-specifieke B- 
cellen.
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De huidige methoden voor het genereren van MAb producerende hybridoma’s 
(PEG-fusie en elektrofusie) worden gekenmerkt door een relatief lage 
immortalisatie-frequentie van B-cellen. Bovendien worden B-cellen willekeurig 
geïmmortaliseerd waardoor slechts een klein percentage van de verkregen 
hybridoma’s de gewenste MAb produceren. Hierdoor zijn deze methodes niet erg 
geschikt voor het immortaliseren van B-cellen die in een zeer lage frequentie 
voorkomen, omdat het epitoop waartegen ze gericht zijn een slecht immunogeen is. 
In hoofdstuk 2 wordt de ontwikkeling van een nieuwe procedure beschreven die 
wordt gekenmerkt door een bijzonder hoge immortalisatie-frequentie. B-cellen 
worden eerst opgekweekt in aanwezigheid van humaan T-cel supernatant en 
bestraalde muize thymoma cellen, en vervolgens geïmmortaliseerd met behulp van 
een mini-elektrofusie procedure. Aldus kunnen ca. 50% van de muize- en ca. 30% 
van de humane B-cellen geïmmortaliseerd worden. Dit betekent dat deze 
procedure voor het immortaliseren van B-cellen minstens 1000 keer efficiënter is 
dan een standaard elektrofusie, en meer dan 100,000 keer efficiënter dan de 
klassieke PEG-fusie techniek. Dit biedt interessante nieuwe mogelijkheden voor 
het genereren van MAb zoals: het immortaliseren van gepreselekteerde antigeen- 
specifieke B-cellen, immortalisatie van B-cellen uit muizenbloed of lymfeknopen, 
en het genereren van MAb uit kleine hoeveelheden humaan bloed. Een bijkomend 
voordeel is dat meerdere hybridoma’s gegenereerd kunnen worden uit één 
oorspronkelijke B-cel. Hierdoor kan een keuze gemaakt worden voor de 
hybridoma met de beste eigenschappen (groei, produktie en stabiliteit). Dit is 
vooral belangrijk bij het genereren van humane MAb omdat daar veel hybridoma’s 
verloren gaan door slechte groei of onbruikbaar worden door verlies van antistof- 
produktie. Verder kan met de ontwikkelde B-cel kweek/mini-elektrofusie 
procedure mogelijk de selektiviteit van EBV-transformaties (leveren voornamelijk 
IgM antistoffen) worden omzeild.
Twee van bovengenoemde mogelijkheden zijn verder uitgewerkt in hoofdstuk 3 en
4. In hoofdstuk 3 wordt aangetoond dat B-cellen geselecteerd via binding aan een 
antigeen, nog uitstekend uitgroeien in het B-cel kweeksysteem. Hierdoor kan de 
efficiëntie van de B-cel kweek/mini-elektrofusie procedure gebruikt worden voor 
het gericht genereren van specifieke MAb. Verschillende condities voor optimale 
selectie van antigeen-specifieke B-cellen door middel van ‘panning’ op antigeen- 
gecoate schaaltjes of door rozettering met behulp van antigeen-gekoppelde 
magnetische bolletjes (‘immunobeads’), zijn met elkaar vergeleken. Met behulp 
van ‘panning’ zijn muize anti-HIV positieve B-cellen verrijkt tot een zuiverheid 
van 24% met een opbrengst van 5%. ‘Immunobead’-selectie van dezelfde anti-HIV
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positieve B-cellen resulteerde in een zuiverheid van 7% met een opbrengst van 
17%.
Verder zijn humane anti-cytomegalovirus (CMV) specifieke B-cellen geselecteerd 
met behulp van ‘panning’ op CMV gecoate schaaltjes (hoofdstuk 4). Deze 
geselecteerde cellen zijn onderworpen aan de B-cel kweek/mini-elektrofusie 
procedure. Tweeëntwintig anti-CMV positieve B-cel klonen zijn verkregen uit 
slechts 1,5 ml donorbloed. Hiervan zijn 60% geïmmortaliseerd tot humane anti- 
CMV IgG producerende hybridoma’s. Sommige van deze MAb hebben een 
specificiteit die tot nu toe niet met EBV-transformatie werd verkregen.
De methoden beschreven in hoofdstuk 2 en 3 zijn echter niet direct toepasbaar 
voor het genereren van anti-clonotype MAb tegen een willekeurige humane T-cel 
receptor omdat onvoldoende gezuiverd antigeen beschikbaar is voor immunisatie, 
selectie van antigeen-specifieke B-cellen, en screening van hybridoma’s en B-cel 
klonen. Hoofdstuk 5 beschrijft de ontwikkeling van een algemene procedure voor 
het genereren van clonotype specifieke MAb. Hiertoe worden muizen 
geïmmuniseerd met hele T-cellen. Uit de miltcel-populatie van deze muizen 
worden de B-cellen gericht tegen CD3 en het constante gedeelte van de TCR 
verwijderd door adsorptie aan TCR/CD3 complexen van een niet-relevante T-cel 
kloon. Vervolgens worden de clonotype-specifieke B-cellen geselecteerd met 
TCR/CD3 complexen van de relevante T-cel kloon. Op deze manier verkregen 
cellen worden onderworpen aan de B-cel kweek/mini-elektrofusie procedure. De 
clonotype-specifieke B-cel klonen en hybridoma’s worden geselecteerd met behulp 
van een één-staps agglutinatietest met zowel de relevante T-cel kloon als een 
controle T-cel kloon.
Er zijn 10 anti-clonotype MAb gegenereerd tegen een T-cel kloon die een epitoop 
herkent van het humane kraakbeen-eiwit HC gp-39, in de context van HLA- 
DRB 1*0401. Dit eiwit is mogelijk als auto-antigeen betrokken bij de ziekte 
reumatoïde artritis. De MAb zijn in staat de antigeen-geïnduceerde proliferatie van 
de HC gp-39 specifieke T-cel kloon te remmen of volledig te blokkeren (hoofdstuk
5). Verder is gebleken dat kleine hoeveelheden geïmmobiliseerde MAb in staat 
zijn de TCR van de HC gp-39 specifieke T-cel kloon partieel te stimuleren. Na 
deze partiële stimulus verkeren de T-cellen in een soort anerge staat waarbij ze niet 
meer reageren op specifiek peptide en APC (hoofdstuk 6). Het mechanisme van de 
geïnduceerde anergie door anti-clonotype MAb is nader onderzocht en vergeleken 
met de bestaande modellen voor T-cel anergie. Anergie is niet het gevolg van 
apoptose of TCR ‘downmodulatie’. Toevoeging van cyclosporine-A voorkomt de 
inductie van anergie, wat suggereert dat een aktief signaal via de
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calcium/calcineurin route nodig is voor de inductie van anergie. De inductie van 
deze anergie is onafhankelijk van de aanwezigheid van IL-2 en/of co-stimulatie, en 
er is geen ‘de novo’ eiwitsynthese noodzakelijk. Hieruit kan geconcludeerd 
worden dat de door anti-clonotype MAb geïnduceerde anergie verschilt van de 
eerder beschreven vormen van anergie. Verder is gebleken dat anerge cellen de 
respons van niet-anerge cellen sterk kunnen remmen. Dit suggereert dat anerge 
cellen een actieve rol kunnen spelen bij de onderdrukking van de immuunrespons 
tegen het auto-antigeen.
Het feit dat de anti-clonotype antistoffen in staat zijn om antigeen-geïnduceerde 
proliferatie te remmen en dat ze in staat zijn tot inductie van T-cel anergie, biedt 
interessante mogelijkheden voor therapeutische toepassing. Echter, eerst zal 
moeten worden aangetoond dat T-cellen met een bepaald clonotype algemeen 
voorkomen bij de betreffende auto-immuunziekten. In het geval van reumatoïde 
artritis zijn de in dit proefschrift beschreven antistoffen hiervoor een belangrijk 
hulpmiddel.
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Abbreviations
APC antigen presenting cell
APL altered peptide ligand
CDR complementarity-determining region
CMV cytomegalovirus
CsA cyclosporin A
DMEM Dulbecco’s modified Eagle medium
EAE experimental allergic encephalomyelitis
EBV Epstein Barr virus
ELISA enzyme-linked immunosorbent assay
FACS fluorescence activated cell sorter
FCS fetal calf serum
FITC fluorescein isothiocyanate
HAMA human anti-mouse antibodies
HC gp-39 human cartilage glycoprotein-39
HRP horse radish peroxidase
IFNg interferon-g
Ig immunoglobulin(s)
IL interleukin
MAb monoclonal antibody/antibodies
MHC major histocompatibility complex
MS multiple sclerosis
NHS normal human serum
PBL peripheral blood lymphocytes
(P)BMC (peripheral blood) mononuclear cells
PBS phosphate buffered saline
PEG polyethylene glycol
PHA phytohemagglutinin
RA rheumatoid arthritis
SCID severe combined immunodeficiency
TCR T-cell receptor(s)
Th T helper
TSN T-cell supernatant
V (gene) variable (gene)
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